Annual Index

Following is the comprehensive index for volume 154 of the *Journal*, which covers all material from January 1997 through December 1997. Two-letter abbreviations are used for months. The complete citation for each article in the Author Index is listed under the name of the first author. Coauthors are listed alphabetically with a cross-reference to the first author; cross-references containing multiple first author names separated by semicolons indicate multiple articles by the coauthor. Book reviews appear in the Author Index under the name of the reviewer and in the Subject Index under the heading Books Reviewed; the books reviewed are arranged alphabetically by the surname of the book's first author or editor. In addition to being indexed by author name, letters to the Editor regarding articles published in 1997 are indicated in parentheses after the citations for those articles.

Each entry in the Subject Index is identified by the surname of the first author only; semicolons between names of authors of letters to the Editor indicate multiple letters. Entries other than Special Articles, Regular Articles, Commentaries, and Brief Reports are given the following designations: editorial (editorial), In Memoriam (in mem), Images in Neuroscience (image, neuro), Images in Psychiatry (image, psych), Clinical Case Conference (case conf), book review (bk rev), letter to the Editor (letter), Official Actions (off acts), supplement (suppl), and Festschrift (festschrift). Corrections are cited with the articles to which they refer and under the heading Corrections in the Subject Index.

Author Index

A

Aaronson S see Bear D

Abrahamson D: On an engaging patient with paranoid schizophrenia (letter). Au 1178

Adès J see Lejoyeux M

Adityanjee see Newman M

Adler D see Piazza LA

Agam G see Shimon H

Agelink MW, Zitzelsberger A, Klieser E: Withdrawal syndrome after discontinuation of venlafaxine (letter). Oc 1473–1474

Ahern GL see Lane RD; Reiman EM

Akil M, Lewis DA: Cytoarchitecture of the entorhinal cortex in schizophrenia. Jy 1010–1012

Akman J: Report of the Committee of Tellers (off acts). Se 1339

Al-Adwani A: Neuroleptics and bone mineral density (letter). Au 1173

Alaghband-Rad J, Hamburger SD, Giedd JN, Frazier JA, Rapoport JL: Childhood-onset schizophrenia: biological markers in relation to clinical characteristics. Ja 64–68

Alaghband-Rad J see Jacobsen LK

Albrecht BE see Crowe RR

Albright DW see Ebeling TA

Alessi NE see Huang MP

Alexander GE, Furey ML, Grady CL, Pietrini P, Brady DR, Mentis MJ, Schapiro MB: Association of premorbid intellectual function with cerebral metabolism in Alzheimer's disease: implications for the cognitive reserve hypothesis. Fe 165–172

Alexander GE see Pietrini P

Alexoff DA see Smith GS

Alexopoulos GS, Meyers BS, Young RC, Kakuma T, Silbersweig D, Charlson M: Clinically defined vascular depression. Ap 562–565

Alexopoulos GS see Kalayam B

Ali SO see Denicoff KD

Allen AJ see Swedo SE

Allen D see Fein D

Alpert JE see Fava M

Alsobrook J see Leckman JF

Altamura AC: bk rev, RJ Hedaya: Understanding Biological Psychiatry. Au 1161–1162

Altemus M see Greenberg BD

Alterman AI see Lifrak PD

Altshuler L: bk rev, RD Broadwell (ed): Neuroscience, Memory, and Language: Papers Presented at a Symposium Series Cosponsored by the National Institute of Mental Health and the Library of Congress. My 705–706

Amador X see Brébion G; Tremeau F

Amador XF see Ieronimo C

American Board of Psychiatry and Neurology, Inc: 1996–1997 annual report of the American Board of Psychiatry and Neurology, Inc (off acts). Au 1181–1183

American Board of Psychiatry and Neurology, Inc: Report on the 1996 examinations (off acts). Au 1184–1194

American Journal of Psychiatry: Reviewers for *The American Journal of Psychiatry* (in appreciation). Ja 140–142

American Psychiatric Association: Practice guideline for the treatment of patients with Alzheimer's disease and other dementias of late life. My suppl (correction: Au 1180)

American Psychiatric Association: Practice guideline for the treatment of patients with schizophrenia. Ap suppl (letters: Dickson; Liberman; reply of Herz, De 1792–1794)

American Psychiatric Association Council on Psychiatry and Law: Position statement on discrimination against persons with previous psychiatric treatment (off acts). Jy 1042

Ames D see Green MF

Amstein M see Hebebrand J

Amsterdam JD, Fawcett J, Quitkin FM, Reimherr FW, Rosenbaum JF, Michelson D, Hornig-Rohan M, Beasley CM: Fluoxetine and norfluoxetine plasma concentrations in major depression: a multicenter study. Jy 963–969

Anand A see Barr LC; Berman RM

Ancill RJ see Talbott JA

Anderson G see Stein MB

Andreasen NC: Festschrift in honor of Melvin Sabshin, MD—Medical Director, American Psychiatric Association, 1974–1997 (festschrift). Je suppl 1

Andreasen NC: Melvin Sabshin: integrator, innovator, and master of metaphor (festschrift). Je suppl 3–5

Andreasen NC: The state of the *Journal* (editorial). Ja 1–2

Andreasen NC: What is psychiatry? (editorial). My 591–593

Andreasen NC see Nopoulos P; Paradiso S

Andreason PJ see Marangell LB

Angrist B see Volkow ND

Antony MM, Brown TA, Barlow DH: Response to hyperventilation and 5.5% CO_2 inhalation of subjects with types of specific phobia, panic disorder, or no mental disorder. Au 1089–1095

Appelbaum PS: Ethics in evolution: the incompatibility of clinical and forensic functions (editorial). Ap 445–446

Appelbaum PS: reply to R Slovenko, E Tanay: Reviewing a review (letter). Fe 295–296
Apter A see Zohar AH
Arai H see Higuchi S
Arfken CL: Self-reported life satisfaction (letter). Oc 1478
Armstrong SC, Schweitzer SM: Delirium associated with paroxetine and benztropine combination (letter). Ap 581–582
Arndt S see Piven J
Arnold SE see Moberg PJ
Aronowitz B see Hollander E
Arranz MJ see Gutiérrez B
Arseneault L see Vitaro F
Asarnow RF see Subotnik KL
Åsberg M see Mårtensson B
Asch DA see Kraft MK
Atkinson M: reply to CL Arfken, BM Rohland: Self-reported life satisfaction (letter). Oc 1479
Atkinson M, Zibin S, Chuang H: Characterizing quality of life among patients with chronic mental illness: a critical examination of the self-report methodology. Ja 99–105 (letters: Arfken; Rohland; reply of Atkinson, Oc 1478–1479)
Avissar S, Nechamkin Y, Roitman G, Schreiber G: Reduced G protein functions and immunoreactive levels in mononuclear leukocytes of patients with depression. Fe 211–217
Aylward E see Frangou S
Ayoub EM see Murphy TK

B

Baer L see Jenike MA
Bailey J see Piven J
Bailey MES see Crowe RR
Baldessarini RJ, Hegarty JD, Bird ED, Benes FM: Meta-analysis of postmortem studies of Alzheimer's disease-like neuropathology in schizophrenia. Je 861–863 (correction: Au 1180)
Baldessarini RJ, Tondo L, Floris G, Rudas N: Reduced morbidity after gradual discontinuation of lithium treatment for bipolar I and II disorders: a replication study. Ap 551–553
Baldessarini RJ see Tondo L
Ball S, Shekhar A: Basilar artery response to hyperventilation in panic disorder. No 1603–1604
Ballenger JC see Brawman-Mintzer O; Hollifield M
Balon R: bk rev, CM Mazure (ed): Does Stress Cause Psychiatric Illness? No 1617
Balon R: Italian psychiatric reform (letter). Oc 1485
Balon R, Mufti R: *Tarasoff* ruling and reporting to the authorities (letter). Se 1321
Balon R, Mufti R, Williams M, Riba M: Possible discrimination in recruitment of psychiatry residents? No 1608–1609
Banner L see Brodie HKH
Barkley RA: Advancing age, declining ADHD (letter). Se 1323–1324
Barlow DH see Antony MM; Shear MK
Barocka A see Neumeister A
Barr LC, Goodman WK, Anand A, McDougle CJ, Price LH: Addition of desipramine to serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder. Se 1293–1295
Barta P see Frangou S
Barta PE, Pearlson GD, Brill LB II, Royall R, McGilchrist IK, Pulver AE, Powers RE, Casanova MF, Tien AY, Frangou S, Petty RG: Planum temporale asymmetry reversal in schizophrenia: replication and relationship to gray matter abnormalities. My 661–667
Bartfai A see Mårtensson B
Batres A see Litz BT
Bear D, Jacobson G, Aaronson S, Hanson A: Telemedicine in psychiatry: making the dream reality (letter). Je 884–885
Beardslee WR, Salt P, Versage EM, Gladstone TRG, Wright EJ, Rothberg PC: Sustained change in parents receiving preventive interventions for families with depression. Ap 510–515
Beasley CM see Amsterdam JD
Beasley CM Jr see Tollefson GD
Beauford JE, McNiel DE, Binder RL: Utility of the initial therapeutic alliance in evaluating psychiatric patients' risk of violence. Se 1272–1276
Bebchuk W see Clemens NA
Becker DF see Grilo CM
Beckmann H see Stöber G
Beer DA see Eisen JL
Beery LC see Prigerson HG
Begley A see Reynolds CF III
Beiser M, Hyman I: Refugees' time perspective and mental health. Jy 996–1002
Beitman BD see Clemens NA
Belanoff J see DeBattista C
Bellodi L see Perna G
Belmaker RH see Shimon H
Belsare TJ, Gaffney GR, Black DW: Compulsive computer use (letter). Fe 289
Benes FM: bk rev, GW Roberts, JM Polak (eds): Molecular Neuropathology. My 706
Benes FM see Baldessarini RJ
Benjamin J see Greenberg BD
Benkelfat C see George DT
Berber MJ: Panic mnemonic (letter). Mr 438
Berent I, Carabeth J, Cordero MM, Cordero R, Sugarman B, Robinson D: Pancreatitis associated with risperidone treatment? (letter). Ja 130–131
Berger M, Vollman J, König A, Lohner H, Voderholzer U, Riemann D: Sleep deprivation combined with consecutive sleep phase advance as a fast-acting therapy in depression: an open pilot trial in medicated and unmedicated patients. Je 870–872
Berglund PA see Kessler RC
Bergman A see Lees Roitman SE
Bergman M see Schuckit MA
Bergström K see Tiihonen J
Berkman A see Susser E
Berman RM, Charney DS: reply to MT Isaac: Pindolol-paroxetine combination (letter). De 1790–1791
Berman RM, Darnell AM, Miller HL, Anand A, Charney DS: Effect of pindolol in hastening response to fluoxetine in the treatment of major depression: a double-blind, placebo-controlled trial. Ja 37–43 (letter: Isaac, reply of Berman, De 1790–1791)
Berquin PC see Jacobsen LK
Berrios GE: bk rev, HS Kirshner (ed): Handbook of Neurological Speech and Language Disorders. Ja 126
Bertranpetit J see Gutiérrez B
Bhatara VS, Sharma JN, Gupta S, Gupta YK: *Rauwolfia serpentina*: the first herbal antipsychotic (image, psych). Jy 894
Bieber MR: bk rev, PS Links (ed): Clinical Assessment and Management of Severe Personality Disorders. Fe 283
Bieber MR: bk rev, RT Woods (ed): Handbook of the Clinical Psychology of Aging. Se 1310
Biederman J see Milberger S
Bierhals AJ see Prigerson HG
Biggart E see Stein SL
Biggs F see Warnock JK
Bilder RM: bk rev, N Brunello, G Racagni, SZ Langer, J Mendlewicz (eds): International Academy for Biomedical and Drug Research, vol 10: Critical Issues in the Treatment of Schizophrenia. Se 1312
Bilker W see Moberg PJ
Binder LM, Rohling ML: reply to EJ Roskes; M Tyndel: Taking care of money matters (letter). Ja 135–136
Binder M see Zohar AH
Binder RL see Beauford JE
Bird ED see Baldessarini RJ
Birkett DP: Lewy bodies (letter). Se 1323
Bisaga A, Gianelli P, Popik P: Opiate withdrawal with dextromethorphan (letter). Ap 584
Bissette G see Sharma RP
Bixler E see Nowell PD
Black DW: bk rev, JM Oldham, E Hollander, AE Skodol (eds): Impulsivity and Compulsivity. Ja 127
Black DW, Gabel J, Schlosser S: Urge to splurge (letter). No 1629–1630
Black DW, Kehrberg LLD, Flumerfelt DL, Schlosser SS: Characteristics of 36 subjects reporting compulsive sexual behavior. Fe 243–249 (letter: Kafka, No 1632)
Black DW see Belsare TJ
Blanchard R, Bogaert AF: reply to JL Eiberson; JT Martin; WJ Turner: Homosexuality and older brothers (letter). Ja 137
Blank A Jr see Engdahl B
Blankfeld H see Lauriello J
Blazer DG: reply to MW Kahn: On the new clinical case conferences (letter). Ja 134
Blazer DG see Krishnan KRR
Blinder BJ see Clemens NA
Blitzstein SM, Brandt GT: Extrapyramidal symptoms from intravenous haloperidol in the treatment of delirium (letter). Oc 1474–1475
Bloch DA see Terr LC
Bloch M, Schmidt PJ, Rubinow DR: Premenstrual syndrome: evidence for symptom stability across cycles. De 1741–1746
Bloom JD see Ganzini L
Blume S: bk rev, Group for the Advancement of Psychiatry Committee on Cultural Psychiatry: Alcoholism in the United States: Racial and Ethnic Considerations. Se 1313–1314
Blyler CR see Fenton WS
Boardman J see Leckman JF
Bodick N see Satlin A
Boehnlein JK see Hamilton NG
Bogaert AF see Blanchard R

Boland R: HIV and depression (letter). No 1632–1633
Boles Ponto LL see Paradiso S
Bolton S see Gunderson JG
Bonanno GA see Horowitz MJ
Bondi C see Leckman JF
Bonnet D, Chabrol H: Visual perception in medicated schizophrenic patients (letter). Ap 585
Boppana V see Rifkin A
Borden EK see Mittmann N
Borenstein DB: Highlights of the 1997 annual meeting (off acts). Oc 1487–1492
Borenstein DB: Report of the Secretary (off acts). Se 1330–1331
Boronow J, Stoline A, Sharfstein SS: Refusal of ECT by a patient with recurrent depression, psychosis, and catatonia (case conf). Se 1285–1291
Borus JS see Fava M
Bottiglieri T see Fava M
Bouman WP, Johnson H, Trescoli-Serrano C, Jones RG: Recurrent hyponatremia associated with sertraline and lofepramine (letter). Ap 580
Bourgeois ML, Geraud M: Jules Baillarger, 1809–1891 (image, psych). Fe 262
Bourne ML see Sax KW
Boutin P see Roy M-A
Bouwer C, Stein DJ: Association of panic disorder with a history of traumatic suffocation. No 1566–1570
Bouwer C see Stein DJ
Bouwer CD, Stein DJ, Hawkridge SM: Exacerbation of respiratory symptoms in patients with panic disorder (letter). My 712–713
Bovet P see Verdoux H
Bowen T see Guy C
Braccia G see DeMaria PA Jr
Bradwejn J see Brawman-Mintzer O
Brady DR see Alexander GE; Jacobsen LK
Brammer M see Woodruff PWR
Brandt GT see Blitzstein SM
Brawman-Mintzer O, Lydiard RB, Bradwejn J, Villarreal G, Knapp R, Emmanuel N, Ware MR, He Q, Ballenger JC: Effects of the cholecystokinin agonist pentagastrin in patients with generalized anxiety disorder. My 700–702
Brébion G, Smith MJ, Amador X, Malaspina D, Gorman JM: Clinical correlates of memory in schizophrenia: differential links between depression, positive and negative symptoms, and two types of memory impairment. No 1538–1543
Breier A, Malhotra AK, Pinals DA, Weisenfeld NI, Pickar D: Association of ketamine-induced psychosis with focal activation of the prefrontal cortex in healthy volunteers. Je 805–811
Breier A see Buchanan RW; Lafargue T
Breitbart W, Rosenfeld BD, Passik SD: reply to HM Chochinov: Assisted suicide for HIV patients (letter). Fe 294–295
Bremner JD, Licinio J, Darnell A, Krystal JH, Owens MJ, Southwick SM, Nemeroff CB, Charney DS: Elevated CSF corticotropin-releasing factor concentrations in posttraumatic stress disorder. My 624–629
Brené S see Jönsson EG
Brennan P see Raine A
Brennan PA, Raine A, Schulsinger F, Kirkegaard-Sorensen L, Knop J, Hutchings B, Rosenberg R, Mednick SA: Psychophysiological protective factors for male subjects at high risk for criminal behavior. Je 853–855
Brieger P, Marneros A: Comorbidity between personality and dysthymic disorders: historical and conceptual issues (letter). Jy 1039
Brill LB II see Barta PE
Briskin JK, Curtis JL: Augmentation of clozapine therapy with ondansetron (letter). Au 1171
Brodie HKH, Banner L: Normatology: a review and commentary with reference to abortion and physician-assisted suicide (festschrift). Je suppl 13–19
Brodie JD see Smith GS
Brodkin KI see Elrod R
Brodsky A see Strasburger LH
Brodsky BS, Dulit RA: reply to J Paris: Dissociation in patients with borderline personality disorder (letter). Ja 138
Brodsky BS, Malone KM, Ellis SP, Dulit RA, Mann JJ: Characteristics of borderline personality disorder associated with suicidal behavior. De 1715–1719
Bromet E see Susser E
Brown GM: Reduced serotonin responsivity in depression (letter). Mr 442
Brown TA see Antony MM; Shear MK
Brown WA: Grete Bibring, MD, 1899–1977 (image, psych). Se 1292
Browner WS see Zatzick DF
Bruce TJ see Spiegel DA
Bryan AL see Denicoff KD
Buchanan RW, Strauss ME, Breier A, Kirkpatrick B, Carpenter WT Jr: Attentional impairments in deficit and nondeficit forms of schizophrenia. Mr 363–370
Buchanan RW see Bustillo JR
Buchsbaum MS see Haznedar MM
Buka SL see Deykin EY
Bullmore ET see Woodruff PWR
Bunker WW see Lovell RW
Bunney WE Jr see Haznedar MM
Burger FL: Durkin versus Durbin (letter). Se 1325
Burke WJ: bk rev, EW Busse, DG Blazer (eds): The American Psychiatric Press Textbook of Geriatric Psychiatry, 2nd ed. Se 1310–1311
Busatto GF, Pilowsky LS, Costa DC, Ell PJ, David AS, Lucey JV, Kerwin RW: Correlation between reduced in vivo benzodiazepine receptor binding and severity of psychotic symptoms in schizophrenia. Ja 56–63 (correction: My 722) (letter: Verhoeff, reply of Busatto, Oc 1480)
Busatto GF, Pilowsky LS, Kerwin RW, Ell PJ: reply to NPLG Verhoeff: Benzodiazepine receptor binding and schizophrenia (letter). Oc 1480
Busch FN, MacKinnon RA: Psychotherapy's role in psychiatry (letter). Oc 1481–1482
Bustillo JR, Thaker G, Buchanan RW, Moran M, Kirkpatrick B, Carpenter WT Jr: Visual information-processing impairments in deficit and nondeficit schizophrenia. My 647–654
Buttolph ML see Jenike MA
Buysse DJ see Nowell PD; Reynolds CF III; Thase ME
Byerly MJ see Dodt JE

C

Callahan AM see Marangell LB
Calsyn RJ see Wolff N
Camargo CA Jr see Carlat DJ
Cannon M, Jones P, Gilvarry C, Rifkin L, McKenzie K, Foerster A, Murray RM: Premorbid social functioning in schizophrenia and bipolar disorder: similarities and differences. No 1544–1550
Carabeth J see Berent I
Cardasis W, Hochman JA, Silk KR: Transitional objects and borderline personality disorder. Fe 250–255 (letter: LaPorta, Oc 1484–1485)
Carlat DJ, Camargo CA Jr, Herzog DB: Eating disorders in males: a report on 135 patients. Au 1127–1132
Carlson GA see Gartner J
Carney C: bk rev, DP Moore, JW Jefferson: Handbook of Medical Psychiatry. Oc 1469
Carpenter WT Jr see Buchanan RW; Bustillo JR; Conley RR
Carr J see Stein DJ
Carroll BJ see Cassidy F
Carson SW see Sallee FR
Carter CS, Mintun M, Nichols T, Cohen JD: Anterior cingulate gyrus dysfunction and selective attention deficits in schizophrenia: $[^{15}O]H_2O$ PET study during single-trial Stroop task performance. De 1670–1675
Carter D see Maskall DD
Carter M see Hogarty GE
Casanova MF see Barta PE
Cassano GB, Michelini S, Shear MK, Coli E, Maser JD, Frank E: The panic-agoraphobic spectrum: a descriptive approach to the assessment and treatment of subtle symptoms (festschrift). Je suppl 27–38
Cassidy F, Murry E, Weiner RD, Carroll BJ: Lack of relapse with tryptophan depletion following successful treatment with ECT. Au 1151–1152
Chabrol H: Abandonment and intrusion fears in borderline personality disorder (letter). Se 1329
Chabrol H, Peresson G: ADHD and maternal smoking during pregnancy (letter). Au 1177
Chabrol H see Bonnet D
Chacko RC, Harper RG, Gotto J, Young J: reply to PA Shapiro: Compliance complications in cardiac patients (letter). No 1627–1628
Chalder T see Deale A
Chandragiri SS: ECT response in medication-resistant patients (letter). My 721–722
Chapman F see Swedo SE
Chapman T see Hollifield M
Charlson M see Alexopoulos GS
Charney D see Johnson DR
Charney DS see Berman RM; Bremner JD; Southwick SM
Charron L see Roy M-A
Chemtob CM, Tomas S, Law W, Cremniter D: Postdisaster psychosocial intervention: a field study of the impact of debriefing on psychological distress. Mr 415–417
Chen G see Mitchell PB
Chen K see Reiman EM
Cherry CR see Thase ME
Chessick RD: bk rev, GO Gabbard, EP Lester:

Boundaries and Boundary Violations in Psychoanalysis. Ap 573–576
Chessick RD: bk rev, L Horwitz, GO Gabbard, JG Allen, SH Frieswyk, DB Colson, GE Newsom, L Coyne: Borderline Personality Disorder: Tailoring the Psychotherapy to the Patient. Fe 281–283
Chessick RD: bk rev, AM Siegel: Heinz Kohut and the Psychology of the Self. Au 1165–1166
Chester B see Robin RW
Chhetri M see Gill DS
Childress D see Piven J
Chochinov HM, Wilson KG: Assisted suicide for HIV patients (letter). Fe 294
Chochinov HM, Wilson KG, Enns M, Lander S: "Are you depressed?" screening for depression in the terminally ill. My 674–676
Chodoff P: bk rev, B Milrod, F Busch, A Cooper, T Shapiro (eds): Manual of Panic-Focused Psychodynamic Psychotherapy. Au 1166–1167
Chodoff P: Turkish dissociative identity disorder (letter). Au 1179
Christensen JD see Moore CM
Christensen RC see Dodt JE
Christenson GA see O'Sullivan RL
Chuang H see Atkinson M
Claffey E see Guy C
Clark CH, Schocket LS, Turner EH, Rosenthal NE: Light visor maintenance of light box response (letter). Au 1172
Clark HW see Weinstock R
Clemens NA, Bebchuk W, Beitman BD, Blinder BJ, Gabbard GO, Goin MK, Hughes MC, Kay J, Kimmich RA, Lazar SG, Reiss D, Szigethy EM, Tasman A: Disputing psychiatry's redefinition (letter). No 1633–1634
Clemons J, Jasser MZ, Noble G, Monahan BP: Gaucher's disease initially diagnosed as depression (letter). Fe 290
Cliche D see Roy M-A
Clipp EC see Elder GH Jr
Coble JR see North MM
Coccaro EF, Kavoussi RJ, Cooper TB, Hauger RL: Central serotonin activity and aggression: inverse relationship with prolactin response to *d*-fenfluramine, but not CSF 5-HIAA concentration, in human subjects. Oc 1430–1435
Cocchi S see Perna G
Cohen B see Kasper JA
Cohen DJ see Leckman JF; Zohar AH
Cohen JD see Carter CS
Cohn CK: Genetic risk factors for bipolar disorder (letter). Oc 1484
Cola PA see Meltzer HY
Cole R see Papp LA
Coli E see Cassano GB
Collins DJ see Kmetz GF
Colson P see Susser E
Compton AD see Ebeling TA
Conley RR, Carpenter WT Jr, Tamminga CA: Time to clozapine response in a standardized trial. Se 1243–1247
Constantino JN, Morris JA, Murphy DL: CSF 5-HIAA and family history of antisocial personality disorder in newborns. De 1771–1773
Cooley S see Hogarty GE
Cooper T see FitzGerald M; Smith GS
Cooper TB see Coccaro EF; Mann JJ
Coplan JD see Papp LA
Copolov D: New name for atypical antipsychotics? (letter). Mr 439
Coppola R see Goldberg TE
Cordero MM see Berent I
Cordero R see Berent I
Cornblatt BA see Lees Roitman SE
Cornelius JR see Salloum IM
Cornes CL see Reynolds CF III; Thase ME
Cortina J see Kasper JA
Corwin F see Deicken RF
Costa DC see Busatto GF
Covey LS, Glassman AH, Stetner F: Major depression following smoking cessation. Fe 263–265
Craddock B, Craddock N: Contractures in neuroleptic malignant syndrome (letter). Mr 436
Craddock N see Craddock B; Guy C
Crawford M see Emmanuel NP
Crawshaw RS see Hamilton NG
Cremniter D see Chemtob CM
Cronquist S see McCurry L
Crosby RD see Meller WH
Crow TJ: bk rev, SJ Watson (ed): Biology of Schizophrenia and Affective Disease. Ap 572–573
Crowe RR, Wang Z, Noyes R Jr, Albrecht BE, Darlison MG, Bailey MES, Johnson KJ, Zoëga T: Candidate gene study of eight $GABA_A$ receptor subunits in panic disorder. Au 1096–1100
Csábi G see Trixler M
Cuadros C see Dodt JE
Cullum CM see Weiner MF
Curran S, Wrigley M: Lewy bodies (letter). Se 1322–1323
Curtis JL see Briskin JK
Cusack JR: bk rev, F McCourt: Angela's Ashes: A Memoir. De 1774–1775

D

Dager SR see Strauss WL
Daghestani AN: al-Razi (Rhazes), 865–925 (image, psych). No 1602
Dalal M see Murphy TK
Daley DC see Salloum IM
Dalkilic A, Grosch WN: Neuroleptic malignant syndrome following initiation of clozapine therapy (letter). Je 881–882
Dalton B see Rosebush PI
Dani A see Pietrini P
Daniel DG see Zimbroff DL
Daniels JK see Guy C
Danielson AL see George MS
Dannals RF see Schlaepfer TE
Darlison MG see Crowe RR
Darnell A see Bremner JD
Darnell AM see Berman RM
DaSilva JD see Kapur S
David AS see Busatto GF; Woodruff PWR
Davidson J see Kocsis JH; Rampes H
Davidson M see Harvey PD
Davidson RJ see Lane RD; Paradiso S; Reiman EM
Davis JM see Nelson JC
Davis KL see Harvey PD
Day N see Prigerson HG
Deale A, Chalder T, Marks I, Wessely S: Cognitive behavior therapy for chronic fatigue syndrome: a randomized controlled trial. Mr 408–414
de Arellano MA see Frueh BC
Deas-Nesmith D see Sallee FR
DeBattista C, Solvason HB, Belanoff J, Schatzberg AF: Treatment of psychotic depression (letter). No 1625–1626
DeCaria CM see Hollander E
Deicken RF, Zhou L, Corwin F, Vinogradov S, Weiner MW: Decreased left frontal lobe *N*-acetylaspartate in schizophrenia. My 688–690
de Jesus MJ see Papp LA
Delgado PL see Moreno FA
Delgiudice-Asch G see Hollander E
Del Mastio M see Faravelli C
DeMaria PA Jr, Rodgers C, Braccia G: Propofol for sedation during rapid opiate detoxification (letter). Fe 290–291
de Marneffe F: McLean Hospital (image, psych). Ja 109
DeMent S see Lauriello J
Denicoff K see Mitchell PB
Denicoff KD, Smith-Jackson EE, Bryan AL, Ali SO, Post RM: Valproate prophylaxis in a prospective clinical trial of refractory bipolar disorder. Oc 1456–1458
Denton DD Jr: Inpatient treatment of combat veterans (letter). Jy 1038
Deter H-C see Hebebrand J
DeVane CL: Rethinking treatment terminology (letter). My 717
DeVane CL, Markowitz JS, Hardesty SJ, Mundy S, Gill HS: Fluvoxamine-induced theophylline toxicity (letter). Se 1317–1318
DeVane CL see Markowitz JS
Devlin MJ see Walsh BT
Dew MA see Reynolds CF III
Dewey SL see Smith GS
Deykin EY, Buka SL: Prevalence and risk factors for posttraumatic stress disorder among chemically dependent adolescents. Je 752–757
Dhossche D, Rubinstein J: Homicidal behavior in drug abusing psychiatric patients (letter). Je 888–889
Dhossche D, Rubinstein J: Violence and cocaine (letter). Oc 1480–1481
DiBarry AL see Hogarty GE
Dicker R see Rifkin A
Dickson RA, Edwards A: Clozapine and fertility (letter). Ap 582–583
Dickson RA, Seeman MV: Schizophrenia practice guideline (letter). De 1792
Diehl DJ see Mann JJ
DiFiglia M: Clinical genetics, II: Huntington's disease: from the gene to pathophysiology (image, neuro). Au 1046
DiGiacomo L see Elrod R
Dikel TN see Engdahl B
Di Matteo C see Faravelli C
Dinnen AH: Physical health and negative life events (letter). Ja 138
Dion C see Roy M-A
Dixon L, McNary S, Lehman A: One-year follow-up of secondary versus primary mental disorder in persons with comorbid substance use disorders. No 1610–1612
Dixon L, Weiden P, Torres M, Lehman A: Assertive community treatment and medication compliance in the homeless mentally ill. Se 1302–1304
Dobscha SK: Physician-assisted suicide and abortion (letter). Au 1173–1174
Dodt JE, Byerly MJ, Cuadros C, Christensen

RC: Treatment of risperidone-induced obsessive-compulsive symptoms with sertraline (letter). Ap 582
Donohue BC see Jacobsen LK
Dooneief G see Schofield PW
Doty RL see Moberg PJ
Dow SP see Swedo SE
Downhill JE see Paradiso S
Downs NS, McCahill ME: Psychiatry's future (letter). Se 1325–1326
Dubin H, Spier S, Giannandrea P: Nefazodone-induced mania (letter). Ap 578–579
Dufeu P see Schmidt LG
Dukoff R, Sunderland T: Durable power of attorney and informed consent with Alzheimer's disease patients: a clinical study. Au 1070–1075
Dulit RA see Brodsky BS
Duman RS, Nestler EJ: Molecular biology, III: tracking DNA: the Southern blot (image, neuro). Ja 3
Duman RS see Malison RT
Dunn M see Fein D
Dunner DL: bk rev, GO Gabbard, SD Atkinson (eds): Synopsis of Treatments of Psychiatric Disorders, 2nd ed; SD Atkinson, GO Gabbard (eds): Study Guide to Treatments of Psychiatric Disorders, 2nd ed. Oc 1467
Dunner DL: bk rev, RM Rapee (ed): Current Controversies in the Anxiety Disorders. Ja 128
Durant NA: bk rev, M McGoldrick, J Giordano, JK Pearce (eds): Ethnicity and Family Therapy, 2nd ed. Oc 1470–1471
Duyme M see Tordjman S
Dycian A see Zohar AH

E

Eagles JM see Verdoux H
Early J see Sheitman BB
Ebeling TA, Compton AD, Albright DW: Clozapine-induced stuttering (letter). Oc 1473
Eberly R see Engdahl B
Eckardt MJ see George DT
Edell WS see Grilo CM
Ednie K see Lewis CF
Edwards A see Dickson RA
Edwards PJ see Hamilton NG
Ehlers CL see Garcia-Andrade C
Ehlich P see Litz BT
Ehlich PJ, Roemer L, Litz BT: PTSD after a peacekeeping mission (letter). Se 1319–1320
Eiberg H see von Gontard A
Eiberson JL: Homosexuality and older brothers (letter). Ja 136
Eisen JL, Beer DA, Pato MT, Venditto TA, Rasmussen SA: Obsessive-compulsive disorder in patients with schizophrenia or schizoaffective disorder. Fe 271–273 (letter: Werner, reply of Eisen, No 1635–1636)
Eisen JL, Beer DA, Pato MT, Venditto TA, Rasmussen SA: reply to A Werner: Obsessive-compulsive symptoms in schizophrenia (letter). No 1635–1636
Eisenberg L: Michael Shepherd: 1923–1995 (image, psych). My 681
Eist HI: Presidential address: strengthening psychiatry's dedication and commitment to compassionate care, educational excellence, and creative research. Oc 1343–1349
Elder G see Hollander E
Elder GH Jr, Shanahan MJ, Clipp EC: Linking combat and physical health: the legacy of World War II in men's lives. Mr 330–336
Ell PJ see Busatto GF
Ellason JW, Ross CA: Two-year follow-up of inpatients with dissociative identity disorder. Je 832–839
Ellis SP see Brodsky BS
Elrod R, Peskind ER, DiGiacomo L, Brodkin KI, Veith RC, Raskind MA: Effects of Alzheimer's disease severity on cerebrospinal fluid norepinephrine concentration. Ja 25–30
Ely T see Stowe ZN
Emamghoreishi M, Schlichter L, Li PP, Parikh S, Sen J, Kamble A, Warsh JJ: High intracellular calcium concentrations in transformed lymphoblasts from subjects with bipolar I disorder. Jy 976–982
Emmanuel N see Brawman-Mintzer O
Emmanuel NP, Lydiard RB, Crawford M: Treatment of irritable bowel syndrome with fluvoxamine (letter). My 711–712
Endicott J see FitzGerald M; Trappler B
Engdahl B, Dikel TN, Eberly R, Blank A Jr: Posttraumatic stress disorder in a community group of former prisoners of war: a normative response to severe trauma. No 1576–1581
Enns M see Chochinov HM
Erdos J see Mann JJ
Esiri MM see Zaidel DW
Esler M see Lambert G
Esman AH: bk rev, JJ Schildkraut, A Otero (eds): Depression and the Spiritual in Modern Art: Homage to Miro. De 1786
Evans DL, Leserman J, Perkins DO, Stern RA, Murphy C, Zheng B, Gettes D, Longmate JA, Silva SG, van der Horst CM, Hall CD, Folds JD, Golden RN, Petitto JM: Severe life stress as a predictor of early disease progression in HIV infection. My 630–634
Evans J see Klapow JC

F

Fabbri C see Faravelli C
Fairbanks LA see Goenjian AK
Fairburn CG: Bulimia outcome (letter). De 1791
Fañanás L, Fuster C, Guillamat R, Miró R: Chromosomal fragile site 1q21 in schizophrenic patients (letter). My 716
Fañanás L see Gutiérrez B
Fancher RT: Misrepresentational review (letter). Oc 1485
Fann WE: bk rev, A-L Björling, A Farkas: Jussi. De 1785–1786
Fann WE: bk rev, B Wyatt-Brown: The House of Percy: Honor, Melancholy, and Imagination in a Southern Family. De 1778–1779
Faraone SV see Milberger S; Toomey R
Faravelli C, Marinoni M, Spiti R, Ginanneschi A, Serena A, Fabbri C, Di Matteo C, Del Mastio M, Inzitari D: Abnormal brain hemodynamic responses during passive orthostatic challenge in panic disorder. Mr 378–383
Farber L see Leon AC; Olfson M
Farren CK, O'Malley S: Sequential use of naltrexone in the treatment of relapsing alcoholism (letter). My 714
Faustman WO see Lauriello J
Fava M, Borus JS, Alpert JE, Nierenberg AA, Rosenbaum JF, Bottiglieri T: Folate, vitamin B_{12}, and homocysteine in major depressive disorder. Mr 426–428
Fava M, Mulroy R, Alpert J, Nierenberg AA, Rosenbaum JF: Emergence of adverse events following discontinuation of treatment with extended-release venlafaxine. De 1760–1762
Fava M see Moore CM
Favazza AR: bk rev, CF Sargent, TM Johnson (eds): Handbook of Medical Anthropology: Contemporary Theory and Method, revised ed. Oc 1471
Fawcett J see Amsterdam JD
Fein D, Allen D, Dunn M, Feinstein C, Green L, Morris R, Rapin I, Waterhouse L: Pitocin induction and autism (letter). Mr 438–439
Feiner NF: Borderline personality and bipolar disorder (letter). Au 1175–1176
Feinstein C see Fein D
Feldman MD: Canine variant of factitious disorder by proxy (letter). Se 1316–1317
Fenn DS see Ganzini L
Fennig S see Susser E
Fenton WS: bk rev, M Aveline, DA Shapiro (eds): Research Foundations for Psychotherapy Practice. Au 1164–1165
Fenton WS, McGlashan TH: We can talk: individual psychotherapy for schizophrenia (editorial). No 1493–1495
Fenton WS, McGlashan TH, Victor BJ, Blyler CR: Symptoms, subtype, and suicidality in patients with schizophrenia spectrum disorders. Fe 199–204
Fenzel T see Pollmächer T
Ferrari P see Tordjman S
Feucht-Haviar T see Kasper JA
Fields R: The Council on Psychiatric Services (off acts). Fe 303–304
Findling RL see Kenny JT; Meltzer HY; Wisner KL
Fintzy RT: bk rev, FR Volkmar (ed): Psychoses and Pervasive Developmental Disorders in Childhood and Adolescence. Jy 1031–1032
Fioritti A, Lo Russo L, Melega V: Reform said or done? the case of Emilia-Romagna within the Italian psychiatric context. Ja 94–98 (letters: Balon; Pergami; reply of Fioritti, Oc 1485–1486)
Fioritti A, Lo Russo L, Melega V: reply to R Balon, A Pergami: Italian psychiatric reform (letter). Oc 1486
Fireman B see Olfson M
FitzGerald M, Malone KM, Li S, Harrison WM, McBride PA, Endicott J, Cooper T, Mann JJ: Blunted serotonin response to fenfluramine challenge in premenstrual dysphoric disorder. Ap 556–558
Fitz-Gerald MJ see Pinkofsky HB
Flaum M see Nopoulos P
Flegenheimer WV: Creativity in psychodynamic psychotherapy (letter). My 721
Fleischhacker WW see Kurzthaler I
Fleiss J see Walsh BT
Flesher S see Hogarty GE
Floris G see Baldessarini RJ; Tondo L

Flumerfelt DL see Black DW
Foerster A see Cannon M
Fogelson DL: Fenfluramine and the cytochrome P450 system (letter). Mr 436–437
Fogelson DL see Subotnik KL
Folds JD see Evans DL
Fontana A, Rosenheck R: Effectiveness and cost of the inpatient treatment of posttraumatic stress disorder: comparison of three models of treatment. Je 758–765
Fontana A see Johnson DR
Foray AT see Shapiro PA
Forde DR see Stein MB
Forrest DV: bk rev, J Horgan: The End of Science: Facing the Limits of Science in the Twilight of the Scientific Age. Je 873–874
Forrest DV: bk rev, A Kleinman: Writing at the Margin: Discourse Between Anthropology and Medicine. De 1781–1782
Foster CL see Kessler RC
Fournier J-P see Roy M-A
Fowler JS see Volkow ND
Frangou S, Aylward E, Warren A, Sharma T, Barta P, Pearlson G: Small planum temporale volume in Down's syndrome: a volumetric MRI study. Oc 1424–1429
Frangou S see Barta PE
Frank E see Cassano GB; Prigerson HG; Reynolds CF III; Thase ME
Frankel FH: Hypnotizability used for diagnostic confirmation? (letter). Ap 587
Frankenburg FR see Zanarini MC
Franzek E see Stöber G
Fras I: bk rev, R Gemelli: Normal Child and Adolescent Development. Se 1309
Frazier JA see Alaghband-Rad J
Frazier JA see Jacobsen LK
French O: Consistency of traumatic memories (letter). No 1628–1629
Freo U see Pietrini P
Friedman L see Kenny JT
Friedman M see Litz BT
Friston KJ see Reiman EM
Frosch WA: bk rev, H Lee: Virginia Woolf. De 1775–1776
Frueh BC, de Arellano MA, Turner SM: Systematic desensitization as an alternative exposure strategy for PTSD (letter). Fe 287–288
Fudge MW see Murphy TK
Fullilove MT: bk rev, JM Taylor, C Gilligan, AM Sullivan: Between Voice and Silence: Women and Girls, Race and Relationship. Ap 571
Fullilove MT: reply to CO Toppelberg: Biopsychosocial model (letter). Se 1328–1329
Fullilove MT see Panzer PG
Fulton MK, Petty F: reply to G Lambert: Origin of homovanillic acid in plasma (letter). Ja 139
Furey ML see Alexander GE; Pietrini P
Fuster C see Fañanás L
Fyer AJ see Hollifield M

G

Gabbard GO: bk rev, RD Chessick: Dialogue Concerning Contemporary Psychodynamic Therapy. Jy 1035–1036
Gabbard GO: bk rev, U Hegi: Stones From the River. De 1776–1777
Gabbard GO: Finding the "person" in personality disorders (editorial). Jy 891–893
Gabbard GO: The Menninger Hospital (image, psych). Je 852
Gabbard GO, Lazar SG, Hornberger J, Spiegel D: The economic impact of psychotherapy: a review. Fe 147–155
Gabbard GO see Clemens NA
Gabel J see Black DW
Gaffney GR see Belsare TJ
Gallenga PE, Lobefalo L, Mastropasqua L, Liberatoscioli A: Photic maculopathy in a patient receiving bright light therapy (letter). Se 1319
Galletly C: Borderline-dissociation comorbidity (letter). No 1629
Ganzini L, Fenn DS, Lee MA, Heintz RT, Bloom JD: reply to NG Hamilton, PA Goodwin: Physician-assisted suicide in Oregon (letter). Se 1327–1328
Gao X-M see Nestler EJ
Garbutt JC see Kampov-Polevoy A
Garcia-Andrade C, Wall TL, Ehlers CL: The firewater myth and response to alcohol in Mission Indians. Jy 983–988
Gardner CO see Kendler KS
Garneau Y see Roy M-A
Gartner J, Weintraub S, Carlson GA: Childhood-onset psychosis: evolution and comorbidity (case conf). Fe 256–261
Geddes JR see Verdoux H
Gelernter J see Mann JJ
Gelman I see Shapiro PA
Genova P: bk rev, L Sperry, PL Brill, KI Howard, GR Grissom: Treatment Outcomes in Psychotherapy and Psychiatric Interventions. Jy 1036
George DT, Benkelfat C, Rawlings RR, Eckardt MJ, Phillips MJ, Nutt DJ, Wynne D, Murphy DL, Linnoila M: Behavioral and neuroendocrine responses to *m*-chlorphenylpiperazine in subtypes of alcoholics and in healthy comparison subjects. Ja 81–87
George LK see Koenig HG
George MS, Wasserman EM, Kimbrell TA, Little JT, Williams WE, Danielson AL, Greenberg BD, Hallett M, Post RM: Mood improvement following daily left prefrontal repetitive transcranial magnetic stimulation in patients with depression: a placebo-controlled crossover trial. De 1752–1756
George MS see Greenberg BD; Marangell LB
Geraud M see Bourgeois ML
Gettes D see Evans DL
Ghadirian A-M: Bulimic purging through blood donation (letter). Mr 435–436
Gianelli P see Bisaga A
Giannandrea P see Dubin H
Giedd JN see Alaghband-Rad J; Jacobsen LK
Gill DS, Chhetri M, Milne JR: Nephrotic syndrome associated with lithium therapy (letter). Se 1318–1319
Gill HS see DeVane CL; Markowitz JS
Giller EL Jr see Yehuda R
Gilman CJ: Psychiatry's future (letter). Se 1326
Gilvarry C see Cannon M
Ginanneschi A see Faravelli C
Gitlin M see Hammen C
Gladstone TRG see Beardslee WR
Glassman AH see Covey LS
Glickman L: bk rev, M Bergener, SI Finkel (eds): Treating Alzheimer's and Other Dementias: Recent Research Advances. Je 877–878
Goenjian AK, Karayan I, Pynoos RS, Minassian D, Najarian LM, Steinberg AM, Fairbanks LA: Outcome of psychotherapy among early adolescents after trauma. Ap 536–542
Goering P see Levitan RD
Goetz R see Papp LA
Goetz RR see Rabkin JG
Goin MK see Clemens NA
Gold JH: bk rev, H Merskey (ed): The Analysis of Hysteria: Understanding Conversion and Dissociation, 2nd ed. Fe 284
Gold JM see Goldberg TE
Goldberg DP see Gureje O
Goldberg TE, Gold JM, Coppola R, Weinberger DR: Unnatural practices, unspeakable actions: a study of delayed auditory feedback in schizophrenia. Je 858–860
Golden RN see Evans DL
Golding JM see Levav I; Zatzick DF
Goldman D see Mann JJ; Robin RW
Goldman RL, Weir CR, Turner CW, Smith CB: Validity of utilization management criteria for psychiatry. Mr 349–354
Goldstein MJ see Subotnik KL
Goldstein MZ: The Council on Aging (off acts). Fe 297–298
Gonevi M see Pergami A
Good MI: Lethal interaction of clozapine and buspirone? (letter). Oc 1472–1473
Good MI: Traumatophilic diathesis, complemental series, and the original conceptual basis of PTSD (letter). Fe 296
Goodman WK see Barr LC; Leckman JF; Murphy TK
Goodwin DW: bk rev, CP Snow: The Two Cultures. De 1776
Goodwin PA: Physician-assisted suicide in Oregon (letter). Se 1327
Goodwin PJ: Breast cancer risk in psychiatric patients (letter). Ap 588
Gordon AG: Anorexia nervosa in the eighteenth century (letter). Jy 1041
Gordon B see Selnes OA
Gordon CT see Jacobsen LK
Gorman JM see Brébion G; Papp LA; Rabkin JG; Shear MK
Gottlieb F: Report of the Treasurer (off acts). Se 1331–1333
Gotto J see Chacko RC
Grady CL see Alexander GE; Pietrini P
Grady TA see Watts BV
Graffeo KA see Tollefson GD
Green AI see Patel JK
Green L see Fein D
Green MF: reply to RP Liberman: Neurocognitive deficits in schizophrenia (letter). Mr 444
Green MF, Marshall BD Jr, Wirshing WC, Ames D, Marder SR, McGurk S, Kern RS, Mintz J: Does risperidone improve verbal working memory in treatment-resistant schizophrenia? Je 799–804
Greenberg BD, George MS, Martin JD, Benjamin J, Schlaepfer TE, Altemus M, Wasserman EM, Post RM, Murphy DL: Effect of prefrontal repetitive transcranial magnetic stimulation in obsessive-compulsive disorder: a preliminary study. Je 867–869
Greenberg BD see George MS
Greenfield SF, Reizes JM, Magruder KM, Muenz LR, Kopans B, Jacobs DG: Effectiveness of community-based screening for depression. Oc 1391–1397

Greenwald D see Hogarty GE
Grice DE see Leckman JF
Griffin MG, Resick PA, Mechanic MB: Objective assessment of peritraumatic dissociation: psychophysiological indicators. Au 1081–1088
Grillon C see Morgan CA III
Grilo CM, Martino S, Walker ML, Becker DF, Edell WS, McGlashan TH: Controlled study of psychiatric comorbidity in psychiatrically hospitalized young adults with substance abuse disorders. Se 1305–1307
Grosch WN see Dalkilic A
Gross S see Simeon D
Guerrini A see Pergami A
Gugelchuk G see Martin JT
Guillamat R see Fañanás L; Gutiérrez B
Gunderson JG: reply to H Chabrol: Abandonment and intrusion fears in borderline personality disorder (letter). Se 1329
Gunderson JG, Bolton S: reply to NF Feiner, R Prakash: Borderline personality and bipolar disorder (letter). Au 1176–1177
Gupta S see Bhatara VS
Gupta YK see Bhatara VS
Gur RC see Moberg PJ
Gur RE see Moberg PJ
Guralnik O see Simeon D
Gureje O, Simon GE, Ustun TB, Goldberg DP: Somatization in cross-cultural perspective: a World Health Organization study in primary care. Jy 989–995
Gustavsson JP see Jönsson EG
Gutheil TG see Strasburger LH
Gutiérrez B, Bertranpetit J, Guillamat R, Vallès V, Arranz MJ, Kerwin R, Fañanás L: Association analysis of the catechol O-methyltransferase gene and bipolar affective disorder. Ja 113–115 (letter: Cohn, reply of Gutiérrez, Oc 1484)
Gutiérrez B, Fañanás L: reply to CK Cohn: Genetic risk factors for bipolar disorder (letter). Oc 1484
Guy C, Bowen T, Daniels JK, Speight G, McKeon P, Mynett-Johnson L, Claffey E, McGuffin P, Owen MJ, Craddock N, O'Donovan MC: Exclusion of expansion of 50 CAG/CTG trinucleotide repeats in bipolar disorder. Au 1146–1147
Guze SB: The Council on Research (off acts). Fe 305–306

H

Hadley TR see Kraft MK
Hadzi-Pavlovic D see Sachdev P
Haier RJ see Haznedar MM
Hajek P see West R
Hakko H see Tiihonen J
Halbreich U: Reply to PJ Goodwin, EF Torrey, PB Mortensen: Breast cancer risk in psychiatric patients (letter). Ap 589–590
Halbreich U see Kocsis JH
Hales RE, Zatzick DF: What is PTSD? (editorial). Fe 143–145
Hall CD see Evans DL
Hall DP Jr: Peacekeeping duty and PTSD (letter). Oc 1482–1483
Hallett M see George MS
Hamburg DA: Toward a strategy for healthy adolescent development (festschrift). Je suppl 7–12
Hamburger SD see Alaghband-Rad J; Jacobsen LK
Hamel M see Maziade M; Roy M-A
Hamilton NG, Edwards PJ, Crawshaw RS, Boehnlein JK, Toenniessen LM: Physician-assisted suicide in Oregon (letter). Se 1326–1327
Hammen C, Gitlin M: Stress reactivity in bipolar patients and its relation to prior history of disorder. Je 856–857
Hanin E: The Council on National Affairs (off acts). Fe 302–303
Hansen JJ: bk rev, DX Parmelee: Child and Adolescent Psychiatry. Je 879
Hanson A see Bear D
Hardesty SJ see DeVane CL
Harel Y see Oyffe I
Harper RG see Chacko RC
Harris MJ see Jeste DV
Harrison PJ see Zaidel DW
Harrison WM see FitzGerald M
Hartmann L: bk rev, Group for the Advancement of Psychiatry Committee on Adolescence: Adolescent Suicide: Report 140. Jy 1031
Hartmann L: Reply to HJ Schwartz: Biased book review (letter). Je 888
Hartwell N see Marzuk PM
Harvey PD, Lombardi J, Leibman M, Parrella M, White L, Powchik P, Mohs RC, Davidson M, Davis KL: Age-related differences in formal thought disorder in chronically hospitalized schizophrenic patients: a cross-sectional study across nine decades. Fe 205–210
Hasan N see Rifkin A
Hasegawa Y see Higuchi S
Haskett RF see Mulsant BH
Hauger RL see Coccaro EF
Hauri PJ see Nowell PD
Havenaar JM, Rumyantzeva GM, van den Brink W, Poelijoe NW, van den Bout J, van Engeland H, Koeter MWJ: Long-term mental health effects of the Chernobyl disaster: an epidemiologic survey in two former Soviet regions. No 1605–1607
Havens L: Harry Stack Sullivan, 1892–1949 (image, psych). Au 1145
Hawkridge S see Stein DJ
Hawkridge SM see Bouwer CD
Haxby JV see Pietrini P
Hayashida M see Higuchi S
Hayes CE see Strauss WL
Hays JC see Krishnan KRR
Hazen AL see Stein MB
Hazlett EA see Haznedar MM
Haznedar MM, Buchsbaum MS, Luu C, Hazlett EA, Siegel BV Jr, Lohr J, Wu J, Haier RJ, Bunney WE Jr: Decreased anterior cingulate gyrus metabolic rate in schizophrenia. My 682–684
Haznedar MM, Buchsbaum MS, Metzger M, Solimando A, Spiegel-Cohen J, Hollander E: Anterior cingulate gyrus volume and glucose metabolism in autistic disorder. Au 1047–1050
He Q see Brawman-Mintzer O
Heatherton TF see Joiner TE Jr
Heaton RK see Jeste DV; Klapow JC
Heaton SC see Jeste DV
Hebebrand J, Himmelmann GW, Herzog W, Herpertz-Dahlmann BM, Steinhausen H-C, Amstein M, Seidel R, Deter H-C, Remschmidt H, Schäfer H: Prediction of low body weight at long-term follow-up in acute anorexia nervosa by low body weight at referral. Ap 566–569
Hegarty JD see Baldessarini RJ
Heikkinen ME see Heilä H
Heilä H, Isometsä ET, Henriksson MM, Heikkinen ME, Marttunen MJ, Lönnqvist JK: Suicide and schizophrenia: a nationwide psychological autopsy study on age- and sex-specific clinical characteristics of 92 suicide victims with schizophrenia. Se 1235–1242
Heiman MF: bk rev, JN Sansonese: The Body of Myth: Mythology, Shamanic Trance, and the Sacred Geography of the Body. De 1782–1784
Heintz RT see Ganzini L
Heilerstein DJ see Kocsis JH
Helminiak TW see Wolff N
Hemsley DR see Russell AJ
Heninger GR see Malison RT
Henriksson MM see Heilä H
Herpertz-Dahlmann BM see Hebebrand J
Herrmann N see Mittmann N
Herscovitch P see Marangell LB
Hersh D, Kranzler HR, Meyer RE: Persistent delirium following cessation of heavy alcohol consumption: diagnostic and treatment implications (case conf). Je 846–851
Herz M, Zarin DA, McIntyre JS: reply to RA Dickson, RP Liberman: Schizophrenia practice guideline (letter). De 1793–1794
Herzog DB see Carlat DJ
Herzog W see Hebebrand J
Hesselbrock VM see Schuckit MA
Heßelmann B see Neumeister A
Heun R see Verdoux H
Hichwa RD see Paradiso S
Higgenbottam J see Talbott JA
Higuchi S, Matsushita S, Hasegawa Y, Muramatsu T, Arai H, Hayashida M: Apolipoprotein E ∈4 allele and pupillary response to tropicamide. My 694–696
Hill JC, Schoener EP: reply to RA Barkley: Advancing age, declining ADHD (letter). Se 1324–1325
Hilty DM: bk rev, E Guthrie, F Creed (eds): Seminars in Liaison Psychiatry. No 1618–1619
Himmelmann GW see Hebebrand J
Hinze-Selch D see Pollmächer T
Hirono N see Mori E
Hirsch AR: High sucrose preference in alcoholic men (letter). No 1631
Hirsch CS see Marzuk PM
Hirschowitz J, Hitzemann R, Vallabhajosula S: SPECT studies of D_2 occupancy in low-dose haloperidol treatment (letter). My 715–716
Hitzemann R see Hirschowitz J; Volkow ND
Hochman J, Pope HG Jr: Debating dissociative diagnoses (letter). Je 887–888
Hochman JA see Cardasis W
Hoehn-Saric R: Hallucinatory changes (letter). Fe 293
Hoff A see Lauriello J
Hoffman RE, McGlashan TH: Synaptic elimination, neurodevelopment, and the mechanism of hallucinated "voices" in schizophrenia. De 1683–1689
Hogarty GE, Greenwald D, Ulrich RF, Kornblith SJ, DiBarry AL, Cooley S, Carter M, Flesher S: Three-year trials of personal therapy among schizophrenic patients liv-

ing with or independent of family, II: effects on adjustment of patients. No 1514–1524
Hogarty GE, Kornblith SJ, Greenwald D, DiBarry AL, Cooley S, Ulrich RF, Carter M, Flesher S: Three-year trials of personal therapy among schizophrenic patients living with or independent of family, I: description of study and effects on relapse rates. No 1504–1513
Hoge SK: The Council on Psychiatry and Law (off acts). Fe 304–305
Hoge SK see Kasper JA
Holcomb HH see Selnes OA
Holen A see Horowitz MJ
Hollander E, Delgiudice-Asch G, Simon L, DeCaria CM, Aronowitz B, Mosovich S, Elder G: Repetitive behaviors and D8/17 positivity (letter). No 1630
Hollander E see Haznedar MM; Simeon D
Holliday S see Talbott JA
Hollifield M, Katon W, Skipper B, Chapman T, Ballenger JC, Mannuzza S, Fyer AJ: Panic disorder and quality of life: variables predictive of functional impairment. Je 766–772
Hollmann E see von Gontard A
Honig L see Weiner MF
Hornberger J see Gabbard GO
Hornig-Rohan M see Amsterdam JD
Horowitz MJ, Siegel B, Holen A, Bonanno GA, Milbrath C, Stinson CH: Diagnostic criteria for complicated grief disorder. Jy 904–910
Horton PC: bk rev, PF Ostwald, LS Zegans (eds): The Threat to the Cosmic Order: Psychological, Social, and Health Implications of Richard Wagner's Ring of the Nibelung. De 1786–1787
Horwitz B see Marangell LB; Pietrini P
Höschl C, Kožený J: Predicting academic performance of medical students: the first three years (festschrift). Je suppl 87–92
Houck PR see Nowell PD; Reynolds CF III
Houle S see Kapur S
Hoven C see Olfson M
Howard RJ see Woodruff PWR
Huang MP, Alessi NE: Reply to Stein DJ: Internet addiction, internet psychotherapy (letter). Je 890
Hughes JR: Substance abuse and ADHD (letter). Ja 132
Hughes MC see Clemens NA
Hummer M see Kurzthaler I
Hurley A see Smith GS
Hutchings B see Brennan PA
Hyde TM see Shimon H
Hyman I see Beiser M
Hyman SE, Nestler EJ: reply to DF Klein: Psychotropic drug action (letter). Mr 440–441

I

Iacono WG see Sherman DK
Ieronimo C, Amador XF: bk rev, A Sims: Symptoms of the Mind, 2nd ed. Au 1163
Ikeda M see Mori E
Ikejiri Y see Mori E
Imamura T see Mori E
Inderbitzin LB, Lewine RRJ: reply to RP Liberman: Replication (letter). Mr 440
Insel TR: A neurobiological basis of social attachment. Je 726–735
Inzitari D see Faravelli C
Iqbal MI see Marzuk PM
Isaac MT, Tomé MB: Pindolol-paroxetine combination (letter). De 1790
Isaacs G see Lerner AG; Oyffe I
Isohanni M see Tiihonen J
Isometsä ET see Heilä H
Ito S, Koren G: Antidepressants and breastfeeding (letter). Au 1174

J

Jackson C see Sallee FR
Jacobi D see Piven J
Jacobs DG see Greenfield SF
Jacobs DM see Schofield PW
Jacobs S see Prigerson HG
Jacobsen LK, Frazier JA, Malhotra AK, Karoum F, McKenna K, Gordon CT, Hamburger SD, Lenane MC, Pickar D, Potter WZ, Rapoport JL: Cerebrospinal fluid monoamine metabolites in childhood-onset schizophrenia. Ja 69–74
Jacobsen LK, Giedd JN, Berquin PC, Krain AL, Hamburger SD, Kumra S, Rapoport JL: Quantitative morphology of the cerebellum and fourth ventricle in childhood-onset schizophrenia. De 1663–1669
Jacobsen LK, Giedd JN, Tanrikut C, Brady DR, Donohue BC, Hamburger SD, Kumra S, Alaghband-Rad J, Rumsey JM, Rapoport JL: Three-dimensional cortical morphometry of the planum temporale in childhood-onset schizophrenia. My 685–687
Jacobson G see Bear D
Jamison KR: bk rev, HJ Eysenck: Genius: The Natural History of Creativity. Mr 430
Jampala C see Newman M
Jandorf L see Susser E
Janicak PG see Sharma RP
Janowsky D see Kampov-Polevoy A
Jaranson JM see Robin RW
Jasser MZ see Clemons J
Jay G: Clinical genetics, IV: Alzheimer's disease: from gene to pathology (image, neuro). Oc 1359
Jefferson JW: bk rev, RS El-Mallakh: Lithium: Actions and Mechanisms. Fe 285–286
Jeffery KJ, Reid IC: Modifiable neuronal connections: an overview for psychiatrists. Fe 156–164
Jenike MA, Baer L, Minichiello WE, Rauch SL, Buttolph ML: Placebo-controlled trial of fluoxetine and phenelzine for obsessive-compulsive disorder. Se 1261–1264
Jensen CF, Keller TW, Peskind ER, McFall ME, Veith RC, Martin D, Wilkinson CW, Raskind MA: Behavioral and neuroendocrine responses to sodium lactate infusion in subjects with posttraumatic stress disorder. Fe 266–268
Jensen PS: bk rev, MF Lenzenweger, JJ Haugaard (eds): Frontiers of Developmental Psychopathology. Fe 280
Jesberger JA see Kenny JT
Jeste DV: Psychiatry of old age is coming of age (editorial). Oc 1356–1358
Jeste DV, Heaton SC, Paulsen JS, Harris MJ, Heaton RK: reply to GD Strauss: Psychotic depression (letter). My 719–720
Jeste DV see Klapow JC
Ji J see Zhang M
Johnson DR, Rosenheck R, Fontana A, Lubin H, Charney D, Southwick S: Reply to DD Denton Jr: Inpatient treatment of combat veterans (letter). Jy 1038–1039
Johnson H see Bouman WP
Johnson KJ see Crowe RR
Johnson-Sabine E see Reiss D
Joiner TE Jr, Heatherton TF, Keel PK: Ten-year stability and predictive validity of five bulimia-related indicators. Au 1133–1138
Jolkovsky L see Mitchell PB
Jones C see Kapur S
Jones P see Cannon M
Jones PB see Russell AJ
Jones RG see Bouman WP
Jönsson EG, Nöthen MM, Gustavsson JP, Neidt H, Brené S, Tylec A, Propping P, Sedvall GC: Lack of evidence for allelic association between personality traits and the dopamine D_4 receptor gene polymorphisms. My 697–699

K

Kaan R see Lipkin DM
Kabat J see Lyons JS
Kafka MP, Prentky RA: Compulsive sexual behavior characteristics (letter). No 1632
Kahn MW: On the new clinical case conferences (letter). Ja 134
Kakuma T see Alexopoulos GS; Kalayam B
Kalayam B, Alexopoulos GS, Musiek FE, Kakuma T, Toro A, Silbersweig D, Young RC: Brainstem evoked response abnormalities in late-life depression with vascular disease. Jy 970–975
Kales A see Nowell PD
Kalichman SC: Progression of viral illness (letter). My 718
Kalinowski A see Patel JK
Kalis N see Stein DJ
Kamble A see Emamghoreishi M
Kamijima K see Miyaoka H
Kampov-Polevoy A, Garbutt JC, Janowsky D: Evidence of preference for a high-concentration sucrose solution in alcoholic men. Fe 269–270 (letter: Hirsch, reply of Kampov-Polevoy, No 1631–1632)
Kampov-Polevoy A, Garbutt JC, Janowsky D: reply to AR Hirsch: High sucrose preference in alcoholic men (letter). No 1631–1632
Kane JM see Zimbroff DL
Kanter ME see Swedo SE
Kaplan GA see Roberts RE
Kapur S: bk rev, DL Schacter, JT Coyle (eds): Memory Distortion: How Minds, Brains, and Societies Reconstruct the Past. Au 1162
Kapur S, Zipursky R, Remington G, Jones C, McKay G, Houle S: PET evidence that loxapine is an equipotent blocker of 5-HT_2 and D_2 receptors: implications for the treatment of schizophrenia. No 1525–1529
Kapur S, Zipursky RB, Jones C, Wilson AA, DaSilva JD, Houle S: Cyproheptadine: a potent in vivo serotonin antagonist (letter). Je 884
Karajgi B see Rifkin A
Karayan I see Goenjian AK
Karkowski-Shuman L see Kendler KS
Karoum F see Jacobsen LK
Kashkin KB see Zimbroff DL
Kasl SV see Prigerson HG

Kasper JA, Hoge SK, Feucht-Haviar T, Cortina J, Cohen B: Prospective study of patients' refusal of antipsychotic medication under a physician discretion review procedure. Ap 483–489
Kasper S see Neumeister A
Kathol RG see Leon AC; Olfson M
Katon W see Hollifield M
Katz B: Report of the Committee on Membership (off acts). Se 1337–1339
Kavoussi RJ see Coccaro EF
Kay J see Clemens NA
Kaye WH: reply to CP Szabo: Perfectionism in anorexia nervosa (letter). Ja 132
Keck PE Jr see McElroy SL; Sax KW; Stanton SP
Keefe RSE see Lees Roitman SE
Keel PK, Mitchell JE: Outcome in bulimia nervosa. Mr 313–321 (letters: Reiss; Fairburn; reply of Keel, De 1791–1792)
Keel PK, Mitchell JE: reply to D Reiss, CG Fairburn: Bulimia outcome (letter). De 1791–1792
Keel PK see Joiner TE Jr
Kehrberg LLD see Black DW
Keller TW see Jensen CF
Kendler KS: Social support: a genetic-epidemiologic analysis. Oc 1398–1404
Kendler KS, Gardner CO, Prescott CA: Religion, psychopathology, and substance use and abuse: a multimeasure, genetic-epidemiologic study. Mr 322–329 (letter: Trappler, reply of Kendler, No 1636)
Kendler KS, Gardner CO, Prescott CA: reply to B Trappler: Religion and psychopathology (letter). No 1636
Kendler KS, Karkowski-Shuman L, O'Neill FA, Straub RE, MacLean CJ, Walsh D: Resemblance of psychotic symptoms and syndromes in affected sibling pairs from the Irish Study of High-Density Schizophrenia Families: evidence for possible etiologic heterogeneity. Fe 191–198
Kennedy K see Rosebush PI
Kennedy SH see Levitan RD
Kenny JT, Friedman L, Findling RL, Swales TP, Strauss ME, Jesberger JA, Schulz SC: Cognitive impairment in adolescents with schizophrenia. No 1613–1615
Kern RS see Green MF
Kerwin R see Gutiérrez B
Kerwin RW see Busatto GF
Keskitalo P see Wahlberg K-E
Kessler RC, Berglund PA, Foster CL, Saunders WB, Stang PE, Walters EE: Social consequences of psychiatric disorders, II: teenage parenthood. Oc 1405–1411
Ketter TA see Marangell LB
Keuthen NJ see O'Sullivan RL
Kilts CD see Stowe ZN
Kimble MO see Nestor PG
Kimbrell TA see George MS
Kim Leff M: bk rev, DW Winnicott: Thinking About Children. Jy 1032–1033
Kimmich RA see Clemens NA
King R see Zohar AH
King SA: Psychiatry's future (letter). Se 1325
Kirchner PT see Paradiso S
Kirisci L see Salloum IM
Kirkegaard-Sorensen L see Brennan PA
Kirkpatrick B see Buchanan RW; Bustillo JR
Kitagaki H see Mori E
Klapow JC, Evans J, Patterson TL, Heaton RK, Koch WL, Jeste DV: Direct assessment of functional status in older patients with schizophrenia. Jy 1022–1024
Klein DF: Psychotropic drug action (letter). Mr 440
Klein DF see Papp LA
Klein DN see Riso LP
Klein HM see Raison CL
Kleinman JE see Shimon H
Klieser E see Agelink MW
Kline L: The Council on Economic Affairs (off acts). Fe 299–300
Klinkenberg WD see Wolff N
Kluft RP: bk rev, KR Silk (ed): Biological and Neurobehavioral Studies of Borderline Personality Disorder. My 703–704
Kmetz GF, McElroy SL, Collins DJ: Response of kleptomania and mixed mania to valproate (letter). Ap 580–581
Knapp R see Brawman-Mintzer O
Knop J see Brennan PA
Koch WL see Klapow JC
Kocsis JH, Zisook S, Davidson J, Shelton R, Yonkers K, Hellerstein DJ, Rosenbaum J, Halbreich U: Double-blind comparison of sertraline, imipramine, and placebo in the treatment of dysthymia: psychosocial outcomes. Mr 390–395
Kocsis JH see Piazza LA
Koenig H, Parkerson GR, Meador KG: Religion index for psychiatric research (letter). Je 885–886
Koenig HG, George LK, Meador KG: Use of antidepressants by nonpsychiatrists in the treatment of medically ill hospitalized depressed elderly patients. Oc 1369–1375
Koenig HG, George LK, Peterson BL, Pieper CF: Depression in medically ill hospitalized older adults: prevalence, characteristics, and course of symptoms according to six diagnostic schemes. Oc 1376–1383
Koenig HG see Weaver AJ
Koeppe RA see Taylor SF
Koeter MWJ see Havenaar JM
Kofoed L see Misra L
Kohl C see Kurzthaler I
Köhler S: Deteriorated affective disorder a rarity? (letter). Mr 442–443
Kohn R see Levav I
Koiranen M see Tiihonen J
Kolassa J see Wahlberg K-E
König A see Berger M
Kopans B see Greenfield SF
Kopelowicz A, Liberman RP, Mintz J, Zarate R: Comparison of efficacy of social skills training for deficit and nondeficit negative symptoms in schizophrenia. Mr 424–425
Koponen H see Tiihonen J
Koran LM, Sallee FR, Pallanti S: Rapid benefit of intravenous pulse loading of clomipramine in obsessive-compulsive disorder. Mr 396–401
Koren G see Ito S
Kornblith SJ see Hogarty GE
Koshes RJ: Use of fluoxetine for obsessive-compulsive behavior in adults with autism (letter). Ap 578
Kožený J see Höschl C
Kraemer HC see Murphy GM Jr
Kraft MK, Rothbard AB, Hadley TR, McClellan AT, Asch DA: Are supplementary services provided during methadone maintenance really cost-effective? Se 1214–1219
Krain AL see Jacobsen LK
Kranzler HR see Hersh D
Kraus T see Pollmächer T
Kremen WS see Toomey R
Krishnan KRR, Hays JC, Blazer DG: MRI-defined vascular depression. Ap 497–501
Kron S see Zohar AH
Krueger JA see Tollefson GD
Krystal JH see Bremner JD
Kuan AJ see Maskall DD
Kuikka J see Tiihonen J
Kumra S see Jacobsen LK
Kupfer DJ see Nowell PD; Reynolds CF III; Thase ME
Kurzthaler I, Hummer M, Kohl C, Miller C, Fleischhacker WW: Propranolol treatment of olanzapine-induced akathisia (letter). Se 1316
Kusumakar V, Yatham LN: Lamotrigine treatment of rapid cycling bipolar disorder (letter). Au 1171–1172

L

Labbate LA, Rubey RR: Lamotrigine for treatment-refractory bipolar disorder (letter). Se 1317
Lafargue T, Breier A: bk rev, SA Mednick, JM Hollister (eds): Neural Development and Schizophrenia: Theory and Research. Ap 571–572
Lafer B see Moore CM
Lahti AC see Lahti RA
Lahti I see Wahlberg K-E
Lahti RA, Lahti AC: Clinical genetics, V: association of genetic and personality characteristics (image, neuro). No 1496
Läksy K see Wahlberg K-E
Lam RW see Maskall DD
Lambert G, Esler M: Origin of homovanillic acid in plasma (letter). Ja 138–139
Lanctôt G see Roy M-A
Lander S see Chochinov HM
Landry JC see Stowe ZN
Lane RD, Reiman EM, Ahern GL, Schwartz GE, Davidson RJ: Neuroanatomical correlates of happiness, sadness, and disgust. Jy 926–933
Lane RD see Reiman EM
Langbehn DR see Rohland BM
LaPorta LD: Borderline personality disorder and transitional objects (letter). Oc 1484–1485
Larson ER see Sax KW
Lauriello J, Hoff A, Wieneke MH, Blankfeld H, Faustman WO, Rosenbloom M, DeMent S, Sullivan EV, Lim KO, Pfefferbaum A: Similar extent of brain dysmorphology in severely ill women and men with schizophrenia. Je 819–825
Lavalée J-C see Roy M-A
Lavelle J see Susser E
Law W see Chemtob CM
Lawrie SM see Verdoux H
Layton ME see Strauss WL
Lazar SG see Clemens NA; Gabbard GO
Lazarus J: Report of the Speaker-Elect (off acts). Se 1335–1336
Leckman JF, Grice DE, Boardman J, Zhang H, Vitale A, Bondi C, Alsobrook J, Peterson BS, Cohen DJ, Rasmussen SA, Goodman WK, McDougle CJ, Pauls DL: Symptoms of obsessive-compulsive disorder. Jy 911–917

Leckman JF see Zohar AH
Lee MA see Ganzini L; Meltzer HY
Lee PWH see Lieh-Mak F
Lees Roitman SE, Cornblatt BA, Bergman A, Obuchowski M, Mitropoulou V, Keefe RSE, Silverman JM, Siever LJ: Attentional functioning in schizotypal personality disorder. My 655–660 (correction: Au 1180)
Lefley HP: bk rev, WM Pinsof: Integrative Problem-Centered Therapy: A Synthesis of Biological, Individual, and Family Therapies. Mr 431–432
Lehman A see Dixon L
Lehmkuhl G see von Gontard A
Leibenluft E: reply to T Zibin: Bipolar women (letter). Mr 441
Leibman M see Harvey PD
Leigh H: bk rev, PA Silver (ed): Psychotropic Drug Use in the Medically Ill. Fe 284–285
Leinonen E see Tiihonen J
Lejoyeux M, Adès J, Solomon J: reply to DW Black: Urge to splurge (letter). No 1630
Lejoyeux M, Adès J, Solomon J: reply to T Maier: Uncontrolled buying (letter). Oc 1477–1478
Lenane MC see Jacobsen LK
Leon AC, Portera L, Olfson M, Weissman MM, Kathol RG, Farber L, Sheehan DV, Pleil AM: False positive results: a challenge for psychiatric screening in primary care. Oc 1462–1464
Leon AC see Marzuk PM; Olfson M; Piazza LA; Tardiff K
Leonard HL see Swedo SE
Lepola U see Tiihonen J
Lerner A see Oyffe I
Lerner AG, Oyffe I, Isaacs G, Sigal M: Naltrexone treatment of hallucinogen persisting perception disorder (letter). Mr 437
Lesage A see Levitan RD
Leserman J see Evans DL
Levav I, Kohn R, Golding JM, Weissman MM: Vulnerability of Jews to affective disorders. Jy 941–947
Levick SE: bk rev, JW Brown: Time, Will, and Mental Process. Je 874–875
Levin A see Zanarini MC
Levitan RD, Lesage A, Parikh SV, Goering P, Kennedy SH: Reversed neurovegetative symptoms of depression: a community study of Ontario. Jy 934–940
Levy ST see Stowe ZN
Lewine R: bk rev, E Laszlo, R Artigiani, A Combs, V Csanyi: Changing Visions: Human Cognitive Maps: Past, Present, and Future. Oc 1465–1466
Lewine RRJ see Inderbitzin LB
Lewinsohn PM see Rohde P
Lewis CF, Ednie K: Koro and homicidal behavior (letter). Au 1169
Lewis DA see Akil M; Woo T-U
Lewis DO, Yeager CA, Swica Y, Pincus JH, Lewis M: Objective documentation of child abuse and dissociation in 12 murderers with dissociative identity disorder. De 1703–1710
Lewis DO see Yeager CA
Lewis M see Lewis DO
Lewis MH see Murphy TK
Lewis RA: Ritual handwashing (letter). Au 1172–1173
Lewis RE see Zanarini MC
Li PP see Emamghoreishi M
Li S see FitzGerald M
Liberatoscioli A see Gallenga PE
Liberman RP: Neurocognitive deficits in schizophrenia (letter). Mr 443–444
Liberman RP: Replication (letter). Mr 440
Liberman RP: Schizophrenia practice guideline (letter). De 1792–1793
Liberman RP see Kopelowicz A
Licinio J see Bremner JD
Lieberman J see Volkow ND
Lieberman JA, Rush AJ: reply to FN Busch: Psychotherapy's role in psychiatry (letter). Oc 1482
Lieberman JA, Rush AJ: reply to NA Clemens: Disputing psychiatry's redefinition (letter). No 1634–1635
Liebowitz MR see Schneier FR
Lieh-Mak F, Lee PWH: Cognitive deficit measures in schizophrenia: factor structure and clinical correlates (festschrift). Je suppl 39–46
Lifrak PD, Alterman AI, O'Brien CP, Volpicelli JR: Naltrexone for alcoholic adolescents (letter). Mr 439–440
Lifson LE: bk rev, RB Makover: Treatment Planning for Psychotherapists. My 708–709
Light DW: Managed care (letter). Mr 443
Lim KO see Lauriello J
Lindgren JC see Sheitman BB
Links PS: bk rev, JF Clarkin, MF Lenzenweger (eds): Major Theories of Personality Disorder. My 704–705
Linnoila M see George DT
Lipkin DM, Papernik M, Kaan R: Chronic fatigue (letter). Se 1322
Lipsitt DR: bk rev, R Mayou, C Bass, M Sharpe (eds): Treatment of Functional Somatic Symptoms. Fe 277–278
Liskow B: bk rev, L Friedman, NF Fleming, DH Roberts, SE Hyman (eds): Source Book of Substance Abuse and Addiction. Se 1313
Little JT see George MS
Litz BT, Orsillo SM, Friedman M: reply to DP Hall Jr: Peacekeeping duty and PTSD (letter). Oc 1483
Litz BT, Orsillo SM, Friedman M, Ehlich P, Batres A: Posttraumatic stress disorder associated with peacekeeping duty in Somalia for US military personnel. Fe 178–184 (correction: My 722) (letter: Hall, Oc 1483)
Litz BT see Ehlich PJ; Roemer L
Llewellyn A see Stowe ZN
Lobefalo L see Gallenga PE
Loeb KL see Walsh BT
Logan J see Smith GS; Volkow ND
Lohner H see Berger M
Lohr J see Haznedar MM
Lombardi J see Harvey PD
Longmate JA see Evans DL
Lönnqvist JK see Heilä H
Looper KJ, Milroy TM: Catatonia 20 years later (letter). Je 883
López-Ibor JJ Jr: The concept and boundaries of personality disorders (festschrift). Je suppl 21–25
Lo Russo L see Fioritti A
Lothstein LM: bk rev, RJ Apfel, B Simon (eds): Minefields in Their Hearts: The Mental Health of Children in War and Communal Violence. Se 1308–1309
Lovell RW, Bunker WW: Lithium assay errors (letter). Oc 1477
Lu S-h see Phillips MR
Lubin H see Johnson DR; Morgan CA III
Luborsky L see Zorrilla EP
Lucey JV see Busatto GF
Luu C see Haznedar MM
Lydiard RB see Brawman-Mintzer O; Emmanuel NP
Lyons JS, O'Mahoney MT, Miller SI, Neme J, Kabat J, Miller F: Predicting readmission to the psychiatric hospital in a managed care environment: implications for quality indicators. Mr 337–340
Lyons MJ see Toomey R

M

MacDonald ME see Tamminga CA
Mack RJ see Zimbroff DL
MacKinnon RA see Busch FN
MacLean CJ see Kendler KS
Magruder KM see Greenfield SF
Mahr RN see Moberg PJ
Maier T: Uncontrolled buying (letter). Oc 1477
Makari GJ, Michels R: The Payne Whitney Clinic (image, psych). De 1751
Makover RB: bk rev, MD Feldman, SJ Eisendrath (eds): The Spectrum of Factitious Disorders. No 1620–1621
Malaspina D see Brébion G; Tremeau F
Malhotra AK see Breier A; Jacobsen LK
Malison RT, Price LH, Nestler EJ, Heninger GR, Duman RS: Efficacy of p-paverine addition for treatment-refractory major depression (letter). Ap 579–580
Mallinger AG see Thase ME
Malm K see Mårtensson B
Malmquist CP: bk rev, SJ Kaplan (ed): Family Violence: A Clinical and Legal Guide. Fe 280–281
Malone KM see Brodsky BS; FitzGerald M; Mann JJ; Mulsant BH
Mammen O, Perel JM, Wheeler SB: Antidepressants and breast-feeding (letter). Au 1174–1175
Manfredi RL see Nowell PD
Mangot D see Pietrini P
Manji HK see Mitchell PB
Mann JJ, Malone KM, Diehl DJ, Perel J, Cooper TB, Mintun MA: reply to GM Brown: Reduced serotonin responsivity in depression (letter). Mr 442
Mann JJ, Malone KM, Nielsen DA, Goldman D, Erdos J, Gelernter J: Possible association of a polymorphism of the tryptophan hydroxylase gene with suicidal behavior in depressed patients. Oc 1451–1453
Mann JJ see Brodsky BS; FitzGerald M; Mulsant BH
Mannuzza S see Hollifield M
Mansueto CS see O'Sullivan RL
Marangell LB, Ketter TA, George MS, Pazzaglia PJ, Callahan AM, Parekh P, Andreason PJ, Horwitz B, Herscovitch P, Post RM: Inverse relationship of peripheral thyrotropin-stimulating hormone levels to brain activity in mood disorders. Fe 224–230
Marcus SC, Olfson M, Pincus HA, Shear MK, Zarin DA: Self-reported anxiety, general medical conditions, and disability bed days. De 1766–1768

Marder K see Schofield PW
Marder SR see Green MF
Marenco S see Schlaepfer TE
Marino MF see Zanarini MC
Marinoni M see Faravelli C
Markowitz JC see Piazza LA
Markowitz JS, Gill HS, DeVane CL, Mintzer JE: Fluoroquinolone inhibition of clozapine metabolism (letter). Je 881
Markowitz JS see DeVane CL
Marks I see Deale A
Marmar CR see Zatzick DF
Marneros A see Brieger P
Marshall BD Jr see Green MF
Marten E see Vinogradov S
Mårtensson B, Murray V, von Arbin M, Åsberg M, Bartfai A, Malm K: Alternative treatment for poststroke depression (letter). Ap 583–584
Martin D see Jensen CF
Martin JD see Greenberg BD
Martin JT, Gugelchuk G: Homosexuality and older brothers (letter). Ja 136
Martin PR see Moore RF
Martinez JM see Papp LA
Martino S see Grilo CM
Marttunen MJ see Heilä H
Marzuk PM, Tardiff K, Leon AC, Hirsch CS, Hartwell N, Portera L, Iqbal MI: HIV seroprevalence among suicide victims in New York City, 1991–1993. De 1720–1725
Marzuk PM, Tardiff K, Leon AC, Hirsch CS, Portera L, Hartwell N, Iqbal MI: Lower risk of suicide during pregnancy. Ja 122–123 (letter: Sharma, reply of Marzuk, Oc 1479–1480)
Marzuk PM, Tardiff K, Leon AC, Hirsch CS, Portera L, Hartwell N, Iqbal MI: reply to V Sharma: Effects of pregnancy on suicidal behavior (letter). Oc 1480
Marzuk PM see Tardiff K
Maser JD see Cassano GB
Maskall DD, Lam RW, Misri S, Carter D, Kuan AJ, Yatham LN, Zis AP: Seasonality of symptoms in women with late luteal phase dysphoric disorder. Oc 1436–1441
Mason C see Sachdev P
Mastropasqua L see Gallenga PE
Matsushita S see Higuchi S
Mawhinney J: The Council on Children, Adolescents, and Their Families (off acts). Fe 298–299
Mayer P, Pope HG Jr: Unusual flashbacks in a Vietnam veteran (letter). My 713
Maziade M, Roy M-A, Mérette C, Hamel M: reply to F Tremeau: Psychosis and etiology (letter). Ja 133–134
Maziade M see Roy M-A
Mazumdar S see Reynolds CF III
Mazurek MF see Rosebush PI
McBride PA see FitzGerald M
McCahill ME see Downs NS
McCarley RW see Nestor PG; O'Donnell BF
McClellan AT see Kraft MK
McConville BJ see McElroy SL
McCreadie RG see Verdoux H
McCurry L, Cronquist S: Pemoline and hepatotoxicity (letter). My 713–714
McDermott JF Jr: Festschrift for John Nemiah (letter). Ap 584
McDougle CJ see Barr LC; Leckman JF
McElroy SL, Strakowski SM, West SA, Keck PE Jr, McConville BJ: Phenomenology of adolescent and adult mania in hospitalized patients with bipolar disorder. Ja 44–49
McElroy SL see Kmetz GF; Sax KW; Stanton SP
McFall ME see Jensen CF
McGilchrist IK see Barta PE
McGlashan TH see Fenton WS; Grilo CM; Hoffman RE
McGrath PJ see Stewart JW
McGue MK see Sherman DK
McGuffin P see Guy C
McGuire PK see Woodruff PWR
McGurk S see Green MF
McIntyre JS see Herz M; Zarin DA
McKay G see Kapur S
McKay JR see Zorrilla EP
McKenna K see Jacobsen LK
McKenzie K see Cannon M
McKeon P see Guy C
McKinney WT: bk rev, ES Paykel, R Jenkins (eds): Prevention in Psychiatry. Mr 429–430
McNary S see Dixon L
McNeil TF see Verdoux H
McNiel DE see Beauford JE
Meador KG see Koenig H
Mechanic MB see Griffin MG
Mednick SA see Brennan PA; Raine A
Méhes K see Trixler M
Melega V see Fioritti A
Meller WH, Zander KM, Crosby RD, Tagatz GE: Luteinizing hormone pulse characteristics in depressed women. Oc 1454–1455
Meltzer HY, Rabinowitz J, Lee MA, Cola PA, Ranjan R, Findling RL, Thompson PA: Age at onset and gender of schizophrenic patients in relation to neuroleptic resistance. Ap 475–482
Mentis MJ see Alexander GE; Pietrini P
Mérette C see Maziade M; Roy M-A
Metayer S see Terr LC
Metzger M see Haznedar MM
Metzler TJ see Zatzick DF
Meyer RE see Hersh D
Meyers BS see Alexopoulos GS
Michel BA see Terr LC
Michelini S see Cassano GB
Michels KJ, Michels R: Clinical case: unknown (case conf). No 1599–1601
Michels R: bk rev, K Pezdek, WP Banks (eds): The Recovered Memory/False Memory Debate. Oc 1465
Michels R see Makari GJ; Michels KJ
Michelson D see Amsterdam JD
Milberger S, Biederman J, Faraone SV: reply to H Chabrol: ADHD and maternal smoking during pregnancy (letter). Au 1177–1178
Milbrath C see Horowitz MJ
Miller C see Kurzthaler I
Miller F see Lyons JS
Miller HL see Berman RM
Miller JL see Woo T-U
Miller LJ: reply to R Hoehn-Saric: Hallucinatory changes (letter). Fe 293–294
Miller NL see Piazza LA
Miller SI see Lyons JS
Milne JR see Gill DS
Milroy TM see Looper KJ
Minassian D see Goenjian AK
Minichiello WE see Jenike MA
Mintun M see Carter CS
Mintun MA see Mann JJ
Mintz J see Green MF; Kopelowicz A
Mintzer JE see Markowitz JS
Miró R see Fañanás L
Misra L, Kofoed L: Risperidone treatment of methamphetamine psychosis (letter). Au 1170
Misri S see Maskall DD
Mitchell JE see Keel PK
Mitchell PB, Manji HK, Chen G, Jolkovsky L, Smith-Jackson E, Denicoff K, Schmidt M, Potter WZ: High levels of $G_s\alpha$ in platelets of euthymic patients with bipolar affective disorder. Fe 218–223
Mitropoulou V see Lees Roitman SE
Mitter S see Mittmann N
Mittleman BB see Swedo SE
Mittmann N, Mitter S, Borden EK, Herrmann N, Naranjo CA, Shear NH: Montgomery-Åsberg severity gradations (letter). Se 1320–1321
Miyaoka H, Shishikura K, Otsubo T, Muramatsu D, Kamijima K: Diazepam-responsive neuroleptic malignant syndrome: a diagnostic subtype? (letter). Je 882
Moberg PJ, Doty RL, Turetsky BI, Arnold SE, Mahr RN, Gur RC, Bilker W, Gur RE: Olfactory identification deficits in schizophrenia: correlation with duration of illness. Jy 1016–1018
Mohs RC see Harvey PD
Monahan BP see Clemons J
Money R see Shear MK
Montgrain N see Roy M-A
Moore CM, Christensen JD, Lafer B, Fava M, Renshaw PF: Lower levels of nucleoside triphosphate in the basal ganglia of depressed subjects: a phosphorous-31 magnetic resonance spectroscopy study. Ja 116–118
Moore DP: On an engaging patient with paranoid schizophrenia (letter). Au 1178
Moore NC, Shukla P: Risperidone overdose (letter). Fe 289–290
Moore RF, Roback HB, Waterhouse GJ, Martin PR: reply to R Weinstock: Confidentiality conundrum (letter). Oc 1483–1484
Moran M see Bustillo JR
Moreno FA, Delgado PL: Hallucinogen-induced relief of obsessions and compulsions (letter). Jy 1037–1038
Morgan CA III, Grillon C, Lubin H, Southwick SM: Startle reflex abnormalities in women with sexual assault-related PTSD. Au 1076–1080
Morgan CA III see Southwick SM
Mori E, Hirono N, Yamashita H, Imamura T, Ikejiri Y, Ikeda M, Kitagaki H, Shimomura T, Yoneda Y: Premorbid brain size as a determinant of reserve capacity against intellectual decline in Alzheimer's disease. Ja 18–24
Moring J see Tiihonen J; Wahlberg K-E
Morris JA see Constantino JN
Morris R see Fein D
Morse GA see Wolff N
Mortensen PB: Breast cancer risk in psychiatric patients (letter). Ap 589
Mosovich S see Hollander E
Muenz LR see Greenfield SF
Mufti R see Balon R
Müller C see Schmidt LG
Mullington J see Pollmächer T
Mulroy R see Fava M
Mulsant BH, Haskett RF, Prudic J, Thase

ME, Malone KM, Mann JJ, Pettinati HM, Sackeim HA: Low use of neuroleptic drugs in the treatment of psychotic major depression. Ap 559–561
Mulsant BH see Zubenko GS
Mundy S see DeVane CL
Munro JC see Russell AJ
Muramatsu D see Miyaoka H
Muramatsu T see Higuchi S
Murphy C see Evans DL
Murphy DL see Constantino JN; George DT; Greenberg BD
Murphy GM Jr, Taylor J, Kraemer HC, Yesavage J, Tinklenberg JR: No association between apolipoprotein E ∈4 allele and rate of decline in Alzheimer's disease. My 603–608
Murphy TK, Goodman WK, Fudge MW, Williams RC Jr, Ayoub EM, Dalal M, Lewis MH, Zabriskie JB: B lymphocyte antigen D8/17: a peripheral marker for childhood-onset obsessive-compulsive disorder and Tourette's syndrome? Mr 402–407
Murray MG, Newman RM: Paroxetine for treatment of obsessive-compulsive disorder and comorbid stuttering (letter). Jy 1037
Murray RM see Cannon M; Russel AJ; Verdoux H; Woodruff PWR; Wright P
Murray V see Mårtensson B
Murry E see Cassidy F
Musick FE see Kalayam B
Myers MF: bk rev, GI Fogel, FM Lane, RS Liebert (eds): The Psychology of Men: New Psychoanalytic Perspectives. Oc 1470
Myers MF: bk rev, PJ Goodnick (ed): Predictors of Treatment Response in Mood Disorders. Mr 432–433
Myers MF: bk rev, JH Kocsis, DN Klein (eds): Diagnosis and Treatment of Chronic Depression. Mr 433
Mynett-Johnson L see Guy C

N

Naarala M see Wahlberg K-E
Nadelson T: reply to WV Flegenheimer: Creativity in psychodynamic psychotherapy (letter). My 721
Najarian LM see Goenjian AK
Naranjo CA see Mittmann N
Nathanson DL: bk rev, KT Strongman: The Psychology of Emotion: Theories of Emotion in Perspective, 4th ed. No 1616–1617
Nechamkin Y see Avissar S
Neidt H see Jönsson EG
Nelson E, Rice J: Stability of diagnosis of obsessive-compulsive disorder in the Epidemiologic Catchment Area study. Je 826–831
Nelson JC, Davis JM: DST studies in psychotic depression: a meta-analysis. No 1497–1503
Neme J see Lyons JS
Nemeroff CB see Bremner JD; Sharma RP; Stowe ZN
Nesbitt L see Sallee FR
Nestler EJ: Molecular biology, IV: identifying DNA transcription factors (image, neuro). Fe 146
Nestler EJ, Gao X-M, Tamminga CA: Molecular biology, V: immediate early genes (image, neuro). Mr 312
Nestler EJ see Duman RS; Hyman SE; Malison RT
Nestor PG, Kimble MO, O'Donnell BF, Smith L, Niznikiewicz M, Shenton ME, McCarley RW: Aberrant semantic activation in schizophrenia: a neurophysiological study. My 640–646
Nestor PG see O'Donnell BF
Neumeister A, Praschak-Rieder N, Heßelmann B, Vitouch O, Rauh M, Barocka A, Kasper S: Rapid tryptophan depletion in drug-free depressed patients with seasonal affective disorder. Au 1153–1155
Newman M, Adityanjee, Jampala C: Atypical neuroleptic malignant syndrome associated with risperidone treatment (letter). Oc 1475
Newman RM see Murray MG
Newsom JT see Prigerson HG
Nichols T see Carter CS
Nicolaou AL see Southwick SM
Nicole L see Roy M-A
Nielsen DA see Mann JJ
Nierenberg AA see Fava M
Nishizono M: Recent developments in American psychiatry and Dr Melvin Sabshin's contributions to them (festschrift). Je suppl 73–76
Niznikiewicz M see Nestor PG
Noble G see Clemons J
Nolet C see Zibin T
Nopoulos P, Flaum M, Andreasen NC: Sex differences in brain morphology in schizophrenia. De 1648–1654
Norman RG see Papp LA
North CS, Smith EM, Spitznagel EL: One-year follow-up of survivors of a mass shooting. De 1696–1702
North MM, North SM, Coble JR: Virtual reality therapy for fear of flying (letter). Ja 130
North SM see North MM
Nöthen MM see Jönsson EG
Nowell PD, Buysse DJ, Reynolds CF III, Hauri PJ, Roth T, Stepanski EJ, Thorpy MJ, Bixler E, Kales A, Manfredi RL, Vgontzas AN, Stapf DM, Houck PR, Kupfer DJ: Clinical factors contributing to the differential diagnosis of primary insomnia and insomnia related to mental disorders. Oc 1412–1416
Noyes R Jr see Crowe RR
Nuechterlein KH see Subotnik KL
Nutt DJ see George DT

O

Ober BA see Vinogradov S
O'Brien CP: Progress in the science of addiction (editorial). Se 1195–1197
O'Brien CP see Lifrak PD
Obuchowski M see Lees Roitman SE
O'Callaghan E see Verdoux H
O'Croinin F see Zibin T
O'Donnell BF, Swearer JM, Nestor PG, Shenton ME, McCarley RW: reply to D Bonnet, B Schwartz: Visual perception in medicated schizophrenic patients (letter). Ap 586–587
O'Donnell BF see Nestor PG
O'Donovan MC see Guy C
Offen WW see Satlin A
Ohse A see Schmidt LG
Oja H see Wahlberg K-E
Okasha A: The future of medical education and teaching: a psychiatric perspective (festschrift). Je suppl 77–85
Oldham JM: bk rev, LA Pervin: The Science of Personality. My 703
Olfson M, Fireman B, Weissman MM, Leon AC, Sheehan DV, Kathol RG, Hoven C, Farber L: Mental disorders and disability among patients in a primary care group practice. De 1734–1740
Olfson M see Leon AC; Marcus SC
Olmstead RE: bk rev, MS Gold: Tobacco. Se 1314–1315
O'Mahoney MT see Lyons JS
O'Malley S see Farren CK
O'Neill FA see Kendler KS
Ordoña TT: bk rev, JM Oldham, MB Riba (eds): The American Psychiatric Press Review of Psychiatry, vol 14. Je 879–880
Ordorica PI: The Council on Addiction Psychiatry (off acts). Fe 297
Orley J: bk rev, J McCulloch: Colonial Psychiatry and "The African Mind." Mr 430–431
Orsillo SM see Litz BT; Roemer L
O'Shanick GJ: Image on progressive dysarthria (letter). Ap 584–585
O'Sullivan RL, Keuthen NJ, Christenson GA, Mansueto CS, Stein DJ, Swedo SE: Trichotillomania: behavioral symptom or clinical syndrome? (case conf). Oc 1442–1449
O[illegible]bo T see Miyaoka H
Owen MJ see Guy C
Owens MJ see Bremner JD; Stowe ZN
Oyffe I, Lerner A, Isaacs G, Harel Y, Sigal M: Clomiphene-induced psychosis (letter). Au 1169–1170
Oyffe I see Lerner AG

P

Pakyurek AM see Preval H
Pallanti S, Quercioli L, Pazzagli A: Relapse in young paranoid schizophrenic patients: a prospective study of stressful life events, P300 measures, and coping. Je 792–798
Pallanti S see Koran LM
Palmer P see Piven J
Panzer PG, Fullilove MT: Belinda's puzzle: assembling the pieces of an illness (case conf). My 677–680
Papernik M see Lipkin DM
Papp LA, Martinez JM, Klein DF, Coplan JD, Norman RG, Cole R, de Jesus MJ, Ross D, Goetz R, Gorman JM: Respiratory psychophysiology of panic disorder: three respiratory challenges in 98 subjects. No 1557–1565
Papp LA see Shear MK
Pappas N see Volkow ND
Paradiso S, Robinson RG, Andreasen NC, Downhill JE, Davidson RJ, Kirchner PT, Watkins GL, Boles Ponto LL, Hichwa RD: Emotional activation of limbic circuitry in elderly normal subjects in a PET study. Mr 384–389
Parekh P see Marangell LB
Parikh SV see Emamghoreishi M; Levitan RD
Paris J, Zweig-Frank H: Dissociation in patients with borderline personality disorder (letter). Ja 137–138
Parker G: bk rev, L Cytryn, DH McKnew: Growing Up Sad: Childhood Depression and Its Treatment. Fe 279–280
Parkerson GR see Koenig H
Parrella M see Harvey PD
Pascani K see Volkow ND
Pasnau R: bk rev, G Berrios, R Porter (eds): A

History of Clinical Psychiatry: The Origin and History of Psychiatric Diseases. De 1779–1780
Passik SD see Breitbart W
Passman TE: Can pulmonary complications cause schizophrenia remission? (letter). Ja 130
Pasternak RE see Zubenko GS
Patel JK, Green AI, Kalinowski A, Tsuang MT: Evaluation of a complex case: the value of a drug washout period (case conf). De 1747–1750
Patel JK, Salzman C, Green AI, Tsuang MT: Chronic schizophrenia: response to clozapine, risperidone, and paroxetine (case conf). Ap 543–546
Pato MT see Eisen JL
Patterson TL see Klapow JC
Pauls DL see Leckman JF; Zohar AH
Paulsen JS see Jeste DV
Paulus W see Ziemann U
Paykel ES: bk rev, DA Ciraulo, RI Shader, DJ Greenblatt, W Creelman: Drug Interactions in Psychiatry, 2nd ed. Ap 577
Paykel ES, Tylee A, Wright A, Priest RG, Rix S, Hart D: The Defeat Depression Campaign: psychiatry in the public arena (festschrift). Je suppl 59–65
Pazzagli A see Pallanti S
Pazzaglia PJ see Marangell LB
Pearce J: bk rev, J Lindesay (ed): Neurotic Disorders in the Elderly. Je 876–877
Pearlson G see Frangou S
Pearlson GD see Barta PE; Schlaepfer TE
Perel J see Mann JJ
Perel JM see Mammen O; Wisner KL
Peresson G see Chabrol H
Pergami A, Gonevi M, Guerrini A: Italian psychiatric reform (letter). Oc 1485–1486
Perkins DO see Evans DL
Perl E see Rifkin A
Perna G, Cocchi S, Politi E, Bellodi L: CO_2 challenge in nonclinical subjects (letter). Je 886–887
Peskind ER see Elrod R; Jensen CF
Peterson BL see Koenig HG
Peterson BS see Leckman JF
Petitto JM see Evans DL
Pettinati HM see Mulsant BH
Petty F see Fulton MK
Petty RG see Barta PE
Pfaehler GT: Report of the Committee on Constitution and Bylaws (off acts). Se 1336–1337
Pfefferbaum A see Lauriello J
Phillips MJ see George DT
Phillips MR, Lu S-h, Wang R-w: Economic reforms and the acute inpatient care of patients with schizophrenia: the Chinese experience. Se 1228–1234
Piazza LA, Markowitz JC, Kocsis JH, Leon AC, Portera L, Miller NL, Adler D: Sexual functioning in chronically depressed patients treated with SSRI antidepressants: a pilot study. De 1757–1759
Pichot PJ: DSM-III and its reception: a European view (festschrift). Je suppl 47–54
Pickar D see Breier A; Jacobsen LK
Pieper CF see Koenig HG
Pietrini P, Dani A, Furey ML, Alexander GE, Freo U, Grady CL, Mentis MJ, Mangot D, Simon EW, Horwitz B, Haxby JV, Schapiro MB: Low glucose metabolism during brain stimulation in older Down's syndrome subjects at risk for Alzheimer's disease prior to dementia. Au 1063–1069
Pietrini P see Alexander GE
Pike KM see Walsh BT
Pilowsky LS see Busatto GF
Pinals DA see Breier A
Pincus HA see Marcus SC; Zarin DA
Pincus JH see Lewis DO
Pinkofsky HB, Fitz-Gerald MJ, Reeves RR: Psychotropic treatment during pregnancy (letter). My 718–719
Pirès A see Roy M-A
Piven J, Bailey J, Ranson BJ, Arndt S: An MRI study of the corpus callosum in autism. Au 1051–1056
Piven J, Palmer P, Jacobi D, Childress D, Arndt S: Broader autism phenotype: evidence from a family history study of multiple-incidence autism families. Fe 185–190
Pleil AM see Leon AC
Poelijoe NW see Havenaar JM
Politi E see Perna G
Pollack S see Rifkin A
Pollmächer T, Hinze-Selch D, Fenzel T, Kraus T, Schuld A, Mullington J: Plasma levels of cytokines and soluble cytokine receptors during treatment with haloperidol. De 1763–1765
Pollock GH: bk rev, F De Waal: Bonobo: The Forgotten Ape. De 1784–1785
Pollock GH: bk rev, RS Wallerstein: The Talking Cures: The Psychoanalyses and the Psychotherapies. My 707
Ponton A-M see Roy M-A
Poole JH see Vinogradov S
Pope HG Jr see Hochman J; Mayer P
Popik P see Bisaga A
Popkin MK: bk rev, JD Auerbach, C Wypijewska, HKH Brodie, Committee on Substance Abuse and Mental Health Issues in AIDS Research Institute of Medicine Division of Biobehavioral Sciences and Mental Disorders (eds): AIDS and Behavior: An Integrated Approach. Fe 279
Portera L see Leon AC; Marzuk PM; Piazza LA; Tardiff K
Post LL: bk rev, PH Wender: Attention-Deficit Hyperactivity Disorders in Adults. Se 1309–1310
Post RM see Denicoff KD; George MS; Greenberg BD; Marangell LB
Potter WZ see Jacobsen LK; Mitchell PB
Potvin A see Roy M-A
Potvin JH see Tollefson GD
Powchik P see Harvey PD
Powers RE see Barta PE
Prakash R, Roback HB: Borderline personality and bipolar disorder (letter). Au 1176
Praschak-Rieder N see Neumeister A
Prentky RA see Kafka MP
Prescott CA see Kendler KS
Preval H, Pakyurek AM: Psychotic episode associated with dexfenfluramine (letter). No 1624–1625
Price LH see Barr LC; Malison RT
Pridmore S: bk rev, JL Pearson, Y Conwell (eds): Suicide and Aging: International Perspectives. No 1622
Prigerson HG, Bierhals AJ, Kasl SV, Reynolds CF III, Shear MK, Day N, Beery LC, Newsom JT, Jacobs S: Traumatic grief as a risk factor for mental and physical morbidity. My 616–623
Prigerson HG, Shear MK, Frank E, Beery LC, Silberman R, Prigerson J, Reynolds CF III: Traumatic grief: a case of loss-induced trauma (case conf). Jy 1003–1009
Prigerson J see Prigerson HG
Propping P see Jönsson EG
Prosen H: bk rev, JM Jones: Affects as Process: An Inquiry Into the Centrality of Affect in Psychological Life. Au 1164
Prudic J, Sackeim HA: reply to SS Chandragiri: ECT response in medication-resistant patients (letter). My 722
Prudic J see Mulsant BH
Pulver AE see Barta PE
Pykäläinen L see Wahlberg K-E
Pynoos RS see Goenjian AK

Q

Quaytman M, Sharfstein SS: Treatment for severe borderline personality disorder in 1987 and 1997 (case conf). Au 1139–1144
Quercioli L see Pallanti S
Quitkin FM see Amsterdam JD; Stewart JW

R

Rabinowitz J see Meltzer HY
Rabins PV: bk rev, P Chadwick, M Birchwood, P Trower: Cognitive Therapy for Delusions, Voices and Paranoia. Se 1312–1313
Rabkin JG, Goetz RR, Remien RH, Williams JBW, Todak G: reply to R Boland: HIV and depression (letter). No 1633
Rabkin JG, Goetz RR, Remien RH, Williams JBW, Todak G, Gorman JM: Stability of mood despite HIV illness progression in a group of homosexual men. Fe 231–238 (letter: Boland, reply of Rabkin, No 1632–1633)
Raby WN: Carnitine for valproic acid-induced hyperammonemia (letter). Au 1168–1169
Raine A, Brennan P, Mednick SA: Interaction between birth complications and early maternal rejection in predisposing individuals to adult violence: specificity to serious, early-onset violence. Se 1265–1271
Raine A see Brennan PA
Raison CL, Klein HM: Psychotic mania associated with fenfluramine and phentermine use (letter). My 711
Rampes H, Davidson J: Samuel Hahnemann, 1755–1843 (image, psych). Oc 1450
Ranjan R see Meltzer HY
Ranson BJ see Piven J
Rapin I see Fein D
Rapoport JL: Child psychiatry comes of age: growing sophistication, evolving strategies (editorial). Au 1043–1045
Rapoport JL see Alaghband-Rad J; Jacobsen LK; Swedo SE
Räsänen P see Tiihonen J
Raskind MA see Elrod R; Jensen CF
Rasmussen JK see Robin RW
Rasmussen SA see Eisen JL; Leckman JF
Ratzoni G see Zohar AH
Rauch SL see Jenike MA
Rauh M see Neumeister A
Rawlings RR see George DT
Reeves RR see Pinkofsky HB
Reich RB see Zanarini MC
Reich W see Schuckit MA

Reid IC see Jeffery KJ
Reiman EM, Lane RD, Ahern GL, Schwartz GE, Davidson RJ, Friston KJ, Yun L-S, Chen K: Neuroanatomical correlates of externally and internally generated human emotion. Jy 918–925
Reiman EM see Lane RD
Reimherr FW see Amsterdam JD
Reinhardt JA see Terr LC
Reiss D, Johnson-Sabine E: Bulimia outcome (letter). De 1791
Reiss D see Clemens NA
Reite M see Rojas DC
Reizes JM see Greenfield SF
Remien RH see Rabkin JG
Remington G see Kapur S
Remschmidt H see Hebebrand J
Renshaw PF see Moore CM; Satlin A
Resick PA see Griffin MG
Reus VI: bk rev, JZ Sadler, OP Wiggins, MA Schwartz (eds): Philosophical Perspectives on Psychiatric Diagnostic Classification. Jy 1035
Rey JM, Walter G: Half a century of ECT use in young people. My 595–602
Reynolds CF III, Frank E, Houck PR, Mazumdar S, Dew MA, Cornes C, Buysse DJ, Begley A, Kupfer DJ: Which elderly patients with remitted depression remain well with continued interpersonal psychotherapy after discontinuation of antidepressant medication? Jy 958–962
Reynolds CF III see Nowell PD; Prigerson HG
Riba M see Balon R
Rice J see Nelson E
Ried T: Molecular biology, VI: metaphase preparation of normal human chromosomes with spectral karyotyping (image, neuro). Ap 447
Ried T: Molecular biology, VII: spectral karyotyping analysis in diagnostic cytogenetics (image, neuro). My 594
Riemann D see Berger M
Rifkin A: bk rev, J Volavka: Neurobiology of Violence. No 1621
Rifkin A, Karajgi B, Dicker R, Perl E, Boppana V, Hasan N, Pollack S: Lithium treatment of conduct disorders in adolescents. Ap 554–555
Rifkin L see Cannon M; Wright P
Riso LP, Klein DN: reply to P Brieger: Comorbidity between personality and dysthymic disorders: historical and conceptual issues (letter). Jy 1039–1040
Risser RC see Weiner MF
Rittig S see von Gontard A
Roazen P: bk rev, P Cushman: Constructing the Self, Constructing America: A Cultural History of Psychotherapy. My 706
Roazen P: bk rev, BE Moore, BD Fine (eds): Psychoanalysis: The Major Concepts. My 707–708
Roback HB see Moore RF
Roberts RE, Kaplan GA, Shema SJ, Strawbridge WJ: Does growing old increase the risk for depression? Oc 1384–1390
Robertson LR: bk rev, RT Fancher: Cultures of Healing: Correcting the Image of American Mental Health Care. Ja 124 (letter: Fancher, Oc 1485)
Robertson LR: bk rev, P Tyrer, F Creed (eds): Community Psychiatry in Action: Analysis and Prospects. Mr 429
Robin RW, Chester B, Rasmussen JK, Jaranson JM, Goldman D: Prevalence and characteristics of trauma and posttraumatic stress disorder in a Southwestern American Indian tribe. No 1582–1588
Robinson D see Berent I
Robinson GE: bk rev, MD Kelleher: New Arenas for Violence: Homicide in the American Workplace. No 1621–1622
Robinson RG see Paradiso S
Rodgers C see DeMaria PA Jr
Rodrigue C see Roy M-A
Roemer L, Litz BT, Orsillo SM: Consistency of traumatic memories (letter). No 1628
Roemer L see Ehlich PJ
Rohde P, Lewinsohn PM, Seeley JR: Comparability of telephone and face-to-face interviews in assessing axis I and II disorders. No 1593–1598
Rohland BM, Langbehn DR: Self-reported life satisfaction (letter). Oc 1478–1479
Rohling ML see Binder LM
Roitman G see Avissar S
Rojas DC, Teale P, Sheeder J, Simon J, Reite M: Sex-specific expression of Heschl's gyrus functional and structural abnormalities in paranoid schizophrenia. De 1655–1662
Rommelspacher H see Schmidt LG
Roose SP see Walsh BT
Rose CP: The Council on Internal Organization (off acts). Fe 300
Rosebush PI, Kennedy K, Dalton B, Mazurek MF: Protracted akathisia after risperidone withdrawal (letter). Mr 437–438
Rosenbaum J see Kocsis JH
Rosenbaum JF see Amsterdam JD; Fava M
Rosenberg R see Brennan PA
Rosenbloom M see Lauriello J
Rosenfeld BD see Breitbart W
Rosenheck R see Fontana A; Johnson DR
Rosenthal NE see Clark CH
Roskes EJ: Taking care of money matters (letter). Ja 135
Ross CA see Ellason JW
Ross D see Papp LA
Rossell S see Woodruff PWR
Roth T see Nowell PD
Rothbard AB see Kraft MK
Rothberg PC see Beardslee WR
Rothchild E: E-mail therapy (letter). Oc 1476–1477
Rothenberger A see Ziemann U
Rothenhaeusler H-B see Soyka M
Roubertoux P see Tordjman S
Roy M-A, Lanctôt G, Mérette C, Cliche D, Fournier J-P, Boutin P, Rodrigue C, Charron L, Turgeon M, Hamel M, Montgrain N, Nicole L, Pirès A, Wallot H, Ponton A-M, Garneau Y, Dion C, Lavalée J-C, Potvin A, Szatmari P, Maziade M: Clinical and methodological factors related to reliability of the best-estimate diagnostic procedure. De 1726–1733
Roy M-A see Maziade M
Royall R see Barta PE
Roy-Byrne P: bk rev, SH Snyder: Drugs and the Brain. Au 1161
Rubey RR see Labbate LA
Rubinow DR see Bloch M
Rubinstein J see Dhossche D
Rudas N see Baldessarini RJ; Tondo L
Ruiz P: The Council on International Affairs (off acts). Fe 301
Rumsey JM see Jacobsen LK
Rumyantzeva GM see Havenaar JM
Rush AJ: bk rev, NS Schutte, JM Malouff: Sourcebook of Adult Assessment Strategies. Jy 1034–1035
Rush AJ see Lieberman JA
Ruskin PE: bk rev, GJ Kennedy (ed): Suicide and Depression in Late Life: Critical Issues in Treatment, Research, and Public Policy. Je 876
Russell AJ, Munro JC, Jones PB, Hemsley DR, Murray RM: Schizophrenia and the myth of intellectual decline. My 635–639
Ryan WG: bk rev, P De Rosa: Rebels: The Irish Rising of 1916. De 1778
Ryan WG: bk rev, CA Goetz, M Bonduelle, T Gelfand: Charcot: Constructing Neurology. De 1780–1781

S

Sabshin M: Harold I Eist, MD, one hundred twenty-fifth president, 1996–1997. Oc 1354–1355
Sabshin M: Report of the Medical Director (off acts). Se 1333–1334
Sachdev P, Mason C, Hadzi-Pavlovic D: Case-control study of neuroleptic malignant syndrome. Au 1156–1158
Sackeim HA see Mulsant BH; Prudic J; Sobin C
Sacks HS: Response to the presidential address: new challenges for proven values. Oc 1350–1353
Sadock BJ: bk rev, FL Mak, CC Nadelson (eds): International Review of Psychiatry, vol 2. Oc 1466–1467
Sallee FR, Nesbitt L, Jackson C, Sine L, Sethuraman G: Relative efficacy of haloperidol and pimozide in children and adolescents with Tourette's disorder. Au 1057–1062
Sallee FR, Vrindavanam NS, Deas-Nesmith D, Carson SW, Sethuraman G: Pulse intravenous clomipramine for depressed adolescents: double-blind, controlled trial. My 668–673
Sallee FR see Koran LM
Salloum IM, Daley DC, Cornelius JR, Kirisci L, Thase ME: reply to D Dhossche: Homicidal behavior in drug abusing psychiatric patients (letter). Je 889
Salt P see Beardslee WR
Salzman C: bk rev, W Wasco, RE Tanzi (eds): Molecular Mechanisms of Dementia. Jy 1033–1034
Salzman C see Patel JK
Samford JA see Weaver AJ
Samson JA see Toomey R
Sanger TM see Tollefson GD
Sano M see Schofield PW
Sansone LA see Sansone RA
Sansone RA, Sansone LA, Wiederman MW: Increased health care utilization as a function of participation in trauma research. Jy 1025–1027
Şar V, Yargiç LI, Tutkun H: reply to P Chodoff: Turkish dissociative identity disorder (letter). Au 1179
Sartorius N: Psychiatry in the framework of primary health care: a threat or boost to psychiatry? (festschrift). Je suppl 67–72
Satlin A, Bodick N, Offen WW, Renshaw PF: Brain proton magnetic resonance spectros-

copy (^{1}H-MRS) in Alzheimer's disease: changes after treatment with xanomeline, an M_1 selective cholinergic agonist. Oc 1459–1461
Satoh K, Someya T, Shibasaki M: Nemonapride for the treatment of schizophrenia (letter). Fe 292
Saunders WB see Kessler RC
Sax KW, Strakowski SM, Keck PE Jr, McElroy SL, West SA, Bourne ML, Larson ER: Comparison of patients with early-, typical-, and late-onset affective psychosis. Se 1299–1301
Schäfer H see Hebebrand J
Schaffer CB, Schaffer LC: Gabapentin in the treatment of bipolar disorder (letter). Fe 291–292
Schaffer LC see Schaffer CB
Schapiro MB see Alexander GE; Pietrini P
Schatzberg AF see DeBattista C
Scheff TJ: bk rev, AJ Reiss Jr, JA Roth (eds): Understanding and Preventing Violence, vol. 3: Social Influences; Understanding and Preventing Violence, vol. 4: Consequences and Control. My 709
Schlaepfer TE, Pearlson GD, Wong DF, Marenco S, Dannals RF: PET study of competition between intravenous cocaine and [^{11}C]raclopride at dopamine receptors in human subjects. Se 1209–1213
Schlaepfer TE see Greenberg BD
Schlenger WE see Zatzick DF
Schlichter L see Emamghoreishi M
Schloesser R see Smith GS
Schlosser SS see Black DW
Schmeidler J see Simeon D
Schmidt K see Schmidt LG; Zorrilla EP
Schmidt LG, Schmidt K, Dufeu P, Ohse A, Rommelspacher H, Müller C: Superiority of carbohydrate-deficient transferrin to γ-glutamyltransferase in detecting relapse in alcoholism. Ja 75–80
Schmidt M see Mitchell PB
Schmidt PJ see Bloch M
Schneier FR, Wexler KB, Liebowitz MR: Social phobia and stuttering (letter). Ja 131
Schocket LS see Clark CH
Schoener EP see Hill JC
Schofield PW, Marder K, Dooneief G, Jacobs DM, Sano M, Stern Y: Association of subjective memory complaints with subsequent cognitive decline in community-dwelling elderly individuals with baseline cognitive impairment. My 609–615
Schreiber G see Avissar S
Schreiber W, Spernal J: Metronidazole-induced pychotic disorder (letter). Au 1170–1171
Schuckit MA, Tipp JE, Bergman M, Reich W, Hesselbrock VM, Smith TL: Comparison of induced and independent major depressive disorders in 2,945 alcoholics. Jy 948–957
Schuld A see Pollmächer T
Schulsinger F see Brennan PA
Schultz SK: bk rev, J Sadavoy, LW Lazarus, LF Jarvik, GT Grossberg (eds): Comprehensive Review of Geriatric Psychiatry—II, 2nd ed. Jy 1034
Schulz SC see Kenny JT
Schwarcz R see Tamminga CA
Schwartz B, Winstead DK: Visual perception in medicated schizophrenic patients (letter). Ap 585–586
Schwartz GE see Lane RD; Reiman EM
Schwartz HJ: Biased book review (letter). Je 888
Schwartz K: Nefazodone and visual side effects (letter). Jy 1038
Schweitzer SM see Armstrong SC
Sebree TB see Zimbroff DL
Sederer LI: bk rev, A Lazarus (ed): Controversies in Managed Mental Health Care. Ja 125–126
Sedvall GC see Jönsson EG
Seeley JR see Rohde P
Seeman MV: Psychopathology in women and men: focus on female hormones. De 1641–1647
Seeman MV see Dickson RA
Seidel R see Hebebrand J
Seidman LJ see Toomey R
Seitamaa M see Wahlberg K-E
Selkoe DJ: Clinical genetics, III: Alzheimer's disease: from genes to pathogenesis (image, neuro). Se 1198
Selnes OA, Holcomb HH, Gordon B: reply to GJ O'Shanick: Image on progressive dysarthria (letter). Ap 585
Sen J see Emamghoreishi M
Senger HL: Borderline mnemonic (letter). Se 1321
Serena A see Faravelli C
Sethuraman G see Sallee FR
Shanahan MJ see Elder GH Jr
Shapiro PA, Williams D, Gelman I, Foray AT, Wukich N: Compliance complications in cardiac patients (letter). No 1627
Shapleske J see Woodruff PWR
Sharfstein SS: Cost-effectiveness of psychiatric care (editorial). Je 723–724
Sharfstein SS see Boronow J; Quaytman M
Sharma JN see Bhatara VS
Sharma RP, Janicak PG, Bissette G, Nemeroff CB: CSF neurotensin concentrations and antipsychotic treatment in schizophrenia and schizoaffective disorder. Jy 1019–1021
Sharma T see Frangou S
Sharma V: Effects of pregnancy on suicidal behavior (letter). Oc 1479–1480
Shear MK, Brown TA, Barlow DH, Money R, Sholomskas DE, Woods SW, Gorman JM, Papp LA: Multicenter collaborative panic disorder severity scale. No 1571–1575
Shear MK see Cassano GB; Marcus SC; Prigerson HG
Shear NH see Mittmann N
Sheeder J see Rojas DC
Sheehan DV see Leon AC; Olfson M
Sheitman BB, Lindgren JC, Early J, Sved M: High-dose olanzapine for treatment-refractory schizophrenia (letter). No 1626
Shekhar A see Ball S
Shelton R see Kocsis JH
Shema SJ see Roberts RE
Shenaut GK see Vinogradov S
Shenton ME see Nestor PG; O'Donnell BF
Sherman DK, McGue MK, Iacono WG: Twin concordance for attention deficit hyperactivity disorder: a comparison of teachers' and mothers' reports. Ap 532–535
Shi H see Terr LC
Shibasaki M see Satoh K
Shimomura T see Mori E
Shimon H, Agam G, Belmaker RH, Hyde TM, Kleinman JE: Reduced frontal cortex inositol levels in postmortem brain of suicide victims and patients with bipolar disorder. Au 1148–1150
Shin KJ see Stewart JT
Shishikura K see Miyaoka H
Sholomskas DE see Shear MK
Shore JH: reply to SA King, NS Downs, CJ Gilman: Psychiatry's future (letter). Se 1326
Shore JH: The Council on Medical Education and Career Development (off acts). Fe 301–302
Shore MF: A lesson in history, circa 2047 (editorial). Mr 307–311
Shukla P see Moore NC
Siegel B see Horowitz MJ
Siegel BV Jr see Haznedar MM
Siever LJ see Lees Roitman SE
Sigal M see Lerner AG; Oyffe I
Silberman EK, Snyderman DA: Research without external funding in North American psychiatry. Au 1159–1160
Silberman R see Prigerson HG
Silbersweig D see Alexopoulos GS; Kalayam B
Silk KR see Cardasis W
Silva SG see Evans DL
Silverman JM see Lees Roitman SE
Simeon D, Gross S, Guralnik O, Stein DJ, Schmeidler J, Hollander E: Feeling unreal: 30 cases of DSM-III-R depersonalization disorder. Au 1107–1113
Simkowitz P see Smith GS
Simon EW see Pietrini P
Simon GE, VonKorff M: Prevalence, burden, and treatment of insomnia in primary care. Oc 1417–1423
Simon GE see Gureje O
Simon J see Rojas DC
Simon L see Hollander E
Simpson JC see Toomey R
Sine L see Sallee FR
Skipper B see Hollifield M
Sledge WH: bk rev, JA Talbott, JC Ballenger, AF Breier, RJ Frances, HY Meltzer, SW Perry, JE Schowalter (eds): The Year Book of Psychiatry and Applied Mental Health 1995. Ja 129
Slovenko R: Reviewing a review (letter). Fe 295
Smith CB see Goldman RL
Smith EM see North CS
Smith GS, Dewey SL, Brodie JD, Logan J, Vitkun SA, Simkowitz P, Schloesser R, Alexoff DA, Hurley A, Cooper T, Volkow ND: Serotonergic modulation of dopamine measured with [^{11}C]raclopride and PET in normal human subjects. Ap 490–496
Smith L see Nestor PG
Smith MJ see Brébion G
Smith TL see Schuckit MA
Smith-Jackson E see Mitchell PB
Smith-Jackson EE see Denicoff KD
Snyderman DA see Silberman EK
Sobin C, Sackeim HA: Psychomotor symptoms of depression. Ja 4–17
Solimando A see Haznedar MM
Solomon J see Lejoyeux M
Solvason HB see DeBattista C; Stein SL
Somerfeld-Ziskind E: bk rev, J Derksen: Personality Disorders: Clinical and Social Perspectives. My 704
Somerfeld-Ziskind E: bk rev, P Heyworth: Otto Klemperer: His Life and Times, vol I: 1885–1933; P Heyworth: Otto Klemperer: His Life and Times, vol II: 1933–1973. De 1787–1789

Someya T see Satoh K
Sorri A see Wahlberg K-E
Sourander A: Risperidone for treatment of childhood schizophrenia (letter). Oc 1476
Southwick SM, Morgan CA III, Charney DS: reply to L Roemer, O French: Consistency of traumatic memories (letter). No 1629
Southwick SM, Morgan CA III, Nicolaou AL, Charney DS: Consistency of memory for combat-related traumatic events in veterans of Operation Desert Storm. Fe 173–177 (letters: Roemer; French; reply of Southwick, No 1628–1629)
Southwick SM see Bremner JD; Johnson DR; Morgan CA III; Yehuda R
Soyka M, Rothenhaeusler H-B: Delta sleep-inducing peptide in opioid detoxification (letter). My 714–715
Speciale S see Weiner MF
Speight G see Guy C
Spernal J see Schreiber W
Spiegel D see Gabbard GO; Stein SL
Spiegel DA, Bruce TJ: Benzodiazepines and exposure-based cognitive behavior therapies for panic disorder: conclusions from combined treatment trials. Je 773–781
Spiegel-Cohen J see Haznedar MM
Spier S see Dubin H
Spinelli MG: Interpersonal psychotherapy for depressed antepartum women: a pilot study. Jy 1028–1030
Spiti R see Faravelli C
Spitznagel EL see North CS
Stang PE see Kessler RC
Stanton SP, Keck PE Jr, McElroy SL: Treatment of acute mania with gabapentin (letter). Fe 287
Stapf DM see Nowell PD
Stein DJ: Internet addiction, internet psychotherapy (letter). Je 890
Stein DJ, Wessels C, Carr J, Hawkridge S, Bouwer C, Kalis N: Hair pulling in a patient with Sydenham's chorea (letter). Se 1320
Stein DJ see Bouwer CD; O'Sullivan RL; Simeon D
Stein MB, Forde DR, Anderson G, Walker JR: Obsessive-compulsive disorder in the community: an epidemiologic survey with clinical reappraisal. Au 1120–1126
Stein MB, Walker JR, Hazen AL, Forde DR: Full and partial posttraumatic stress disorder: findings from a community survey. Au 1114–1119
Stein SL, Solvason HB, Biggart E, Spiegel D: reply to FH Frankel: Hypnotizability used for diagnostic confirmation? (letter). Ap 587–588
Steinberg AM see Goenjian AK
Steinberg M: Dissociation and the Holocaust (letter). My 720–721
Steinhausen H-C see Hebebrand J
Stepanski EJ see Nowell PD
Stern RA see Evans DL
Stern Y see Schofield PW
Stetner F see Covey LS
Stewart A see Zatzick DF
Stewart JT, Shin KJ: Paroxetine treatment of sexual disinhibition in dementia (letter). Oc 1474
Stewart JW, Tricamo E, McGrath PJ, Quitkin FM: Prophylactic efficacy of phenelzine and imipramine in chronic atypical depression: likelihood of recurrence on discontinuation after 6 months' remission. Ja 31–36
Stinson CH see Horowitz MJ
Stöber G, Franzek E, Beckmann H: Maternal infectious illness and schizophrenia (letter). Fe 292–293
Stöber G see Verdoux H
Stoline A see Boronow J
Stone AA: bk rev, DL Schacter: Searching for Memory: The Brain, the Mind, and the Past. Je 875–876
Stotland NL: bk rev, SR Shuchter, N Downs, S Zisook: Biologically Informed Psychotherapy for Depression. Mr 433
Stotland NL: Refusal of medical treatment: psychiatric emergency? (case conf). Ja 106–108
Stoudemire A: bk rev, M Stein, A Baum (eds): Chronic Diseases. Fe 278–279
Stowe ZN, Levy ST, Nemeroff CB: Comorbid postpartum depression and bereavement: a complicated case (case conf). Mr 418–422
Stowe ZN, Owens MJ, Landry JC, Kilts CD, Ely T, Llewellyn A, Nemeroff CB: Sertraline and desmethylsertraline in human breast milk and nursing infants. Se 1255–1260
Strakowski SM see McElroy SL; Sax KW
Strasburger LH, Gutheil TG, Brodsky A: On wearing two hats: role conflict in serving as both psychotherapist and expert witness. Ap 448–456
Straub RE see Kendler KS
Strauss GD: Psychotic depression (letter). My 719
Strauss ME see Buchanan RW; Kenny JT
Strauss WL, Layton ME, Hayes CE, Dager SR: ^{19}F magnetic resonance spectroscopy investigation in vivo of acute and steady-state brain fluvoxamine levels in obsessive-compulsive disorder. Ap 516–522
Strawbridge WJ see Roberts RE
Street JS see Tollefson GD
Subotnik KL, Nuechterlein KH, Asarnow RF, Fogelson DL, Goldstein MJ, Talovic SA: Depressive symptoms in the early course of schizophrenia: relationship to familial psychiatric illness. No 1551–1556
Sudak HS: bk rev, JT Maltsberger, MJ Goldblatt (eds): Essential Papers on Suicide. No 1622–1623
Sudak HS: The Pennsylvania Hospital (image, psych). Ap 547
Sugarman B see Berent I
Sullivan EV see Lauriello J
Sulmont V see Tordjman S
Sunderland T see Dukoff R
Susser E, Colson P, Jandorf L, Berkman A, Lavelle J, Fennig S, Waniek C, Bromet E: HIV infection among young adults with psychotic disorders. Je 864–866
Sved M see Sheitman BB
Swales TP see Kenny JT
Swartz CM: Subconvulsive magnetic brain stimulation no replacement for ECT (letter). My 716–717
Swartz HA: bk rev, H Lerman: Pigeonholing Women's Misery: A History and Critical Analysis of the Psychodiagnosis of Women in the Twentieth Century. Oc 1469–1470
Swearer JM see O'Donnell BF
Swedo SE: reply to E Hollander: Repetitive behaviors and D8/17 positivity (letter). No 1630–1631
Swedo SE, Leonard HL, Mittleman BB, Allen AJ, Rapoport JL, Dow SP, Kanter ME, Chapman F, Zabriskie J: Identification of children with pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections by a marker associated with rheumatic fever. Ja 110–112 (letter: Hollander, reply of Swedo, No 1630–1631)
Swedo SE see O'Sullivan RL
Sweet RA see Zubenko GS
Swica Y see Lewis DO
Szabo CP, Terre Blanche MJ: Perfectionism in anorexia nervosa (letter). Ja 132
Szabó G see Trixler M
Szatmari P see Roy M-A
Szigethy EM see Clemens NA

T

Tagatz GE see Meller WH
Takei N see Verdoux H; Wright P
Talbott JA, Ancill RJ, Holliday S, Higgenbottam J: Review (letter). Au 1180
Talovic SA see Subotnik KL
Tamminga CA, Schwarcz R, MacDonald ME: Clinical genetics, I: Huntington's disease: from disease to gene (image, neuro). Je 725
Tamminga CA see Conley RR; Nestler EJ; Zimbroff DL
Tamura RN see Tollefson GD
Tanay E: Reviewing a review (letter). Fe 295
Tandon R: bk rev, A Breier (ed): The New Pharmacotherapy of Schizophrenia. Ap 576–577
Tandon R see Taylor SF
Tanrikut C see Jacobsen LK
Tardiff K, Marzuk PM, Leon AC, Portera L: reply to D Dhossche: Violence and cocaine (letter). Oc 1481
Tardiff K, Marzuk PM, Leon AC, Portera L, Weiner C: Violence by patients admitted to a private psychiatric hospital. Ja 88–93 (letter: Dhossche, reply of Tardiff, Oc 1480–1481)
Tardiff K see Marzuk PM
Tasman A see Clemens NA
Taylor J see Murphy GM Jr
Taylor SF, Tandon R, Koeppe RA: PET study of greater visual activation in schizophrenia. Se 1296–1298
Teale P see Rojas DC
Tebes JK see Wolff N
Tényi T see Trixler M
Terr LC, Bloch DA, Michel BA, Shi H, Reinhardt JA, Metayer S: Children's thinking in the wake of *Challenger*. Je 744–751
Terre Blanche MJ see Szabo CP
Thaker G see Bustillo JR
Thase ME, Buysse DJ, Frank E, Cherry CR, Cornes CL, Mallinger AG, Kupfer DJ: Which depressed patients will respond to interpersonal psychotherapy? the role of abnormal EEG sleep profiles. Ap 502–509
Thase ME see Mulsant BH; Salloum IM
Thieme ME see Tollefson GD
Thompson PA see Meltzer HY
Thompson TL II: bk rev, TA Widiger, AJ Frances, HA Pincus, R Ross, MB First, WW Davis (eds): DSM-IV Sourcebook, vol

2; A Frances, R Ross (eds): DSM-IV Case Studies: A Clinical Guide to Differential Diagnosis. Oc 1467–1468
Thorpy MJ see Nowell PD
Tielens JAE: Vitamin C for paroxetine- and fluvoxamine-associated bleeding (letter). Je 883–884
Tien AY see Barta PE
Tienari P see Wahlberg K-E
Tiffany ST: bk rev, S Dowling (ed): The Psychology and Treatment of Addictive Behavior: Workshop Series of the American Psychoanalytic Association Monograph 8. My 709–710
Tiihonen J, Isohanni M, Räsänen P, Koiranen M, Moring J: Specific major mental disorders and criminality: a 26-year prospective study of the 1966 Northern Finland birth cohort. Je 840–845
Tiihonen J, Kuikka J, Bergström K, Lepola U, Koponen H, Leinonen E: Dopamine reuptake site densities in patients with social phobia. Fe 239–242
Tiihonen J, Räsänen P, Hakko H: Seasonal variation in the occurrence of homicide in Finland. De 1711–1714
Tinklenberg JR see Murphy GM Jr
Tipp JE see Schuckit MA
Todak G see Rabkin JG
Toenniessen LM see Hamilton NG
Tollefson GD, Beasley CM Jr, Tamura RN, Tran PV, Potvin JH: Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol. Se 1248–1254
Tollefson GD, Beasley CM Jr, Tran PV, Street JS, Krueger JA, Tamura RN, Graffeo KA, Thieme ME: Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Ap 457–465
Tollefson GD, Sanger TM: Negative symptoms: a path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine. Ap 466–474
Tomas S see Chemtob CM
Tomé MB see Isaac MT
Tondo L, Baldessarini RJ, Floris G, Rudas N: Effectiveness of restarting lithium treatment after its discontinuation in bipolar I and bipolar II disorders. Ap 548–550
Tondo L see Baldessarini RJ
Toomey R, Kremen WS, Simpson JC, Samson JA, Seidman LJ, Lyons MJ, Faraone SV, Tsuang MT: Revisiting the factor structure for positive and negative symptoms: evidence from a large heterogeneous group of psychiatric patients. Mr 371–377
Toppelberg CO: Biopsychosocial model (letter). Se 1328
Tordjman S, Ferrari P, Sulmont V, Duyme M, Roubertoux P: Androgenic activity in autism (letter). No 1626–1627
Toro A see Kalayam B
Torres M see Dixon L
Torrey EF: Breast cancer risk in psychiatric patients (letter). Ap 588–589
Tran PV see Tollefson GD
Trappler B, Endicott J: Religion and psychopathology (letter). No 1636
Tremblay RE see Vitaro F
Tremeau F, Amador X, Malaspina D: Psychosis and etiology (letter). Ja 132–133
Trescoli-Serrano C see Bouman WP
Tricamo E see Stewart JW
Trimble MR: bk rev, KK Jain: Drug-Induced Neurological Disorders. Ja 126–127
Trixler M, Tényi T, Csábi G, Szabó G, Méhes K: Informative morphogenetic variants in patients with schizophrenia and alcohol-dependent patients: beyond the Waldrop scale. My 691–693
Trusty ML see Wolff N
Tsuang MT: The Massachusetts Mental Health Center (image, psych). Mr 423
Tsuang MT see Patel JK; Toomey R
Tu XM see Zubenko GS
Turetsky BI see Moberg PJ
Turgeon M see Roy M-A
Turner CW see Goldman RL
Turner EH see Clark CH
Turner SM see Frueh BC
Turner WJ: Homosexuality and older brothers (letter). Ja 136–137
Tutkun H see Şar V
Tylec A see Jönsson EG
Tyndel FJ see Tyndel M
Tyndel M, Tyndel FJ: Taking care of money matters (letter). Ja 135

U

Ulrich RF see Hogarty GE
Ustun TB see Gureje O

V

Vallabhajosula S see Hirschowitz J
Vallès V see Gutiérrez B
van den Bout J see Havenaar JM
van den Brink W see Havenaar JM
van der Horst CM see Evans DL
van Engeland H see Havenaar JM
Veenhuis PE: bk rev, F Cournos, N Bakalar (eds): AIDS and People With Severe Mental Illness: A Handbook for Mental Health Professionals. No 1619–1620
Veith RC see Elrod R; Jensen CF
Venditto TA see Eisen JL
Vera SC see Zanarini MC
Verdoux H, Geddes JR, Takei N, Lawrie SM, Bovet P, Eagles JM, Heun R, McCreadie RG, McNeil TF, O'Callaghan E, Stöber G, Willinger U, Wright P, Murray RM: Obstetric complications and age at onset in schizophrenia: an international collaborative meta-analysis of individual patient data. Se 1220–1227
Verhoeff NPLG: Benzodiazepine receptor binding and schizophrenia (letter). Oc 1480
Versage EM see Beardslee WR
Vgontzas AN see Nowell PD
Victor BJ see Fenton WS
Villarreal G see Brawman-Mintzer O
Vinekar SS: Report of the Elections Committee (off acts). Se 1339–1340
Vinogradov S: bk rev, MF Jensvold, U Halbreich, JA Hamilton (eds): Psychopharmacology and Women: Sex, Gender, and Hormones. Ap 570
Vinogradov S, Willis-Shore J, Poole JH, Marten E, Ober BA, Shenaut GK: Clinical and neurocognitive aspects of source monitoring errors in schizophrenia. No 1530–1537
Vinogradov S see Deicken RF
Vitale A see Leckman JF
Vitaro F, Arseneault L, Tremblay RE: Dispositional predictors of problem gambling in male adolescents. De 1769–1770
Vitkun SA see Smith GS
Vitouch O see Neumeister A
Voderholzer U see Berger M
Volkmar FR: bk rev, JL Rapoport, DR Ismond: DSM-IV Training Guide for Diagnosis of Childhood Disorders. Je 878
Volkow ND, Wang G-J, Fowler JS, Hitzemann R, Pappas N, Pascani K, Wong C: Gender differences in cerebellar metabolism: test-retest reproducibility. Ja 119–121
Volkow ND, Wang G-J, Fowler JS, Logan J, Angrist B, Hitzemann R, Lieberman J, Pappas N: Effects of methylphenidate on regional brain glucose metabolism in humans: relationship to dopamine D_2 receptors. Ja 50–55
Volkow ND see Smith GS
Vollman J see Berger M
Volpicelli JR see Lifrak PD
von Arbin M see Mårtensson B
von Gontard A, Eiberg H, Hollmann E, Rittig S, Lehmkuhl G: Genetic heterogeneity in nocturnal enuresis (letter). Je 885
VonKorff M see Simon GE
Vrindavanam NS see Sallee FR

W

Wahlberg K-E, Wynne LC, Oja H, Keskitalo P, Pykäläinen L, Lahti I, Moring J, Naarala M, Sorri A, Seitamaa M, Läksy K, Kolassa J, Tienari P: Gene-environment interaction in vulnerability to schizophrenia: findings from the Finnish Adoptive Family Study of Schizophrenia. Mr 355–362
Walker JR see Stein MB
Walker ML see Grilo CM
Walker RD: Report of the Speaker (off acts). Se 1334–1335
Wall TL see Garcia-Andrade C
Wallin BA see Zimbroff DL
Wallot H see Roy M-A
Walsh BT, Wilson GT, Loeb KL, Devlin MJ, Pike KM, Roose SP, Fleiss J, Waternaux C: Medication and psychotherapy in the treatment of bulimia nervosa. Ap 523–531
Walsh D see Kendler KS
Walsh R: bk rev, RN Remen: Kitchen Table Wisdom: Stories That Heal. De 1782
Walter G see Rey JM
Walters EE see Kessler RC
Wang G-J see Volkow ND
Wang R-w see Phillips MR
Wang Z see Crowe RR
Waniek C see Susser E
Ware MR see Brawman-Mintzer O
Warnock JK, Biggs F: Nefazodone-induced hypoglycemia in a diabetic patient with major depression (letter). Fe 288–289
Warren A see Frangou S
Warsh JJ see Emamghoreishi M
Washburn SL: bk rev, RK Schreter, SS Sharfstein, CA Schreter (eds): Allies and Adversaries: The Impact of Managed Care on Mental Health Services. Ja 124–125
Wasserman EM see George MS; Greenberg BD
Waterhouse GJ see Moore RF
Waterhouse L see Fein D

Waternaux C see Walsh BT
Watkins GL see Paradiso S
Watts BV, Grady TA: Tramadol-induced mania (letter). No 1624
Waugaman RM: bk rev, L Rangell, R Moses-Hrushovski (eds): Psychoanalysis at the Political Border: Essays in Honor of Rafael Moses. Ap 573
Waziri R: bk rev, OG Cameron (ed): Adrenergic Dysfunction and Psychobiology. No 1620
Weaver AJ, Samford JA, Koenig HG: Depression awareness training and the clergy (letter). My 717–718
Weiden P see Dixon L
Weinberger DR see Goldberg TE
Weiner C see Tardiff K
Weiner MF, Cullum CM, Risser RC, Honig L, White C III, Speciale S: reply to S Curran, DP Birkett: Lewy bodies (letter). Se 1323
Weiner MW see Deicken RF
Weiner RD see Cassidy F
Weinstock R, Clark HW: Confidentiality conundrum (letter). Oc 1483
Weintraub S see Gartner J
Weir CR see Goldman RL
Weisenfeld NI see Breier A
Weiss DS see Zatzick DF
Weissman MM see Leon AC; Levav I; Olfson M
Wells KB see Zatzick DF
Wells RD: Triplet repeat diseases in man, microbes, and molecules (letter). Je 887
Werner A: Obsessive-compulsive symptoms in schizophrenia (letter). No 1635
Wessels C see Stein DJ
Wessely S: reply to DM Lipkin: Chronic fatigue (letter). Se 1322
Wessely S see Deale A
West JC see Zarin DA
West R, Hajek P: What happens to anxiety levels on giving up smoking? No 1589–1592
West SA see McElroy SL; Sax KW
Westen D: Divergences between clinical and research methods for assessing personality disorders: implications for research and the evolution of axis II. Jy 895–903
Wexler KB see Schneier FR
Wharton R: bk rev, MF Basch: Doing Brief Psychotherapy. Mr 431
Wheeler SB see Mammen O
Whiskin FE: bk rev, F Burwick: Poetic Madness and the Romantic Imagination. De 1777–1778
White C III see Weiner MF
White L see Harvey PD
Wiederman MW see Sansone RA
Wieneke MH see Lauriello J
Wilkinson CW see Jensen CF
Williams AA see Zanarini MC
Williams D see Shapiro PA
Williams JBW see Rabkin JG
Williams M see Balon R
Williams RC Jr see Murphy TK
Williams SCR see Woodruff PWR
Williams WE see George MS
Willinger U see Verdoux H
Willis-Shore J see Vinogradov S
Wilson AA see Kapur S
Wilson GT see Walsh BT
Wilson KG see Chochinov HM
Winstead DK see Schwartz B
Wirshing WC see Green MF
Wiseman EJ: Androgens and alcohol (letter). Jy 1040–1041
Wisner KL, Findling RL, Perel JM: reply to S Ito, O Mammen: Antidepressants and breast-feeding (letter). Au 1175
Wolff N, Helminiak TW, Morse GA, Calsyn RJ, Klinkenberg WD, Trusty ML: Cost-effectiveness evaluation of three approaches to case management for homeless mentally ill clients. Mr 341–348
Wolff N, Helminiak TW, Tebes JK: Getting the cost right in cost-effectiveness analyses. Je 736–743
Wong C see Volkow ND
Wong DF see Schlaepfer TE
Wong N: bk rev, RG Druss: The Psychology of Illness: In Sickness and in Health. No 1617–1618
Woo T-U, Miller JL, Lewis DA: Schizophrenia and the parvalbumin-containing class of cortical local circuit neurons. Jy 1013–1015
Woodman CL: bk rev, JM Ellison (ed): Integrative Treatment of Anxiety Disorders. Ja 127–128
Woodman CL: bk rev, M Hersen, VB Van Hasselt (eds): Psychological Treatment of Older Adults: An Introductory Text. Se 1311–1312
Woodruff PWR, Wright IC, Bullmore ET, Brammer M, Howard RJ, Williams SCR, Shapleske J, Rossell S, David AS, McGuire PK, Murray RM: Auditory hallucinations and the temporal cortical response to speech in schizophrenia: a functional magnetic resonance imaging study. De 1676–1682
Woods SW see Shear MK
Wozniak PJ see Zimbroff DL
Wright EJ see Beardslee WR
Wright IC see Woodruff PWR
Wright P, Takei N, Rifkin L, Murray RM: reply to G Stöber: Maternal infectious illness and schizophrenia (letter). Fe 293
Wright P see Verdoux H
Wrigley M see Curran S
Wu J see Haznedar MM
Wukich N see Shapiro PA
Wynne D see George DT
Wynne LC see Wahlberg K-E

Y

Yamashita H see Mori E
Yan H see Zhang M
Yargiç LI see Şar V
Yates WR: bk rev, JR Rundell, MG Wise (eds): The American Psychiatric Press Textbook of Consultation-Liaison Psychiatry. Ja 128–129
Yatham LN see Kusumakar V; Maskall DD
Yeager CA, Lewis DO: False memories of cult abuse (letter). Mr 435
Yeager CA see Lewis DO
Yehuda R, Southwick SM, Giller EL Jr: reply to M Steinberg: Dissociation and the Holocaust (letter). My 721
Yesavage J see Murphy GM Jr
Yoneda Y see Mori E
Yong L see Zanarini MC
Yonkers K see Kocsis JH
Young J see Chacko RC
Young JL: bk rev, JA Valciukas: Forensic Neuropsychology: Conceptual Foundations and Clinical Practice. Au 1162–1163
Young L: Academic versus clinical views on lithium use (letter). Jy 1040
Young RC see Alexopoulos GS; Kalayam B
Yudofsky SC: Reply to AG Gordon: Anorexia nervosa in the eighteenth century (letter). Jy 1041
Yun L-S see Reiman EM

Z

Zabriskie J see Swedo SE
Zabriskie JB see Murphy TK
Zaidel DW, Esiri MM, Harrison PJ: Size, shape, and orientation of neurons in the left and right hippocampus: investigation of normal asymmetries and alterations in schizophrenia. Je 812–818
Zanarini MC, Williams AA, Lewis RE, Reich RB, Vera SC, Marino MF, Levin A, Yong L, Frankenburg FR: Reported pathological childhood experiences associated with the development of borderline personality disorder. Au 1101–1106
Zander KM see Meller WH
Zarate R see Kopelowicz A
Zarin DA, Pincus HA, West JC, McIntyre JS: Practice-based research in psychiatry. Se 1199–1208
Zarin DA see Herz M; Marcus SC
Zatzick DF, Marmar CR, Weiss DS, Browner WS, Metzler TJ, Golding JM, Stewart A, Schlenger WE, Wells KB: Posttraumatic stress disorder and functioning and quality of life outcomes in a nationally representative sample of male Vietnam veterans. De 1690–1695
Zatzick DF see Hales RE
Zhang H see Leckman JF
Zhang M, Ji J, Yan H: New perspectives in mental health services in Shanghai (festschrift). Je suppl 55–58
Zheng B see Evans DL
Zhou L see Deicken RF
Zibin S see Atkinson M
Zibin T, Nolet C, O'Croinin F: Bipolar women (letter). Mr 441
Ziemann U, Paulus W, Rothenberger A: Decreased motor inhibition in Tourette's disorder: evidence from transcranial magnetic stimulation. Se 1277–1284
Zimbroff DL, Kane JM, Tamminga CA, Daniel DG, Mack RJ, Wozniak PJ, Sebree TB, Wallin BA, Kashkin KB: Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Je 782–791
Zipursky RB see Kapur S
Zis AP see Maskall DD
Zisook S: bk rev, DG Blazer II: Depression in Late Life, 2nd ed. Je 877
Zisook S see Kocsis JH
Zitzelsberger A see Agelink MW
Zoëga T see Crowe RR
Zohar AH, Pauls DL, Ratzoni G, Apter A, Dycian A, Binder M, King R, Leckman JF, Kron S, Cohen DJ: Obsessive-compulsive disorder with and without tics in an epidemiological sample of adolescents. Fe 274–276
Zorrilla EP, McKay JR, Luborsky L, Schmidt K: reply to SC Kalichman: Progression of viral illness (letter). My 718
Zubenko GS, Mulsant BH, Sweet RA, Pasternak RE, Tu XM: Mortality of elderly patients with psychiatric disorders. Oc 1360–1368
Zweig-Frank H see Paris J

Subject Index

A

Abortion
Normatology: a review and commentary with reference to abortion and physician-assisted suicide (festschrift). Brodie, Je suppl 13–19
Physician-assisted suicide and abortion (letter). Dobscha, Au 1173–1174
Academic Psychiatry
Research without external funding in North American psychiatry. Silberman, Au 1159–1160
***N*-acetylaspartate**
Decreased left frontal lobe *N*-acetylaspartate in schizophrenia. Deicken, My 688–690
Acetylcholine
Brain proton magnetic resonance spectroscopy (^{1}H-MRS) in Alzheimer's disease: changes after treatment with xanomeline, an M_1 selective cholinergic agonist. Satlin, Oc 1459–1461
Acquired Immune Deficiency Syndrome see HIV
Addiction see also Substance Abuse
Internet addiction, internet psychotherapy (letter). Stein, reply of Huang, Je 890
Progress in the science of addiction (editorial). O'Brien, Se 1195–1197
Adolescents
B lymphocyte antigen D8/17: a peripheral marker for childhood-onset obsessive-compulsive disorder and Tourette's syndrome? Murphy, Mr 402–407
Children's thinking in the wake of *Challenger*. Terr, Je 744–751
Cognitive impairment in adolescents with schizophrenia. Kenny, No 1613–1615
Dispositional predictors of problem gambling in male adolescents. Vitaro, De 1769–1770
Half a century of ECT use in young people. Rey, My 595–602
Lithium treatment of conduct disorders in adolescents. Rifkin, Ap 554–555
Naltrexone for alcoholic adolescents (letter). Lifrak, Mr 439–440
Obsessive-compulsive disorder with and without tics in an epidemiological sample of adolescents. Zohar, Fe 274–276
Outcome of psychotherapy among early adolescents after trauma. Goenjian, Ap 536–542
Prevalence and risk factors for posttraumatic stress disorder among chemically dependent adolescents. Deykin, Je 752–757
Pulse intravenous clomipramine for depressed adolescents: double-blind, controlled trial. Sallee, My 668–673
Quantitative morphology of the cerebellum and fourth ventricle in childhood-onset schizophrenia. Jacobsen, De 1663–1669
Relative efficacy of haloperidol and pimozide in children and adolescents with Tourette's disorder. Sallee, Au 1057–1062
Social consequences of psychiatric disorders, II: teenage parenthood. Kessler, Oc 1405–1411
Three-dimensional cortical morphometry of the planum temporale in childhood-onset schizophrenia. Jacobsen, My 685–687
Toward a strategy for healthy adolescent development (festschrift). Hamburg, Je suppl 7–12
Aftercare see Deinstitutionalization
Age see also Onset of Illness
Advancing age, declining ADHD (letter). Barkley, reply of Hill, Se 1323–1325
Age-related differences in formal thought disorder in chronically hospitalized schizophrenic patients: a cross-sectional study across nine decades. Harvey, Fe 205–210
Emotional activation of limbic circuitry in elderly normal subjects in a PET study. Paradiso, Mr 384–389
Suicide and schizophrenia: a nationwide psychological autopsy study on age- and sex-specific clinical characteristics of 92 suicide victims with schizophrenia. Heilä, Se 1235–1242
Aggression see Violence
Aging see Geriatric Psychiatry
Agoraphobia
Panic-agoraphobic spectrum: a descriptive approach to the assessment and treatment of subtle symptoms (festschrift). Cassano, Je suppl 27–38
AIDS see HIV
Akathisia
Propranolol treatment of olanzapine-induced akathisia (letter). Kurzthaler, Se 1316
Protracted akathisia after risperidone withdrawal (letter). Rosebush, Mr 437–438
Alcohol and Alcoholism
Androgens and alcohol (letter). Wiseman, Jy 1040–1041
Behavioral and neuroendocrine responses to *m*-chlorphenylpiperazine in subtypes of alcoholics and in healthy comparison subjects. George, Ja 81–87
Comparison of induced and independent major depressive disorders in 2,945 alcoholics. Schuckit, Jy 948–957
Evidence of preference for a high-concentration sucrose solution in alcoholic men. Kampov-Polevoy, Fe 269–270 (letter: Hirsch, reply of Kampov-Polevoy, No 1631–1632)
Firewater myth and response to alcohol in Mission Indians. Garcia-Andrade, Jy 983–988
High sucrose preference in alcoholic men (letter). Hirsch, reply of Kampov-Polevoy, No 1631–1632
Homicidal behavior in drug abusing psychiatric patients (letter). Dhossche, reply of Salloum, Je 888–889
Naltrexone for alcoholic adolescents (letter). Lifrak, Mr 439–440
Origin of homovanillic acid in plasma (letter). Lambert, reply of Fulton, Ja 138–139
Persistent delirium following cessation of heavy alcohol consumption: diagnostic and treatment implications (case conf). Hersh, Je 846–851
Prevalence and risk factors for posttraumatic stress disorder among chemically dependent adolescents. Deykin, Je 752–757
Sequential use of naltrexone in the treatment of relapsing alcoholism (letter). Farren, My 714
Superiority of carbohydrate-deficient transferrin to γ-glutamyltransferase in detecting relapse in alcoholism. Schmidt, Ja 75–80
al-Razi
al-Razi (Rhazes), 865–925 (image, psych). Daghestani, No 1602
Alzheimer's Disease see also Dementia
Association of premorbid intellectual function with cerebral metabolism in Alzheimer's disease: implications for the cognitive reserve hypothesis. Alexander, Fe 165–172
Brain proton magnetic resonance spectroscopy (^{1}H-MRS) in Alzheimer's disease: changes after treatment with xanomeline, an M_1 selective cholinergic agonist. Satlin, Oc 1459–1461
Clinical genetics, III: Alzheimer's disease: from genes to pathogenesis (image, neuro). Selkoe, Se 1198
Clinical genetics, IV: Alzheimer's disease: from gene to pathology (image, neuro). Jay, Oc 1359
Durable power of attorney and informed consent with Alzheimer's disease patients: a clinical study. Dukoff, Au 1070–1075
Effects of Alzheimer's disease severity on cerebrospinal fluid norepinephrine concentration. Elrod, Ja 25–30
Lewy bodies (letters). Curran; Birkett, reply of Weiner, Se 1322–1323
Low glucose metabolism during brain stimulation in older Down's syndrome subjects at risk for Alzheimer's disease prior to dementia. Pietrini, Au 1063–1069
Meta-analysis of postmortem studies of Alzheimer's disease-like neuropathology in schizophrenia. Baldessarini, Je 861–863 (correction: Au 1180)
No association between apolipoprotein E ∈4 allele and rate of decline in Alzheimer's disease. Murphy, My 603–608
Practice guideline for the treatment of patients with Alzheimer's disease and other dementias of late life. American Psychiatric Association, My suppl (correction: Au 1180)
Premorbid brain size as a determinant of reserve capacity against intellectual decline in Alzheimer's disease. Mori, Ja 18–24
American Board of Psychiatry and Neurology
1996–1997 annual report of the American Board of Psychiatry and Neurology, Inc (off acts). American Board of Psychiatry and Neurology, Inc, Au 1181–1183
Report on the 1996 examinations (off acts).

American Board of Psychiatry and Neurology, Inc, Au 1184–1194
American Journal of Psychiatry
Reviewers for *The American Journal of Psychiatry* (in appreciation). American Journal of Psychiatry, Ja 140–142
State of the *Journal* (editorial). Andreasen, Ja 1–2
American Psychiatric Association
Council on Addiction Psychiatry (off acts). Ordorica, Fe 297
Council on Aging (off acts). Goldstein, Fe 297–298
Council on Children, Adolescents, and Their Families (off acts). Mawhinney, Fe 298–299
Council on Economic Affairs (off acts). Kline, Fe 299–300
Council on Internal Organization (off acts). Rose, Fe 300
Council on International Affairs (off acts). Ruiz, Fe 301
Council on Medical Education and Career Development (off acts). Shore, Fe 301–302
Council on National Affairs (off acts). Hanin, Fe 302–303
Council on Psychiatric Services (off acts). Fields, Fe 303–304
Council on Psychiatry and Law (off acts). Hoge, Fe 304–305
Council on Research (off acts). Guze, Fe 305–306
Harold I Eist, MD, one hundred twenty-fifth president, 1996–1997. Sabshin, Oc 1354–1355
Highlights of the 1997 annual meeting (off acts). Borenstein, Oc 1487–1492
Position statement on discrimination against persons with previous psychiatric treatment (off acts). American Psychiatric Association Council on Psychiatry and Law, Jy 1042
Practice-based research in psychiatry. Zarin, Se 1199–1208
Practice guideline for the treatment of patients with schizophrenia. American Psychiatric Association, Ap suppl (letters: Dickson; Liberman; reply of Herz, De 1792–1794)
Presidential address: strengthening psychiatry's dedication and commitment to compassionate care, educational excellence, and creative research. Eist, Oc 1343–1349
Report of the Committee of Tellers (off acts). Akman, Se 1339
Report of the Committee on Constitution and Bylaws (off acts). Pfaehler, Se 1336–1337
Report of the Committee on Membership (off acts). Katz, Se 1337–1339
Report of the Elections Committee (off acts). Vinekar, Se 1339–1340
Report of the Medical Director (off acts). Sabshin, Se 1333–1334
Report of the Secretary (off acts). Borenstein, Se 1330–1331
Report of the Speaker (off acts). Walker, Se 1334–1335
Report of the Speaker-Elect (off acts). Lazarus, Se 1335–1336
Report of the Treasurer (off acts). Gottlieb, Se 1331–1333
Response to the presidential address: new challenges for proven values. Sacks, Oc 1350–1353
Americans With Disabilities Act
Position statement on discrimination against persons with previous psychiatric treatment (off acts). American Psychiatric Association Council on Psychiatry and Law, Jy 1042
γ-Aminobutyric Acid
Candidate gene study of eight $GABA_A$ receptor subunits in panic disorder. Crowe, Au 1096–1100
Correlation between reduced in vivo benzodiazepine receptor binding and severity of psychotic symptoms in schizophrenia. Busatto, Ja 56–63 (correction: My 722) (letter: Verhoeff, reply of Busatto, Oc 1480)
Androgens see Steroids
Anorexia Nervosa see also Bulimia; Eating Disorders
Anorexia nervosa in the eighteenth century (letter). Gordon, reply of Yudofsky, Jy 1041
Perfectionism in anorexia nervosa (letter). Szabo, reply of Kaye, Ja 132
Prediction of low body weight at long-term follow-up in acute anorexia nervosa by low body weight at referral. Hebebrand, Ap 566–569
Antibodies
B lymphocyte antigen D8/17: a peripheral marker for childhood-onset obsessive-compulsive disorder and Tourette's syndrome? Murphy, Mr 402–407
Anticipation see Onset of Illness
Antidepressants see also specific drugs
Antidepressants and breast-feeding (letters). Ito; Mammen; reply of Wisner, Au 1174–1175
Medication and psychotherapy in the treatment of bulimia nervosa. Walsh, Ap 523–531
Use of antidepressants by nonpsychiatrists in the treatment of medically ill hospitalized depressed elderly patients. Koenig, Oc 1369–1375
Antisocial Personality Disorder
CSF 5-HIAA and family history of antisocial personality disorder in newborns. Constantino, De 1771–1773
Anxiety
Effects of the cholecystokinin agonist pentagastrin in patients with generalized anxiety disorder. Brawman-Mintzer, My 700–702
Self-reported anxiety, general medical conditions, and disability bed days. Marcus, De 1766–1768
Virtual reality therapy for fear of flying (letter). North, Ja 130
What happens to anxiety levels on giving up smoking? West, No 1589–1592
Apolipoprotein E ∈ 4
Apolipoprotein E ∈ 4 allele and pupillary response to tropicamide. Higuchi, My 694–696
No association between apolipoprotein E ∈ 4 allele and rate of decline in Alzheimer's disease. Murphy, My 603–608
Asians
Refugees' time perspective and mental health. Beiser, Jy 996–1002
Assaultive Behavior see Violence
Assertive Community Treatment
Cost-effectiveness evaluation of three approaches to case management for homeless mentally ill clients. Wolff, Mr 341–348
Attachment
Abandonment and intrusion fears in borderline personality disorder (letter). Chabrol, reply of Gunderson, Se 1329
Neurobiological basis of social attachment. Insel, Je 726–735
Attention
Anterior cingulate gyrus dysfunction and selective attention deficits in schizophrenia: $[^{15}O]H_2O$ PET study during single-trial Stroop task performance. Carter, De 1670–1675
Attentional functioning in schizotypal personality disorder. Lees Roitman, My 655–660 (correction: Au 1180)
Attention Deficit Hyperactivity Disorder
ADHD and maternal smoking during pregnancy (letter). Chabrol, reply of Milberger, Au 1177–1178
Advancing age, declining ADHD (letter). Barkley, reply of Hill, Se 1323–1325
Pemoline and hepatotoxicity (letter). McCurry, My 713–714
Substance abuse and ADHD (letter). Hughes, Ja 132
Twin concordance for attention deficit hyperactivity disorder: a comparison of teachers' and mothers' reports. Sherman, Ap 532–535
Auditory Evoked Potentials see Evoked Potentials
Autism
Androgenic activity in autism (letter). Tordjman, No 1626–1627
Anterior cingulate gyrus volume and glucose metabolism in autistic disorder. Haznedar, Au 1047–1050
Broader autism phenotype: evidence from a family history study of multiple-incidence autism families. Piven, Fe 185–190
MRI study of the corpus callosum in autism. Piven, Au 1051–1056
Pitocin induction and autism (letter). Fein, Mr 438–439
Use of fluoxetine for obsessive-compulsive behavior in adults with autism (letter). Koshes, Ap 578
Autoimmunity
B lymphocyte antigen D8/17: a peripheral marker for childhood-onset obsessive-compulsive disorder and Tourette's syndrome? Murphy, Mr 402–407

B

Baillarger, Jules
Jules Baillarger, 1809–1891 (image, psych). Bourgeois, Fe 262
Basilar Artery
Basilar artery response to hyperventilation in panic disorder. Ball, No 1603–1604
Bed-Wetting
Genetic heterogeneity in nocturnal enuresis (letter). von Gontard, Je 885
Benzodiazepines see also specific drugs
Benzodiazepine receptor binding and schizophrenia (letter). Verhoeff, reply of Busatto, Oc 1480
Benzodiazepines and exposure-based cognitive behavior therapies for panic disorder: conclusions from combined treatment trials. Spiegel, Je 773–781
Benztropine
Delirium associated with paroxetine and

benztropine combination (letter). Armstrong, Ap 581–582
Bereavement
Comorbid postpartum depression and bereavement: a complicated case (case conf). Stowe, Mr 418–422
Outcome of psychotherapy among early adolescents after trauma. Goenjian, Ap 536–542
Traumatic grief: a case of loss-induced trauma (case conf). Prigerson, Jy 1003–1009
Traumatic grief as a risk factor for mental and physical morbidity. Prigerson, My 616–623
Bibring, Grete
Grete Bibring, MD, 1899–1977 (image, psych). Brown, Se 1292
Biological Rhythms see Seasonal Affective Disorder
Biopsychosocial Perspective
Biopsychosocial model (letter). Toppelberg, reply of Fullilove, Se 1328–1329
Bipolar Disorder
Association analysis of the catechol O-methyltransferase gene and bipolar affective disorder. Gutiérrez, Ja 113–115 (letter: Cohn, reply of Gutiérrez, Oc 1484)
Atypical neuroleptic malignant syndrome associated with risperidone treatment (letter). Newman, Oc 1475
Bipolar women (letter). Zibin, reply of Leibenluft, Mr 441
Borderline personality and bipolar disorder (letters). Feiner; Prakash; reply of Gunderson, Au 1175–1177
Effectiveness of restarting lithium treatment after its discontinuation in bipolar I and bipolar II disorders. Tondo, Ap 548–550
Exclusion of expansion of 50 CAG/CTG trinucleotide repeats in bipolar disorder. Guy, Au 1146–1147
Gabapentin in the treatment of bipolar disorder (letter). Schaffer, Fe 291–292
Genetic risk factors for bipolar disorder (letter). Cohn, reply of Gutiérrez, Oc 1484
High intracellular calcium concentrations in transformed lymphoblasts from subjects with bipolar I disorder. Emamghoreishi, Jy 976–982
Lamotrigine for treatment-refractory bipolar disorder (letter). Labbate, Se 1317
Lamotrigine treatment of rapid cycling bipolar disorder (letter). Kusumakar, Au 1171–1172
Nephrotic syndrome associated with lithium therapy (letter). Gill, Se 1318–1319
Phenomenology of adolescent and adult mania in hospitalized patients with bipolar disorder. McElroy, Ja 44–49
Premorbid social functioning in schizophrenia and bipolar disorder: similarities and differences. Cannon, No 1544–1550
Psychosis and etiology (letter). Tremeau, reply of Maziade, Ja 132–134
Reduced frontal cortex inositol levels in postmortem brain of suicide victims and patients with bipolar disorder. Shimon, Au 1148–1150
Stress reactivity in bipolar patients and its relation to prior history of disorder. Hammen, Je 856–857
Tramadol-induced mania (letter). Watts, No 1624
Valproate prophylaxis in a prospective clinical trial of refractory bipolar disorder. Denicoff, Oc 1456–1458
Birth Order
Homosexuality and older brothers (letters). Eiberson; Martin; Turner; reply of Blanchard, Ja 136–137
Blood Flow see Cerebral Blood Flow
Blood Levels
Fluoxetine and norfluoxetine plasma concentrations in major depression: a multicenter study. Amsterdam, 963–969
Bone Mineral Density
Neuroleptics and bone mineral density (letter). Al-Adwani, Au 1173
Books Reviewed
Apfel RJ, Simon B (eds): Minefields in Their Hearts: The Mental Health of Children in War and Communal Violence. Lothstein, Se 1308–1309
Atkinson SD, Gabbard GO (eds): Study Guide to Treatments of Psychiatric Disorders, 2nd ed. Dunner, Oc 1467
Auerbach JD, Wypijewska C, Brodie HKH, Committee on Substance Abuse and Mental Health Issues in AIDS Research Institute of Medicine Division of Biobehavioral Sciences and Mental Disorders (eds): AIDS and Behavior: An Integrated Approach. Popkin, Fe 279
Aveline M, Shapiro DA (eds): Research Foundations for Psychotherapy Practice. Fenton, Au 1164–1165
Basch MF: Doing Brief Psychotherapy. Wharton, Mr 431
Bergener M, Finkel SI (eds): Treating Alzheimer's and Other Dementias: Recent Research Advances. Glickman, Je 877–878
Berrios G, Porter R (eds): A History of Clinical Psychiatry: The Origin and History of Psychiatric Diseases. Pasnau, De 1779–1780
Björling A-L, Farkas A: Jussi. Fann, De 1785–1786
Blazer DG II: Depression in Late Life, 2nd ed. Zisook, Je 877
Breier A (ed): The New Pharmacotherapy of Schizophrenia. Tandon, Ap 576–577
Broadwell RD (ed): Neuroscience, Memory, and Language: Papers Presented at a Symposium Series Cosponsored by the National Institute of Mental Health and the Library of Congress. Altshuler, My 705–706
Brown JW: Time, Will, and Mental Process. Levick, Je 874–875
Brunello N, Racagni G, Langer SZ, Mendlewicz J (eds): International Academy for Biomedical and Drug Research, vol 10: Critical Issues in the Treatment of Schizophrenia. Bilder, Se 1312
Burwick F: Poetic Madness and the Romantic Imagination. Whiskin, De 1777–1778
Busse EW, Blazer DG (eds): The American Psychiatric Press Textbook of Geriatric Psychiatry, 2nd ed. Burke, Se 1310–1311
Cameron OG (ed): Adrenergic Dysfunction and Psychobiology. Waziri, No 1620
Chadwick P, Birchwood M, Trower P: Cognitive Therapy for Delusions, Voices and Paranoia. Rabins, Se 1312–1313
Chessick RD: Dialogue Concerning Contemporary Psychodynamic Therapy. Gabbard, Jy 1035–1036
Ciraulo DA, Shader RI, Greenblatt DJ, Creelman W: Drug Interactions in Psychiatry, 2nd ed. Paykel, Ap 577
Clarkin JF, Lenzenweger MF (eds): Major Theories of Personality Disorder. Links, My 704–705
Cournos F, Bakalar N (eds): AIDS and People With Severe Mental Illness: A Handbook for Mental Health Professionals. Veenhuis, No 1619–1620
Cushman P: Constructing the Self, Constructing America: A Cultural History of Psychotherapy. Roazen, My 706
Cytryn L, McKnew DH: Growing Up Sad: Childhood Depression and Its Treatment. Parker, Fe 279–280
Derksen J: Personality Disorders: Clinical and Social Perspectives. Somerfeld-Ziskind, My 704
De Rosa P: Rebels: The Irish Rising of 1916. Ryan, De 1778
De Waal F: Bonobo: The Forgotten Ape. Pollock, De 1784–1785
Dowling S (ed): The Psychology and Treatment of Addictive Behavior: Workshop Series of the American Psychoanalytic Association Monograph 8. Tiffany, My 709–710
Druss RG: The Psychology of Illness: In Sickness and in Health. Wong, No 1617–1618
El-Mallakh RS: Lithium: Actions and Mechanisms. Jefferson, Fe 285–286
Ellison JM (ed): Integrative Treatment of Anxiety Disorders. Woodman, Ja 127–128
Eysenck HJ: Genius: The Natural History of Creativity. Jamison, Mr 430
Fancher RT: Cultures of Healing: Correcting the Image of American Mental Health Care. Robertson, Ja 124 (letter: Fancher, Oc 1485)
Feldman MD, Eisendrath SJ (eds): The Spectrum of Factitious Disorders. Makover, No 1620–1621
Fogel GI, Lane FM, Liebert RS (eds): The Psychology of Men: New Psychoanalytic Perspectives. Myers, Oc 1470
Frances A, Ross R (eds): DSM-IV Case Studies: A Clinical Guide to Differential Diagnosis. Thompson, Oc 1467–1468
Friedman L, Fleming NF, Roberts DH, Hyman SE (eds): Source Book of Substance Abuse and Addiction. Liskow, Se 1313
Gabbard GO, Atkinson SD (eds): Synopsis of Treatments of Psychiatric Disorders, 2nd ed. Dunner, Oc 1467
Gabbard GO, Lester EP: Boundaries and Boundary Violations in Psychoanalysis. Chessick, Ap 573–576
Gemelli R: Normal Child and Adolescent Development. Fras, Se 1309
Goetz CA, Bonduelle M, Gelfand T: Charcot: Constructing Neurology. Ryan, De 1780–1781
Gold MS: Tobacco. Olmstead, Se 1314–1315
Goodnick PJ (ed): Predictors of Treatment Response in Mood Disorders. Myers, Mr 432–433
Group for the Advancement of Psychiatry Committee on Adolescence: Adolescent Suicide: Report 140. Hartmann, Jy 1031
Group for the Advancement of Psychiatry Committee on Cultural Psychiatry: Alcoholism in the United States: Racial and Ethnic Considerations. Blume, Se 1313–1314

Guthrie E, Creed F (eds): Seminars in Liaison Psychiatry. Hilty, No 1618–1619
Hedaya RJ: Understanding Biological Psychiatry. Altamura, Au 1161–1162
Hegi U: Stones From the River. Gabbard, De 1776–1777
Hersen M, Van Hasselt VB (eds): Psychological Treatment of Older Adults: An Introductory Text. Woodman, Se 1311–1312
Heyworth P: Otto Klemperer: His Life and Times, vol I: 1885–1933. Somerfeld-Ziskind, De 1787–1789
Heyworth P: Otto Klemperer: His Life and Times, vol II: 1933–1973. Somerfeld-Ziskind, De 1787–1789
Horgan J: The End of Science: Facing the Limits of Science in the Twilight of the Scientific Age. Forrest, Je 873–874
Horwitz L, Gabbard GO, Allen JG, Frieswyk SH, Colson DB, Newsom GE, Coyne L: Borderline Personality Disorder: Tailoring the Psychotherapy to the Patient. Chessick, Fe 281–283
Jain KK: Drug-Induced Neurological Disorders. Trimble, Ja 126–127
Jensvold MF, Halbreich U, Hamilton JA (eds): Psychopharmacology and Women: Sex, Gender, and Hormones. Vinogradov, Ap 570
Jones JM: Affects as Process: An Inquiry Into the Centrality of Affect in Psychological Life. Prosen, Au 1164
Kaplan SJ (ed): Family Violence: A Clinical and Legal Guide. Malmquist, Fe 280–281
Kelleher MD: New Arenas for Violence: Homicide in the American Workplace. Robinson, No 1621–1622
Kennedy GJ (ed): Suicide and Depression in Late Life: Critical Issues in Treatment, Research, and Public Policy. Ruskin, Je 876
Kirshner HS (ed): Handbook of Neurological Speech and Language Disorders. Berrios, Ja 126
Kleinman A: Writing at the Margin: Discourse Between Anthropology and Medicine. Forrest, De 1781–1782
Kocsis JH, Klein DN (eds): Diagnosis and Treatment of Chronic Depression. Myers, Mr 433
Laszlo E, Artigiani R, Combs A, Csanyi V: Changing Visions: Human Cognitive Maps: Past, Present, and Future. Lewine, Oc 1465–1466
Lazarus A (ed): Controversies in Managed Mental Health Care. Sederer, Ja 125–126
Lee H: Virginia Woolf. Frosch, De 1775–1776
Lenzenweger MF, Haugaard JJ (eds): Frontiers of Developmental Psychopathology. Jensen, Fe 280
Lerman H: Pigeonholing Women's Misery: A History and Critical Analysis of the Psychodiagnosis of Women in the Twentieth Century. Swartz, Oc 1469–1470
Lindesay J (ed): Neurotic Disorders in the Elderly. Pearce, Je 876–877
Links PS (ed): Clinical Assessment and Management of Severe Personality Disorders. Bieber, Fe 283
Mak FL, Nadelson CC (eds): International Review of Psychiatry, vol 2. Sadock, Oc 1466–1467
Makover RB: Treatment Planning for Psychotherapists. Lifson, My 708–709
Maltsberger JT, Goldblatt MJ (eds): Essential Papers on Suicide. Sudak, No 162–1623
Mayou R, Bass C, Sharpe M (eds): Treatment of Functional Somatic Symptoms. Lipsitt, Fe 277–278
Mazure CM (ed): Does Stress Cause Psychiatric Illness? Balon, No 1617
McCourt F: Angela's Ashes: A Memoir. Cusack, De 1774–1775
McCulloch J: Colonial Psychiatry and "The African Mind." Orley, Mr 430–431
McGoldrick M, Giordano J, Pearce JK (eds): Ethnicity and Family Therapy, 2nd ed. Durant, Oc 1470–1471
Mednick SA, Hollister JM (eds): Neural Development and Schizophrenia: Theory and Research. Lafargue, Ap 571–572
Merskey H (ed): The Analysis of Hysteria: Understanding Conversion and Dissociation, 2nd ed. Gold, Fe 284
Milrod B, Busch F, Cooper A, Shapiro T (eds): Manual of Panic-Focused Psychodynamic Psychotherapy. Chodoff, Au 1166–1167
Moore BE, Fine BD (eds): Psychoanalysis: The Major Concepts. Roazen, My 707–708
Moore DP, Jefferson JW: Handbook of Medical Psychiatry. Carney, Oc 1469
Oldham JM, Hollander E, Skodol AE (eds): Impulsivity and Compulsivity. Black, Ja 127
Oldham JM, Riba MB (eds): The American Psychiatric Press Review of Psychiatry, vol 14. Ordoña, Je 879–880
Ostwald PF, Zegans LS (eds): The Threat to the Cosmic Order: Psychological, Social, and Health Implications of Richard Wagner's Ring of the Nibelung. Horton, De 1786–1787
Parmelee DX: Child and Adolescent Psychiatry. Hansen, Je 879
Paykel ES, Jenkins R (eds): Prevention in Psychiatry. McKinney, Mr 429–430
Pearson JL, Conwell Y (eds): Suicide and Aging: International Perspectives. Pridmore, No 1622
Pervin LA: The Science of Personality. Oldham, My 703
Pezdek K, Banks WP (eds): The Recovered Memory/False Memory Debate. Michels, Oc 1465
Pinsof WM: Integrative Problem-Centered Therapy: A Synthesis of Biological, Individual, and Family Therapies. Lefley, Mr 431–432
Rangell L, Moses-Hrushovski R (eds): Psychoanalysis at the Political Border: Essays in Honor of Rafael Moses. Waugaman, Ap 573
Rapee RM (ed): Current Controversies in the Anxiety Disorders. Dunner, Ja 128
Rapoport JL, Ismond DR: DSM-IV Training Guide for Diagnosis of Childhood Disorders. Volkmar, Je 878
Reiss AJ Jr, Roth JA (eds): Understanding and Preventing Violence, vol 3: Social Influences. Scheff, My 709
Reiss AJ Jr, Roth JA (eds): Understanding and Preventing Violence, vol 4: Consequences and Control. Scheff, My 709
Remen RN: Kitchen Table Wisdom: Stories That Heal. Walsh, De 1782
Roberts GW, Polak JM (eds): Molecular Neuropathology. Benes, My 706
Rundell JR, Wise MG (eds): The American Psychiatric Press Textbook of Consultation-Liaison Psychiatry. Yates, Ja 128–129
Sadavoy J, Lazarus LW, Jarvik LF, Grossberg GT (eds): Comprehensive Review of Geriatric Psychiatry—II, 2nd ed. Schultz, Jy 1034
Sadler JZ, Wiggins OP, Schwartz MA (eds): Philosophical Perspectives on Psychiatric Diagnostic Classification. Reus, Jy 1035
Sansonese JN: The Body of Myth: Mythology, Shamanic Trance, and the Sacred Geography of the Body. Heiman, De 1782–1784
Sargent CF, Johnson TM (eds): Handbook of Medical Anthropology: Contemporary Theory and Method, revised ed. Favazza, Oc 1471
Schacter DL: Searching for Memory: The Brain, the Mind, and the Past. Stone, Je 875–876
Schacter DL, Coyle JT (eds): Memory Distortion: How Minds, Brains, and Societies Reconstruct the Past. Kapur, Au 1162
Schildkraut JJ, Otero A (eds): Depression and the Spiritual in Modern Art: Homage to Miro. Esman, De 1786
Schreter RK, Sharfstein SS, Schreter CA (eds): Allies and Adversaries: The Impact of Managed Care on Mental Health Services. Washburn, Ja 124–125
Schutte NS, Malouff JM: Sourcebook of Adult Assessment Strategies. Rush, Jy 1034–1035
Shuchter SR, Downs N, Zisook S: Biologically Informed Psychotherapy for Depression. Stotland, Mr 433
Siegel AM: Heinz Kohut and the Psychology of the Self. Chessick, Au 1165–1166
Silk KR (ed): Biological and Neurobehavioral Studies of Borderline Personality Disorder. Kluft, My 703–704
Silver PA (ed): Psychotropic Drug Use in the Medically Ill. Leigh, Fe 284–285
Sims A: Symptoms of the Mind, 2nd ed. Ieronimo C, Au 1163
Snow CP: The Two Cultures. Goodwin, De 1776
Snyder SH: Drugs and the Brain. Roy-Byrne, Au 1161
Sperry L, Brill PL, Howard KI, Grissom GR: Treatment Outcomes in Psychotherapy and Psychiatric Interventions. Genova, Jy 1036
Stein M, Baum A (eds): Chronic Diseases. Stoudemire, Fe 278–279
Strongman KT: The Psychology of Emotion: Theories of Emotion in Perspective, 4th ed. Nathanson, No 1616–1617
Talbott JA, Ballenger JC, Breier AF, Frances RJ, Meltzer HY, Perry SW, Schowalter JE (eds): The Year Book of Psychiatry and Applied Mental Health 1995. Sledge, Ja 129
Taylor JM, Gilligan C, Sullivan AM: Between Voice and Silence: Women and Girls, Race and Relationship. Fullilove, Ap 571
Tyrer P, Creed F (eds): Community Psychiatry in Action: Analysis and Prospects. Robertson, Mr 429
Valciukas JA: Forensic Neuropsychology: Conceptual Foundations and Clinical Practice. Young, Au 1162–1163

Volavka J: Neurobiology of Violence. Rifkin, No 1621
Volkmar FR (ed): Psychoses and Pervasive Developmental Disorders in Childhood and Adolescence. Fintzy, Jy 1031–1032
Wallerstein RS: The Talking Cures: The Psychoanalyses and the Psychotherapies. Pollock, My 707
Wasco W, Tanzi RE (eds): Molecular Mechanisms of Dementia. Salzman, Jy 1033–1034
Watson SJ (ed): Biology of Schizophrenia and Affective Disease. Crow, Ap 572–573
Wender PH: Attention-Deficit Hyperactivity Disorders in Adults. Post, Se 1309–1310
Widiger TA, Frances AJ, Pincus HA, Ross R, First MB, Davis WW (eds): DSM-IV Sourcebook, vol 2. Thompson, Oc 1467–1468
Winnicott DW: Thinking About Children. Kim Leff, Jy 1032–1033
Woods RT (ed): Handbook of the Clinical Psychology of Aging. Bieber, Se 1310
Wyatt-Brown B: The House of Percy: Honor, Melancholy, and Imagination in a Southern Family. Fann, De 1778–1779

Borderline Personality Disorder
Abandonment and intrusion fears in borderline personality disorder (letter). Chabrol, reply of Gunderson, Se 1329
Borderline-dissociation comorbidity (letter). Galletly, No 1629
Borderline mnemonic (letter). Senger, Se 1321
Borderline personality and bipolar disorder (letters). Feiner; Prakash; reply of Gunderson, Au 1175–1177
Borderline personality disorder and transitional objects (letter). LaPorta, Oc 1484–1485
Characteristics of borderline personality disorder associated with suicidal behavior. Brodsky, De 1715–1719
Dissociation in patients with borderline personality disorder (letter). Paris, reply of Brodsky, Ja 137–138
Reported pathological childhood experiences associated with the development of borderline personality disorder. Zanarini, Au 1101–1106
Transitional objects and borderline personality disorder. Cardasis, Fe 250–255 (letter: LaPorta, Oc 1484–1485)
Treatment for severe borderline personality disorder in 1987 and 1997 (case conf). Quaytman, Au 1139–1144

Brain Asymmetry see Cerebral Lateralization

Brain Disorders
Brainstem evoked response abnormalities in late-life depression with vascular disease. Kalayam, Jy 970–975
Small planum temporale volume in Down's syndrome: a volumetric MRI study. Frangou, Oc 1424–1429

Brain Metabolism see Metabolism

Brain Physiology see Evoked Potentials; Metabolism

Brain Structure see also Cerebral Lateralization; Cognition; Ventricle Size
Anterior cingulate gyrus volume and glucose metabolism in autistic disorder. Haznedar, Au 1047–1050
Cytoarchitecture of the entorhinal cortex in schizophrenia. Akil, Jy 1010–1012
Decreased left frontal lobe N-acetylaspartate in schizophrenia. Deicken, My 688–690
MRI study of the corpus callosum in autism. Piven, Au 1051–1056
Neuroanatomical correlates of externally and internally generated human emotion. Reiman, Jy 918–925
Neuroanatomical correlates of happiness, sadness, and disgust. Lane, Jy 926–933
Planum temporale asymmetry reversal in schizophrenia: replication and relationship to gray matter abnormalities. Barta, My 661–667
Quantitative morphology of the cerebellum and fourth ventricle in childhood-onset schizophrenia. Jacobsen, De 1663–1669
Reduced frontal cortex inositol levels in postmortem brain of suicide victims and patients with bipolar disorder. Shimon, Au 1148–1150
Schizophrenia and the parvalbumin-containing class of cortical local circuit neurons. Woo, Jy 1013–1015
Sex-specific expression of Heschl's gyrus functional and structural abnormalities in paranoid schizophrenia. Rojas, De 1655–1662
Similar extent of brain dysmorphology in severely ill women and men with schizophrenia. Lauriello, Je 819–825
Size, shape, and orientation of neurons in the left and right hippocampus: investigation of normal asymmetries and alterations in schizophrenia. Zaidel, Je 812–818

Breast-feeding
Antidepressants and breast-feeding (letters). Ito; Mammen; reply of Wisner, Au 1174–1175
Sertraline and desmethylsertraline in human breast milk and nursing infants. Stowe, Se 1255–1260

Brief Psychotic Disorder see Psychosis

Brothers see Siblings

Bulimia Nervosa see also Anorexia Nervosa; Eating Disorders
Bulimia outcome (letters). Reiss; Fairburn; reply of Keel, De 1791–1792
Bulimic purging through blood donation (letter). Ghadirian, Mr 435–436
Medication and psychotherapy in the treatment of bulimia nervosa. Walsh, Ap 523–531
Outcome in bulimia nervosa. Keel, Mr 313–321 (letters: Reiss; Fairburn; reply of Keel, De 1791–1792)
Ten-year stability and predictive validity of five bulimia-related indicators. Joiner, Au 1133–1138

Buspirone
Alternative treatment for poststroke depression (letter). Mårtensson, Ap 583–584
Lethal interaction of clozapine and buspirone? (letter). Good, Oc 1472–1473

C

Calcium
High intracellular calcium concentrations in transformed lymphoblasts from subjects with bipolar I disorder. Emamghoreishi, Jy 976–982

Cancer
Breast cancer risk in psychiatric patients (letters). Goodwin; Torrey; Mortensen; reply of Halbreich, Ap 588–590

Carbamazepine
Valproate prophylaxis in a prospective clinical trial of refractory bipolar disorder. Denicoff, Oc 1456–1458

Carbohydrate-Deficient Transferrin
Superiority of carbohydrate-deficient transferrin to γ-glutamyltransferase in detecting relapse in alcoholism. Schmidt, Ja 75–80

Carbon Dioxide
CO_2 challenge in nonclinical subjects (letter). Perna, Je 886–887
Respiratory psychophysiology of panic disorder: three respiratory challenges in 98 subjects. Papp, No 1557–1565
Response to hyperventilation and 5.5% CO_2 inhalation of subjects with types of specific phobia, panic disorder, or no mental disorder. Antony, Au 1089–1095

Cardiac Function
Compliance complications in cardiac patients (letter). Shapiro, reply of Chacko, No 1627–1628

Carnitine
Carnitine for valproic acid-induced hyperammonemia (letter). Raby, Au 1168–1169

Catatonia
Catatonia 20 years later (letter). Looper, Je 883
Refusal of ECT by a patient with recurrent depression, psychosis, and catatonia (case conf). Boronow, Se 1285–1291

Catechol-O-methyltransferase
Association analysis of the catechol O-methyltransferase gene and bipolar affective disorder. Gutiérrez, Ja 113–115 (letter: Cohn, reply of Gutiérrez, Oc 1484)
Genetic risk factors for bipolar disorder (letter). Cohn, reply of Gutiérrez, Oc 1484

Cerebellar Pathology see Brain Disorders

Cerebral Blood Flow
Abnormal brain hemodynamic responses during passive orthostatic challenge in panic disorder. Faravelli, Mr 378–383
Association of premorbid intellectual function with cerebral metabolism in Alzheimer's disease: implications for the cognitive reserve hypothesis. Alexander, Fe 165–172
Basilar artery response to hyperventilation in panic disorder. Ball, No 1603–1604
Emotional activation of limbic circuitry in elderly normal subjects in a PET study. Paradiso, Mr 384–389
Inverse relationship of peripheral thyrotropin-stimulating hormone levels to brain activity in mood disorders. Marangell, Fe 224–230
PET study of greater visual activation in schizophrenia. Taylor, Se 1296–1298

Cerebral Lateralization
Planum temporale asymmetry reversal in schizophrenia: replication and relationship to gray matter abnormalities. Barta, My 661–667
Size, shape, and orientation of neurons in the left and right hippocampus: investigation of normal asymmetries and alterations in schizophrenia. Zaidel, Je 812–818
Three-dimensional cortical morphometry of the planum temporale in childhood-onset schizophrenia. Jacobsen, My 685–687

Cerebrospinal Fluid
Cerebrospinal fluid monoamine metabolites

in childhood-onset schizophrenia. Jacobsen, Ja 69–74
Elevated CSF corticotropin-releasing factor concentrations in posttraumatic stress disorder. Bremner, My 624–629
Cerebrovascular Accident see Stroke; Vascular Disease
***Challenger* Explosion**
Children's thinking in the wake of *Challenger*. Terr, Je 744–751
Character Disorder see Personality Disorders
Chernobyl
Long-term mental health effects of the Chernobyl disaster: an epidemiologic survey in two former Soviet regions. Havenaar, No 1605–1607
Child Abuse see also Sexual Abuse
Objective documentation of child abuse and dissociation in 12 murderers with dissociative identity disorder. Lewis, De 1703–1710
Reported pathological childhood experiences associated with the development of borderline personality disorder. Zanarini, Au 1101–1106
Childbirth
Interaction between birth complications and early maternal rejection in predisposing individuals to adult violence: specificity to serious, early-onset violence. Raine, Se 1265–1271
Obstetric complications and age at onset in schizophrenia: an international collaborative meta-analysis of individual patient data. Verdoux, Se 1220–1227
Pitocin induction and autism (letter). Fein, Mr 438–439
Child Psychiatry
Child psychiatry comes of age: growing sophistication, evolving strategies (editorial). Rapoport, Au 1043–1045
Children
B lymphocyte antigen D8/17: a peripheral marker for childhood-onset obsessive-compulsive disorder and Tourette's syndrome? Murphy, Mr 402–407
Childhood-onset psychosis: evolution and comorbidity (case conf). Gartner, Fe 256–261
Childhood-onset schizophrenia: biological markers in relation to clinical characteristics. Alaghband-Rad, Ja 64–68
Children's thinking in the wake of *Challenger*. Terr, Je 744–751
CSF 5-HIAA and family history of antisocial personality disorder in newborns. Constantino, De 1771–1773
Half a century of ECT use in young people. Rey, My 595–602
Quantitative morphology of the cerebellum and fourth ventricle in childhood-onset schizophrenia. Jacobsen, De 1663–1669
Relative efficacy of haloperidol and pimozide in children and adolescents with Tourette's disorder. Sallee, Au 1057–1062
Risperidone for treatment of childhood schizophrenia (letter). Sourander, Oc 1476
China
Economic reforms and the acute inpatient care of patients with schizophrenia: the Chinese experience. Phillips, Se 1228–1234
New perspectives in mental health services in Shanghai (festschrift). Zhang, Je suppl 55–58
***m*-Chlorophenylpiperazine**
Behavioral and neuroendocrine responses to *m*-chlorphenylpiperazine in subtypes of alcoholics and in healthy comparison subjects. George, Ja 81–87
Cholecystokinin
Effects of the cholecystokinin agonist pentagastrin in patients with generalized anxiety disorder. Brawman-Mintzer, My 700–702
Choline see Acetylcholine
Chronic Fatigue Syndrome
Chronic fatigue (letter). Lipkin, reply of Wessely, Se 1322
Cognitive behavior therapy for chronic fatigue syndrome: a randomized controlled trial. Deale, Mr 408–414
Chronically Ill Patients
Characterizing quality of life among patients with chronic mental illness: a critical examination of the self-report methodology. Atkinson, Ja 99–105 (letters: Arfken; Rohland; reply of Atkinson, Oc 1478–1479)
Cost-effectiveness evaluation of three approaches to case management for homeless mentally ill clients. Wolff, Mr 341–348
Cigarettes see Nicotine
Classification see Diagnosis and Classification
Clinical Case Conferences
Belinda's puzzle: assembling the pieces of an illness. Panzer, My 677–680
Childhood-onset psychosis: evolution and comorbidity. Gartner, Fe 256–261
Chronic schizophrenia: response to clozapine, risperidone, and paroxetine. Patel, Ap 543–546
Clinical case: unknown. Michels, No 1599–1601
Evaluation of a complex case: the value of a drug washout period. Patel, De 1747–1750
On the new clinical case conferences (letter). Kahn, reply of Blazer, Ja 134
Persistent delirium following cessation of heavy alcohol consumption: diagnostic and treatment implications. Hersh, Je 846–851
Refusal of ECT by a patient with recurrent depression, psychosis, and catatonia. Boronow, Se 1285–1291
Refusal of medical treatment: psychiatric emergency? Stotland, Ja 106–108
Traumatic grief: a case of loss-induced trauma. Prigerson, Jy 1003–1009
Treatment for severe borderline personality disorder in 1987 and 1997. Quaytman, Au 1139–1144
Trichotillomania: behavioral symptom or clinical syndrome? O'Sullivan, Oc 1442–1449
Clomiphene
Clomiphene-induced psychosis (letter). Oyffe, Au 1169–1170
Clomipramine
Pulse intravenous clomipramine for depressed adolescents: double-blind, controlled trial. Sallee, My 668–673
Rapid benefit of intravenous pulse loading of clomipramine in obsessive-compulsive disorder. Koran, Mr 396–401
Clozapine
Augmentation of clozapine therapy with ondansetron (letter). Briskin, Au 1171
Clozapine and fertility (letter). Dickson, Ap 582–583
Clozapine-induced stuttering (letter). Ebeling, Oc 1473
Fluoroquinolone inhibition of clozapine metabolism (letter). Markowitz, Je 881
Lethal interaction of clozapine and buspirone? (letter). Good, Oc 1472–1473
Neuroleptic malignant syndrome following initiation of clozapine therapy (letter). Dalkilic, Je 881–882
Time to clozapine response in a standardized trial. Conley, Se 1243–1247
Cocaine
Chronic schizophrenia: response to clozapine, risperidone, and paroxetine (case conf). Patel, Ap 543–546
Homicidal behavior in drug abusing psychiatric patients (letter). Dhossche, reply of Salloum, Je 888–889
PET study of competition between intravenous cocaine and [^{11}C]raclopride at dopamine receptors in human subjects. Schlaepfer, Se 1209–1213
Violence and cocaine (letter). Dhossche, reply of Tardiff, Oc 1480–1481
Cognition see also Brain Structure
Association of subjective memory complaints with subsequent cognitive decline in community-dwelling elderly individuals with baseline cognitive impairment. Schofield, My 609–615
Children's thinking in the wake of *Challenger*. Terr, Je 744–751
Clinical and neurocognitive aspects of source monitoring errors in schizophrenia. Vinogradov, No 1530–1537
Cognitive deficit measures in schizophrenia: factor structure and clinical correlates (festschrift). Lieh-Mak, Je suppl 39–46
Cognitive impairment in adolescents with schizophrenia. Kenny, No 1613–1615
Does risperidone improve verbal working memory in treatment-resistant schizophrenia? Green, Je 799–804
Modifiable neuronal connections: an overview for psychiatrists. Jeffery, Fe 156–164
Neuroanatomical correlates of externally and internally generated human emotion. Reiman, Jy 918–925
Neuroanatomical correlates of happiness, sadness, and disgust. Lane, Jy 926–933
Neurocognitive deficits in schizophrenia (letter). Liberman, reply of Green, Mr 443–444
Cognitive Behavior Therapy
Benzodiazepines and exposure-based cognitive behavior therapies for panic disorder: conclusions from combined treatment trials. Spiegel, Je 773–781
Cognitive behavior therapy for chronic fatigue syndrome: a randomized controlled trial. Deale, Mr 408–414
Medication and psychotherapy in the treatment of bulimia nervosa. Walsh, Ap 523–531
Combat
Consistency of memory for combat-related traumatic events in veterans of Operation Desert Storm. Southwick, Fe 173–177 (letters: Roemer; French; reply of Southwick, No 1628–1629)
Consistency of traumatic memories (letters). Roemer; French; reply of Southwick, No 1628–1629
Linking combat and physical health: the leg-

acy of World War II in men's lives. Elder, Mr 330–336
Posttraumatic stress disorder associated with peacekeeping duty in Somalia for US military personnel. Litz, Fe 178–184 (correction: My 722) (letter: Hall, reply of Litz, Oc 1482–1483)
Systematic desensitization as an alternative exposure strategy for PTSD (letter). Frueh, Fe 287–288
Combined Drug Therapy see Drug Combinations
Community Care see Deinstitutionalization
Community Mental Health Centers see Mental Health Services, Delivery and Utilization of
Comorbidity
Borderline-dissociation comorbidity (letter). Galletly, No 1629
Clinical factors contributing to the differential diagnosis of primary insomnia and insomnia related to mental disorders. Nowell, Oc 1412–1416
Comorbid postpartum depression and bereavement: a complicated case (case conf). Stowe, Mr 418–422
Comorbidity between personality and dysthymic disorders: historical and conceptual issues (letter). Brieger, reply of Riso, Jy 1039–1040
Compulsive sexual behavior characteristics (letter). Kafka, No 1632
Controlled study of psychiatric comorbidity in psychiatrically hospitalized young adults with substance abuse disorders. Grilo, Se 1305–1307
Mental disorders and disability among patients in a primary care group practice. Olfson, De 1734–1740
Obsessive-compulsive disorder in patients with schizophrenia or schizoaffective disorder. Eisen, Fe 271–273 (letter: Werner, reply of Eisen, No 1635–1636)
Self-reported anxiety, general medical conditions, and disability bed days. Marcus, De 1766–1768
Stability of mood despite HIV illness progression in a group of homosexual men. Rabkin, Fe 231–238 (letter: Boland, reply of Rabkin, No 1632–1633)
Substance abuse and ADHD (letter). Hughes, Ja 132
Compliance
Assertive community treatment and medication compliance in the homeless mentally ill. Dixon, Se 1302–1304
Compliance complications in cardiac patients (letter). Shapiro, reply of Chacko, No 1627–1628
Refusal of ECT by a patient with recurrent depression, psychosis, and catatonia (case conf). Boronow, Se 1285–1291
Complicated Grief Disorder see Grief
Computers
Compulsive computer use (letter). Belsare, Fe 289
E-mail therapy (letter). Rothchild, Oc 1476–1477
Conduct Disorder
Lithium treatment of conduct disorders in adolescents. Rifkin, Ap 554–555
Confidentiality
Confidentiality conundrum (letter). Weinstock, reply of Moore, Oc 1483–1484
Consultation-Liaison Psychiatry
Refusal of medical treatment: psychiatric emergency? (case conf). Stotland, Ja 106–108
Convulsive Therapy see ECT
Coping Strategies
Relapse in young paranoid schizophrenic patients: a prospective study of stressful life events, P300 measures, and coping. Pallanti, Je 792–798
Corpus Callosum
MRI study of the corpus callosum in autism. Piven, Au 1051–1056
Corrections
American Psychiatric Association: Practice guideline for the treatment of patients with Alzheimer's disease and other dementias of late life (My suppl). Au 1180
Baldessarini RJ, Hegarty JD, Bird ED, Benes FM: Meta-analysis of postmortem studies of Alzheimer's disease-like neuropathology in schizophrenia (Je 861–863). Au 1180
Busatto GF, Pilowsky LS, Costa DC, Ell PJ, David AS, Lucey JV, Kerwin RW: Correlation between reduced in vivo benzodiazepine receptor binding and severity of psychotic symptoms in schizophrenia (154: 56–63). My 722
Durkin versus Durbin (letter). Burger, Se 1325
Lees Roitman SE, Cornblatt BA, Bergman A, Obuchowski M, Mitropoulou V, Keefe RSE, Silverman JM, Siever LJ: Attentional functioning in schizotypal personality disorder (154:655–660). Au 1180
Litz BT, Orsillo SM, Friedman M, Ehlich P, Batres A: Posttraumatic stress disorder associated with peacekeeping duty in Somalia for US military personnel (154: 178–184). My 722
Corticotropin-Releasing Factor
Elevated CSF corticotropin-releasing factor concentrations in posttraumatic stress disorder. Bremner, My 624–629
Cortisol see Dexamethasone Suppression Test
Costs of Medical Care
Are supplementary services provided during methadone maintenance really cost-effective? Kraft, Se 1214–1219
Cost-effectiveness of psychiatric care (editorial). Sharfstein, Je 723–724
Economic impact of psychotherapy: a review. Gabbard, Fe 147–155
Economic reforms and the acute inpatient care of patients with schizophrenia: the Chinese experience. Phillips, Se 1228–1234
Effectiveness and cost of the inpatient treatment of posttraumatic stress disorder: comparison of three models of treatment. Fontana, Je 758–765
Getting the cost right in cost-effectiveness analyses. Wolff, Je 736–743
Treatment for severe borderline personality disorder in 1987 and 1997 (case conf). Quaytman, Au 1139–1144
Counseling
Postdisaster psychosocial intervention: a field study of the impact of debriefing on psychological distress. Chemtob, Mr 415–417
Course of Illness
One-year follow-up of survivors of a mass shooting. North, De 1696–1702
Severe life stress as a predictor of early disease progression in HIV infection. Evans, My 630–634
Stability of mood despite HIV illness progression in a group of homosexual men. Rabkin, Fe 231–238 (letter: Boland, reply of Rabkin, No 1632–1633)
Stress reactivity in bipolar patients and its relation to prior history of disorder. Hammen, Je 856–857
Court Decisions see Forensic Psychiatry; specific cases
Crime
Psychophysiological protective factors for male subjects at high risk for criminal behavior. Brennan, Je 853–855
Specific major mental disorders and criminality: a 26-year prospective study of the 1966 Northern Finland birth cohort. Tiihonen, Je 840–845
Cultural Psychiatry
Reform said or done? the case of Emilia-Romagna within the Italian psychiatric context. Fioritti, Ja 94–98 (letters: Balon; Pergami; reply of Fioritti, Oc 1485–1486)
Refugees' time perspective and mental health. Beiser, Jy 996–1002
Somatization in cross-cultural perspective: a World Health Organization study in primary care. Gureje, Jy 989–995
Cyproheptadine
Cyproheptadine: a potent in vivo serotonin antagonist (letter). Kapur, Je 884
Cytochrome P450
Fenfluramine and the cytochrome P450 system (letter). Fogelson, Mr 436–437
Cytokines
Plasma levels of cytokines and soluble cytokine receptors during treatment with haloperidol. Pollmächer, De 1763–1765

D

D8/17 see Monoclonal Antibody D8/17
Dangerousness see Violence
Deficit Syndrome
Attentional impairments in deficit and nondeficit forms of schizophrenia. Buchanan, Mr 363–370
Comparison of efficacy of social skills training for deficit and nondeficit negative symptoms in schizophrenia. Kopelowicz, Mr 424–425
Symptoms, subtype, and suicidality in patients with schizophrenia spectrum disorders. Fenton, Fe 199–204
Visual information-processing impairments in deficit and nondeficit schizophrenia. Bustillo, My 647–654
Deinstitutionalization
Italian psychiatric reform (letters). Balon; Pergami; reply of Fioritti, Oc 1485–1486
Reform said or done? the case of Emilia-Romagna within the Italian psychiatric context. Fioritti, Ja 94–98 (letters: Balon; Pergami; reply of Fioritti, Oc 1485–1486)
Delirium
Delirium associated with paroxetine and benztropine combination (letter). Armstrong, Ap 581–582
Extrapyramidal symptoms from intravenous haloperidol in the treatment of delirium (letter). Blitzstein, Oc 1474–1475
Persistent delirium following cessation of heavy alcohol consumption: diagnostic

and treatment implications (case conf). Hersh, Je 846–851

Delta Sleep-Inducing Peptide

Delta sleep-inducing peptide in opioid detoxification (letter). Soyka, My 714–715

Dementia see also Alzheimer's Disease

Paroxetine treatment of sexual disinhibition in dementia (letter). Stewart, Oc 1474

Depersonalization see also Dissociation

Feeling unreal: 30 cases of DSM-III-R depersonalization disorder. Simeon, Au 1107–1113

Depression—Diagnosis of, see also Dexamethasone Suppression Test

"Are you depressed?" screening for depression in the terminally ill. Chochinov, My 674–676

Clinically defined vascular depression. Alexopoulos, Ap 562–565

Defeat Depression Campaign: psychiatry in the public arena (festschrift). Paykel, Je suppl 59–65

Depression in medically ill hospitalized older adults: prevalence, characteristics, and course of symptoms according to six diagnostic schemes. Koenig, Oc 1376–1383

Effectiveness of community-based screening for depression. Greenfield, Oc 1391–1397

HIV and depression (letter). Boland, reply of Rabkin, No 1632–1633

MRI-defined vascular depression. Krishnan, Ap 497–501

Reversed neurovegetative symptoms of depression: a community study of Ontario. Levitan, Jy 934–940

Depression—Research in

Brainstem evoked response abnormalities in late-life depression with vascular disease. Kalayam, Jy 970–975

Clinical correlates of memory in schizophrenia: differential links between depression, positive and negative symptoms, and two types of memory impairment. Brébion, No 1538–1543

Comparison of induced and independent major depressive disorders in 2,945 alcoholics. Schuckit, Jy 948–957

Depression awareness training and the clergy (letter). Weaver, My 717–718

Depression in medically ill hospitalized older adults: prevalence, characteristics, and course of symptoms according to six diagnostic schemes. Koenig, Oc 1376–1383

Depressive symptoms in the early course of schizophrenia: relationship to familial psychiatric illness. Subotnik, No 1551–1556

Does growing old increase the risk for depression? Roberts, Oc 1384–1390

Effect of pindolol in hastening response to fluoxetine in the treatment of major depression: a double-blind, placebo-controlled trial. Berman, Ja 37–43 (letter: Isaac, reply of Berman, De 1790–1791)

Effectiveness of community-based screening for depression. Greenfield, Oc 1391–1397

Fluoxetine and norfluoxetine plasma concentrations in major depression: a multicenter study. Amsterdam, 963–969

Folate, vitamin B_{12}, and homocysteine in major depressive disorder. Fava, Mr 426–428

Lower levels of nucleoside triphosphate in the basal ganglia of depressed subjects: a phosphorous-31 magnetic resonance spectroscopy study. Moore, Ja 116–118

Luteinizing hormone pulse characteristics in depressed women. Meller, Oc 1454–1455

Major depression following smoking cessation. Covey, Fe 263–265

Montgomery-Åsberg severity gradations (letter). Mittmann, Se 1320–1321

Possible association of a polymorphism of the tryptophan hydroxylase gene with suicidal behavior in depressed patients. Mann, Oc 1451–1453

Progression of viral illness (letter). Kalichman, reply of Zorrilla, My 718

Prophylactic efficacy of phenelzine and imipramine in chronic atypical depression: likelihood of recurrence on discontinuation after 6 months' remission. Stewart, Ja 31–36

Psychomotor symptoms of depression. Sobin, Ja 4–17

Rapid tryptophan depletion in drug-free depressed patients with seasonal affective disorder. Neumeister, Au 1153–1155

Reduced G protein functions and immunoreactive levels in mononuclear leukocytes of patients with depression. Avissar, Fe 211–217

Reduced serotonin responsivity in depression (letter). Brown, reply of Mann, Mr 442

Refugees' time perspective and mental health. Beiser, Jy 996–1002

Reversed neurovegetative symptoms of depression: a community study of Ontario. Levitan, Jy 934–940

Sexual functioning in chronically depressed patients treated with SSRI antidepressants: a pilot study. Piazza, De 1757–1759

Stability of mood despite HIV illness progression in a group of homosexual men. Rabkin, Fe 231–238 (letter: Boland, reply of Rabkin, No 1632–1633)

Which depressed patients will respond to interpersonal psychotherapy? the role of abnormal EEG sleep profiles. Thase, Ap 502–509

Depression—Treatment of

Alternative treatment for poststroke depression (letter). Mårtensson, Ap 583–584

Antidepressants and breast-feeding (letters). Ito; Mammen; reply of Wisner, Au 1174–1175

Belinda's puzzle: assembling the pieces of an illness (case conf). Panzer, My 677–680

Clinical case: unknown (case conf). Michels, No 1599–1601

Comorbid postpartum depression and bereavement: a complicated case (case conf). Stowe, Mr 418–422

Defeat Depression Campaign: psychiatry in the public arena (festschrift). Paykel, Je suppl 59–65

ECT response in medication-resistant patients (letter). Chandragiri, reply of Prudic, My 721–722

Efficacy of papaverine addition for treatment-refractory major depression (letter). Malison, Ap 579–580

Emergence of adverse events following discontinuation of treatment with extended-release venlafaxine. Fava, De 1760–1762

Fluvoxamine-induced theophylline toxicity (letter). DeVane, Se 1317–1318

Interpersonal psychotherapy for depressed antepartum women: a pilot study. Spinelli, Jy 1028–1030

Low use of neuroleptic drugs in the treatment of psychotic major depression. Mulsant, Ap 559–561

Mood improvement following daily left prefrontal repetitive transcranial magnetic stimulation in patients with depression: a placebo-controlled crossover trial. George, De 1752–1756

Nefazodone and visual side effects (letter). Schwartz, Jy 1038

Nefazodone-induced hypoglycemia in a diabetic patient with major depression (letter). Warnock, Fe 288–289

Pindolol-paroxetine combination (letter). Isaac, reply of Berman, De 1790–1791

Prophylactic efficacy of phenelzine and imipramine in chronic atypical depression: likelihood of recurrence on discontinuation after 6 months' remission. Stewart, Ja 31–36

Psychotic episode associated with dexfenfluramine (letter). Preval, No 1624–1625

Pulse intravenous clomipramine for depressed adolescents: double-blind, controlled trial. Sallee, My 668–673

Recurrent hyponatremia associated with sertraline and lofepramine (letter). Bouman, Ap 580

Sleep deprivation combined with consecutive sleep phase advance as a fast-acting therapy in depression: an open pilot trial in medicated and unmedicated patients. Berger, Je 870–872

Subconvulsive magnetic brain stimulation no replacement for ECT (letter). Swartz, My 716–717

Sustained change in parents receiving preventive interventions for families with depression. Beardslee, Ap 510–515

Treatment of psychotic depression (letter). DeBattista, No 1625–1626

Use of antidepressants by nonpsychiatrists in the treatment of medically ill hospitalized depressed elderly patients. Koenig, Oc 1369–1375

Which depressed patients will respond to interpersonal psychotherapy? the role of abnormal EEG sleep profiles. Thase, Ap 502–509

Which elderly patients with remitted depression remain well with continued interpersonal psychotherapy after discontinuation of antidepressant medication? Reynolds, Jy 958–962

Withdrawal syndrome after discontinuation of venlafaxine (letter). Agelink, Oc 1473–1474

Depression Spectrum Disease see Depression—Research in

Desipramine

Addition of desipramine to serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder. Barr, Se 1293–1295

Despair

Gloria revisited (letter). Silberman, Au 1179

Deteriorated Affective Disorder see Mood Disorders

Developmental Processes

Toward a strategy for healthy adolescent development (festschrift). Hamburg, Je suppl 7–12

Dexamethasone Suppression Test
DST studies in psychotic depression: a meta-analysis. Nelson, No 1497–1503
Dexfenfluramine
Psychotic episode associated with dexfenfluramine (letter). Preval, No 1624–1625
Dextromethorphan
Opiate withdrawal with dextromethorphan (letter). Bisaga, Ap 584
Diabetes
Nefazodone-induced hypoglycemia in a diabetic patient with major depression (letter). Warnock, Fe 288–289
Diagnosis and Classification
Abnormal brain hemodynamic responses during passive orthostatic challenge in panic disorder. Faravelli, Mr 378–383
Advancing age, declining ADHD (letter). Barkley, reply of Hill, Se 1323–1325
Belinda's puzzle: assembling the pieces of an illness (case conf). Panzer, My 677–680
Borderline mnemonic (letter). Senger, Se 1321
Borderline personality and bipolar disorder (letters). Feiner; Prakash; reply of Gunderson, Au 1175–1177
Characteristics of 36 subjects reporting compulsive sexual behavior. Black, Fe 243–249 (letter: Kafka, No 1632)
Childhood-onset psychosis: evolution and comorbidity (case conf). Gartner, Fe 256–261
Childhood-onset schizophrenia: biological markers in relation to clinical characteristics. Alaghband-Rad, Ja 64–68
Chronic fatigue (letter). Lipkin, reply of Wessely, Se 1322
Clinical and methodological factors related to reliability of the best-estimate diagnostic procedure. Roy, De 1726–1733
Clinical case: unknown (case conf). Michels, No 1599–1601
Clinical factors contributing to the differential diagnosis of primary insomnia and insomnia related to mental disorders. Nowell, Oc 1412–1416
Clinically defined vascular depression. Alexopoulos, Ap 562–565
Comparability of telephone and face-to-face interviews in assessing axis I and II disorders. Rohde, No 1593–1598
Concept and boundaries of personality disorders (festschrift). López-Ibor, Je suppl 21–25
Debating dissociative diagnoses (letter). Hochman, Je 887–888
Depression in medically ill hospitalized older adults: prevalence, characteristics, and course of symptoms according to six diagnostic schemes. Koenig, Oc 1376–1383
Diagnostic criteria for complicated grief disorder. Horowitz, Jy 904–910
Diazepam-responsive neuroleptic malignant syndrome: a diagnostic subtype? (letter). Miyaoka, Je 882
Divergences between clinical and research methods for assessing personality disorders: implications for research and the evolution of axis II. Westen, Jy 895–903
DSM-III and its reception: a European view (festschrift). Pichot, Je suppl 47–54
DST studies in psychotic depression: a meta-analysis. Nelson, No 1497–1503
Evaluation of a complex case: the value of a drug washout period (case conf). Patel, De 1747–1750
False positive results: a challenge for psychiatric screening in primary care. Leon, Oc 1462–1464
Feeling unreal: 30 cases of DSM-III-R depersonalization disorder. Simeon, Au 1107–1113
Finding the "person" in personality disorders (editorial). Gabbard, Jy 891–893
Full and partial posttraumatic stress disorder: findings from a community survey. Stein, Au 1114–1119
Gaucher's disease initially diagnosed as depression (letter). Clemons, Fe 290
Gloria revisited (letter). Silberman, Au 1179
Hypnotizability used for diagnostic confirmation? (letter). Frankel, reply of Stein, Ap 587
Identification of children with pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections by a marker associated with rheumatic fever. Swedo, Ja 110–112 (letter: Hollander, reply of Swedo, No 1630–1631)
Informative morphogenetic variants in patients with schizophrenia and alcohol-dependent patients: beyond the Waldrop scale. Trixler, My 691–693
Lewy bodies (letters). Curran; Birkett, reply of Weiner, Se 1322–1323
MRI-defined vascular depression. Krishnan, Ap 497–501
New name for atypical antipsychotics? (letter). Copolov, Mr 439
Obsessive-compulsive disorder with and without tics in an epidemiological sample of adolescents. Zohar, Fe 274–276
Obsessive-compulsive symptoms in schizophrenia (letter). Werner, reply of Eisen, No 1635–1636
Panic-agoraphobic spectrum: a descriptive approach to the assessment and treatment of subtle symptoms (festschrift). Cassano, Je suppl 27–38
Panic mnemonic (letter). Berber, Mr 438
Phenomenology of adolescent and adult mania in hospitalized patients with bipolar disorder. McElroy, Ja 44–49
Premenstrual syndrome: evidence for symptom stability across cycles. Bloch, De 1741–1746
Psychomotor symptoms of depression. Sobin, Ja 4–17
Psychosis and etiology (letter). Tremeau, reply of Maziade, Ja 132–134
Psychotic depression (letter). Strauss, reply of Jeste, My 719–720
Reduced G protein functions and immunoreactive levels in mononuclear leukocytes of patients with depression. Avissar, Fe 211–217
Religion index for psychiatric research (letter). Koenig, Je 885–886
Repetitive behaviors and D8/17 positivity (letter). Hollander, reply of Swedo, No 1630–1631
Resemblance of psychotic symptoms and syndromes in affected sibling pairs from the Irish Study of High-Density Schizophrenia Families: evidence for possible etiologic heterogeneity. Kendler, Fe 191–198
Revisiting the factor structure for positive and negative symptoms: evidence from a large heterogeneous group of psychiatric patients. Toomey, Mr 371–377
Ritual handwashing (letter). Lewis, Au 1172–1173
Social phobia and stuttering (letter). Schneier, Ja 131
Stability of diagnosis of obsessive-compulsive disorder in the Epidemiologic Catchment Area study. Nelson, Je 826–831
Symptoms of obsessive-compulsive disorder. Leckman, Jy 911–917
Transitional objects and borderline personality disorder. Cardasis, Fe 250–255 (letter: LaPorta, Oc 1484–1485)
Traumatophilic diathesis, complemental series, and the original conceptual basis of PTSD (letter). Good, Fe 296
Trichotillomania: behavioral symptom or clinical syndrome? (case conf). O'Sullivan, Oc 1442–1449
Turkish dissociative identity disorder (letter). Chodoff, reply of Şar, Au 1179
Which depressed patients will respond to interpersonal psychotherapy? the role of abnormal EEG sleep profiles. Thase, Ap 502–509
Diagnostic and Statistical Manual (all editions) see Diagnosis and Classification
Diazepam
Diazepam-responsive neuroleptic malignant syndrome: a diagnostic subtype? (letter). Miyaoka, Je 882
Disability
Direct assessment of functional status in older patients with schizophrenia. Klapow, Jy 1022–1024
Mental disorders and disability among patients in a primary care group practice. Olfson, De 1734–1740
Self-reported anxiety, general medical conditions, and disability bed days. Marcus, De 1766–1768
Disaster see also Posttraumatic Stress Disorder
Children's thinking in the wake of *Challenger*. Terr, Je 744–751
One-year follow-up of survivors of a mass shooting. North, De 1696–1702
Long-term mental health effects of the Chernobyl disaster: an epidemiologic survey in two former Soviet regions. Havenaar, No 1605–1607
Outcome of psychotherapy among early adolescents after trauma. Goenjian, Ap 536–542
Postdisaster psychosocial intervention: a field study of the impact of debriefing on psychological distress. Chemtob, Mr 415–417
Discrimination
Position statement on discrimination against persons with previous psychiatric treatment (off acts). American Psychiatric Association Council on Psychiatry and Law, Jy 1042
Possible discrimination in recruitment of psychiatry residents? Balon, No 1608–1609
Displacement
Biopsychosocial model (letter). Toppelberg, reply of Fullilove, Se 1328–1329
Dissociation
Borderline-dissociation comorbidity (letter). Galletly, No 1629
Dissociation and the Holocaust (letter). Steinberg, reply of Yehuda, My 720–721

Dissociation in patients with borderline personality disorder (letter). Paris, reply of Brodsky, Ja 137–138
Feeling unreal: 30 cases of DSM-III-R depersonalization disorder. Simeon, Au 1107–1113
Objective assessment of peritraumatic dissociation: psychophysiological indicators. Griffin, Au 1081–1088
Objective documentation of child abuse and dissociation in 12 murderers with dissociative identity disorder. Lewis, De 1703–1710
Dissociative Identity Disorder
Debating dissociative diagnoses (letter). Hochman, Je 887–888
False memories of cult abuse (letter). Yeager, Mr 435
Objective documentation of child abuse and dissociation in 12 murderers with dissociative identity disorder. Lewis, De 1703–1710
Turkish dissociative identity disorder (letter). Chodoff, reply of Şar, Au 1179
Two-year follow-up of inpatients with dissociative identity disorder. Ellason, Je 832–839
Dopamine
Clinical genetics, V: association of genetic and personality characteristics (image, neuro). Lahti, No 1496
Dopamine reuptake site densities in patients with social phobia. Tiihonen, Fe 239–242
Effects of methylphenidate on regional brain glucose metabolism in humans: relationship to dopamine D_2 receptors. Volkow, Ja 50–55
Lack of evidence for allelic association between personality traits and the dopamine D_4 receptor gene polymorphisms. Jönsson, My 697–699
PET evidence that loxapine is an equipotent blocker of 5-HT_2 and D_2 receptors: implications for the treatment of schizophrenia. Kapur, No 1525–1529
PET study of competition between intravenous cocaine and [^{11}C]raclopride at dopamine receptors in human subjects. Schlaepfer, Se 1209–1213
Serotonergic modulation of dopamine measured with [^{11}C]raclopride and PET in normal human subjects. Smith, Ap 490–496
SPECT studies of D_2 occupancy in low-dose haloperidol treatment (letter). Hirschowitz, My 715–716
Dosage
Case-control study of neuroleptic malignant syndrome. Sachdev, Au 1156–1158
High-dose olanzapine for treatment-refractory schizophrenia (letter). Sheitman, No 1626
Pulse intravenous clomipramine for depressed adolescents: double-blind, controlled trial. Sallee, My 668–673
Down's Syndrome
Low glucose metabolism during brain stimulation in older Down's syndrome subjects at risk for Alzheimer's disease prior to dementia. Pietrini, Au 1063–1069
Small planum temporale volume in Down's syndrome: a volumetric MRI study. Frangou, Oc 1424–1429
Drinking see Alcohol and Alcoholism
Drug Abuse see Addiction; Alcohol and Alcoholism; Substance Abuse; specific drugs
Drug Combinations
Addition of desipramine to serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder. Barr, Se 1293–1295
Augmentation of clozapine therapy with ondansetron (letter). Briskin, Au 1171
Chronic schizophrenia: response to clozapine, risperidone, and paroxetine (case conf). Patel, Ap 543–546
Delirium associated with paroxetine and benztropine combination (letter). Armstrong, Ap 581–582
Fenfluramine and the cytochrome P450 system (letter). Fogelson, Mr 436–437
Fluoroquinolone inhibition of clozapine metabolism (letter). Markowitz, Je 881
Fluvoxamine-induced theophylline toxicity (letter). DeVane, Se 1317–1318
Lethal interaction of clozapine and buspirone? (letter). Good, Oc 1472–1473
Pindolol-paroxetine combination (letter). Isaac, reply of Berman, De 1790–1791
Psychotic mania associated with fenfluramine and phentermine use (letter). Raison, My 711
Drug Dependence see Addiction; Substance Abuse; specific drugs
Drug Discontinuation see Withdrawal of Drugs
Drug Interactions see Drug Combinations
Drug Levels see Blood Levels
Drug Overdose see Overdose
Drug Side Effects see specific drugs
Drugs, Psychotropic, see also specific drugs
Child psychiatry comes of age: growing sophistication, evolving strategies (editorial). Rapoport, Au 1043–1045
Prospective study of patients' refusal of antipsychotic medication under a physician discretion review procedure. Kasper, Ap 483–489
Psychotic depression (letter). Strauss, reply of Jeste, My 719–720
Psychotropic drug action (letter). Klein, reply of Hyman, Mr 440–441
Psychotropic treatment during pregnancy (letter). Pinkofsky, My 718–719
Rethinking treatment terminology (letter). DeVane, My 717
DSM (all editions) see Diagnosis and Classification
DST see Dexamethasone Suppression Test
Durable Power of Attorney
Durable power of attorney and informed consent with Alzheimer's disease patients: a clinical study. Dukoff, Au 1070–1075
Dynamic Susceptibility Contrast MRI see Magnetic Resonance Imaging
Dysarthria
Image on progressive dysarthria (letter). O'Shanick, reply of Selnes, Ap 584–585
Dyskinesia see Tardive Dyskinesia
Dysthymia
Comorbidity between personality and dysthymic disorders: historical and conceptual issues (letter). Brieger, reply of Riso, Jy 1039–1040
Double-blind comparison of sertraline, imipramine, and placebo in the treatment of dysthymia: psychosocial outcomes. Kocsis, Mr 390–395

E

Eating Disorders see also Anorexia Nervosa; Bulimia Nervosa
Eating disorders in males: a report on 135 patients. Carlat, Au 1127–1132
Economic Issues see Costs of Medical Care
ECT
ECT response in medication-resistant patients (letter). Chandragiri, reply of Prudic, My 721–722
Half a century of ECT use in young people. Rey, My 595–602
Lack of relapse with tryptophan depletion following successful treatment with ECT. Cassidy, Au 1151–1152
Refusal of ECT by a patient with recurrent depression, psychosis, and catatonia (case conf). Boronow, Se 1285–1291
Subconvulsive magnetic brain stimulation no replacement for ECT (letter). Swartz, My 716–717
Education, Medical
Defeat Depression Campaign: psychiatry in the public arena (festschrift). Paykel, Je suppl 59–65
Future of medical education and teaching: a psychiatric perspective (festschrift). Okasha, Je suppl 77–85
Predicting academic performance of medical students: the first three years (festschrift). Höschl, Je suppl 87–92
Education, Psychiatric
Disputing psychiatry's redefinition (letter). Clemens, reply of Lieberman, No 1633–1635
Future of medical education and teaching: a psychiatric perspective (festschrift). Okasha, Je suppl 77–85
EEG
Which depressed patients will respond to interpersonal psychotherapy? the role of abnormal EEG sleep profiles. Thase, Ap 502–509
Elderly Patients see Geriatric Psychiatry
Electroconvulsive Therapy see ECT
E-mail see Computers
Emotion
Emotional activation of limbic circuitry in elderly normal subjects in a PET study. Paradiso, Mr 384–389
Neuroanatomical correlates of externally and internally generated human emotion. Reiman, Jy 918–925
Neuroanatomical correlates of happiness, sadness, and disgust. Lane, Jy 926–933
Emotional Disorders see Psychopathology; specific diagnoses
Endocrinology see Neuroendocrine Function
Entorhinal Cortex
Cytoarchitecture of the entorhinal cortex in schizophrenia. Akil, Jy 1010–1012
Environment
Obsessive-compulsive disorder in the community: an epidemiologic survey with clinical reappraisal. Stein, Au 1120–1126
Religion, psychopathology, and substance use and abuse: a multimeasure, genetic-epidemiologic study. Kendler, Mr 322–329 (letter: Trappler, reply of Kendler, No 1636)
Epidemiology
Deteriorated affective disorder a rarity? (letter). Kohler, Mr 442–443

Long-term mental health effects of the Chernobyl disaster: an epidemiologic survey in two former Soviet regions. Havenaar, No 1605–1607

Estrogens

Psychopathology in women and men: focus on female hormones. Seeman, De 1641–1647

Ethics

Ethics in evolution: the incompatibility of clinical and forensic functions (editorial). Appelbaum, Ap 445–446

Ethnic Differences see Cultural Psychiatry

Etiology

Association of panic disorder with a history of traumatic suffocation. Bouwer, No 1566–1570

Comparison of induced and independent major depressive disorders in 2,945 alcoholics. Schuckit, Jy 948–957

Europe

DSM-III and its reception: a European view (festschrift). Pichot, Je suppl 47–54

Evaluation, Psychiatric

Compliance complications in cardiac patients (letter). Shapiro, reply of Chacko, No 1627–1628

Evoked Potentials

Aberrant semantic activation in schizophrenia: a neurophysiological study. Nestor, My 640–646

Brainstem evoked response abnormalities in late-life depression with vascular disease. Kalayam, Jy 970–975

Relapse in young paranoid schizophrenic patients: a prospective study of stressful life events, P300 measures, and coping. Pallanti, Je 792–798

Extrapyramidal Side Effects see also Tardive Dyskinesia

Extrapyramidal symptoms from intravenous haloperidol in the treatment of delirium (letter). Blitzstein, Oc 1474–1475

New name for atypical antipsychotics? (letter). Copolov, Mr 439

Eyes

Apolipoprotein E ∈4 allele and pupillary response to tropicamide. Higuchi, My 694–696

Photic maculopathy in a patient receiving bright light therapy (letter). Gallenga, Se 1319

F

Factitious Illness

Canine variant of factitious disorder by proxy (letter). Feldman, Se 1316–1317

Families

Gene-environment interaction in vulnerability to schizophrenia: findings from the Finnish Adoptive Family Study of Schizophrenia. Wahlberg, Mr 355–362

Sustained change in parents receiving preventive interventions for families with depression. Beardslee, Ap 510–515

Three-year trials of personal therapy among schizophrenic patients living with or independent of family, I: description of study and effects on relapse rates. Hogarty, No 1504–1513

Three-year trials of personal therapy among schizophrenic patients living with or independent of family, II: effects on adjustment of patients. Hogarty, No 1514–1524

Family History see Genetics

Fathers

Psychophysiological protective factors for male subjects at high risk for criminal behavior. Brennan, Je 853–855

d-Fenfluramine

Central serotonin activity and aggression: inverse relationship with prolactin response to *d*-fenfluramine, but not CSF 5-HIAA concentration, in human subjects. Coccaro, Oc 1430–1435

Fenfluramine and the cytochrome P450 system (letter). Fogelson, Mr 436–437

Psychotic mania associated with fenfluramine and phentermine use (letter). Raison, My 711

***dl*-Fenfluramine**

Serotonergic modulation of dopamine measured with [^{11}C]raclopride and PET in normal human subjects. Smith, Ap 490–496

Fertility

Clozapine and fertility (letter). Dickson, Ap 582–583

Financial Incentives for Illness Behavior

Taking care of money matters (letters). Roskes; Tyndel; reply of Binder, Ja 135–136

Financing Medical Care see Costs of Medical Care

Finnish Adoptive Family Study of Schizophrenia

Gene-environment interaction in vulnerability to schizophrenia: findings from the Finnish Adoptive Family Study of Schizophrenia. Wahlberg, Mr 355–362

Flashbacks

Behavioral and neuroendocrine responses to sodium lactate infusion in subjects with posttraumatic stress disorder. Jensen, Fe 266–268

Unusual flashbacks in a Vietnam veteran (letter). Mayer, My 713

Fluoroquinolones

Fluoroquinolone inhibition of clozapine metabolism (letter). Markowitz, Je 881

Fluoxetine

Effect of pindolol in hastening response to fluoxetine in the treatment of major depression: a double-blind, placebo-controlled trial. Berman, Ja 37–43 (letter: Isaac, reply of Berman, De 1790–1791)

Fluoxetine and norfluoxetine plasma concentrations in major depression: a multicenter study. Amsterdam, 963–969

Folate, vitamin B_{12}, and homocysteine in major depressive disorder. Fava, Mr 426–428

Placebo-controlled trial of fluoxetine and phenelzine for obsessive-compulsive disorder. Jenike, Se 1261–1264

Use of fluoxetine for obsessive-compulsive behavior in adults with autism (letter). Koshes, Ap 578

Fluvoxamine

Fluvoxamine-induced theophylline toxicity (letter). DeVane, Se 1317–1318

^{19}F magnetic resonance spectroscopy investigation in vivo of acute and steady-state brain fluvoxamine levels in obsessive-compulsive disorder. Strauss, Ap 516–522

Treatment of irritable bowel syndrome with fluvoxamine (letter). Emmanuel, My 711–712

Urge to splurge (letter). Black, reply of Lejoyeux, No 1629–1630

Vitamin C for paroxetine- and fluvoxamine-associated bleeding (letter). Tielens, Je 883–884

Folate

Folate, vitamin B_{12}, and homocysteine in major depressive disorder. Fava, Mr 426–428

Forensic Psychiatry

Ethics in evolution: the incompatibility of clinical and forensic functions (editorial). Appelbaum, Ap 445–446

Objective documentation of child abuse and dissociation in 12 murderers with dissociative identity disorder. Lewis, De 1703–1710

On wearing two hats: role conflict in serving as both psychotherapist and expert witness. Strasburger, Ap 448–456

Reviewing a review (letters). Slovenko; Tanay; reply of Appelbaum, Fe 295–296

Tarasoff ruling and reporting to the authorities (letter). Balon, Se 1321

Functional Assessment

Direct assessment of functional status in older patients with schizophrenia. Klapow, Jy 1022–1024

G

G Proteins

High levels of $G_s\alpha$ in platelets of euthymic patients with bipolar affective disorder. Mitchell, Fe 218–223

Reduced G protein functions and immunoreactive levels in mononuclear leukocytes of patients with depression. Avissar, Fe 211–217

GABA see γ-Aminobutyric Acid

Gabapentin

Gabapentin in the treatment of bipolar disorder (letter). Schaffer, Fe 291–292

Treatment of acute mania with gabapentin (letter). Stanton, Fe 287

Gambling

Dispositional predictors of problem gambling in male adolescents. Vitaro, De 1769–1770

Gaucher's Disease

Gaucher's disease initially diagnosed as depression (letter). Clemons, Fe 290

Gender see Sex Differences

Genetics

Association analysis of the catechol O-methyltransferase gene and bipolar affective disorder. Gutiérrez, Ja 113–115 (letter: Cohn, reply of Gutiérrez, Oc 1484)

Broader autism phenotype: evidence from a family history study of multiple-incidence autism families. Piven, Fe 185–190

Candidate gene study of eight $GABA_A$ receptor subunits in panic disorder. Crowe, Au 1096–1100

Chromosomal fragile site 1q21 in schizophrenic patients (letter). Fananas, My 716

Clinical and methodological factors related to reliability of the best-estimate diagnostic procedure. Roy, De 1726–1733

Clinical genetics, I: Huntington's disease: from disease to gene (image, neuro). Tamminga, Je 725

Clinical genetics, II: Huntington's disease: from the gene to pathophysiology (image, neuro). DiFiglia, Au 1046

Clinical genetics, III: Alzheimer's disease:

from genes to pathogenesis (image, neuro). Selkoe, Se 1198
Clinical genetics, IV: Alzheimer's disease: from gene to pathology (image, neuro). Jay, Oc 1359
Clinical genetics, V: association of genetic and personality characteristics (image, neuro). Lahti, No 1496
Clinical genetics, VI: linkage and association in complex genetic diseases (image, neuro). Sanders, De 1640
CSF 5-HIAA and family history of antisocial personality disorder in newborns. Constantino, De 1771–1773
Depressive symptoms in the early course of schizophrenia: relationship to familial psychiatric illness. Subotnik, No 1551–1556
clusion of expansion of 50 CAG/CTG trinucleotide repeats in bipolar disorder. Guy, Au 1146–1147
Gene-environment interaction in vulnerability to schizophrenia: findings from the Finnish Adoptive Family Study of Schizophrenia. Wahlberg, Mr 355–362
Genetic heterogeneity in nocturnal enuresis (letter). von Gontard, Je 885
Genetic risk factors for bipolar disorder (letter). Cohn, reply of Gutiérrez, Oc 1484
Identification of children with pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections by a marker associated with rheumatic fever. Swedo, Ja 110–112 (letter: Hollander, reply of Swedo, No 1630–1631)
Lack of evidence for allelic association between personality traits and the dopamine D_4 receptor gene polymorphisms. Jönsson, My 697–699
Molecular biology, VI: metaphase preparation of normal human chromosomes with spectral karyotyping (image, neuro). Ried, Ap 447
No association between apolipoprotein E ∈ 4 allele and rate of decline in Alzheimer's disease. Murphy, My 603–608
Possible association of a polymorphism of the tryptophan hydroxylase gene with suicidal behavior in depressed patients. Mann, Oc 1451–1453
Repetitive behaviors and D8/17 positivity (letter). Hollander, reply of Swedo, No 1630–1631
Social support: a genetic-epidemiologic analysis. Kendler, Oc 1398–1404
Triplet repeat diseases in man, microbes, and molecules (letter). Wells, Je 887
Geriatric Psychiatry
Association of subjective memory complaints with subsequent cognitive decline in community-dwelling elderly individuals with baseline cognitive impairment. Schofield, My 609–615
Brainstem evoked response abnormalities in late-life depression with vascular disease. Kalayam, Jy 970–975
Clinically defined vascular depression. Alexopoulos, Ap 562–565
Depression in medically ill hospitalized older adults: prevalence, characteristics, and course of symptoms according to six diagnostic schemes. Koenig, Oc 1376–1383
Direct assessment of functional status in older patients with schizophrenia. Klapow, Jy 1022–1024
Does growing old increase the risk for depression? Roberts, Oc 1384–1390
Mortality of elderly patients with psychiatric disorders. Zubenko, Oc 1360–1368
Practice guideline for the treatment of patients with Alzheimer's disease and other dementias of late life. American Psychiatric Association, My suppl (correction: Au 1180)
Psychiatry of old age is coming of age (editorial). Jeste, Oc 1356–1358
Use of antidepressants by nonpsychiatrists in the treatment of medically ill hospitalized depressed elderly patients. Koenig, Oc 1369–1375
Which elderly patients with remitted depression remain well with continued interpersonal psychotherapy after discontinuation of antidepressant medication? Reynolds, Jy 958–962
Gilles de la Tourette's Syndrome see Tourette's Disorder
Glucose
Nefazodone-induced hypoglycemia in a diabetic patient with major depression (letter). Warnock, Fe 288–289
γ-Glutamyltransferase
Superiority of carbohydrate-deficient transferrin to γ-glutamyltransferase in detecting relapse in alcoholism. Schmidt, Ja 75–80
Grief
Diagnostic criteria for complicated grief disorder. Horowitz, Jy 904–910
Traumatic grief: a case of loss-induced trauma (case conf). Prigerson, Jy 1003–1009
Traumatic grief as a risk factor for mental and physical morbidity. Prigerson, My 616–623

H

Hahnemann, Samuel
Samuel Hahnemann, 1755–1843 (image, psych). Rampes, Oc 1450
Hallucinations
Auditory hallucinations and the temporal cortical response to speech in schizophrenia: a functional magnetic resonance imaging study. Woodruff, De 1676–1682
Hallucinatory changes (letter). Hoehn-Saric, reply of Miller, Fe 293–294
Naltrexone treatment of hallucinogen persisting perception disorder (letter). Lerner, Mr 437
Synaptic elimination, neurodevelopment, and the mechanism of hallucinated "voices" in schizophrenia. Hoffman, De 1683–1689
Unnatural practices, unspeakable actions: a study of delayed auditory feedback in schizophrenia. Goldberg, Je 858–860
Haloperidol
Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol. Tollefson, Se 1248–1254
Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Zimbroff, Je 782–791
Extrapyramidal symptoms from intravenous haloperidol in the treatment of delirium (letter). Blitzstein, Oc 1474–1475
Negative symptoms: a path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine. Tollefson, Ap 466–474
Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Tollefson, Ap 457–465
Plasma levels of cytokines and soluble cytokine receptors during treatment with haloperidol. Pollmächer, De 1763–1765
Relative efficacy of haloperidol and pimozide in children and adolescents with Tourette's disorder. Sallee, Au 1057–1062
SPECT studies of D_2 occupancy in low-dose haloperidol treatment (letter). Hirschowitz, My 715–716
Health Maintenance Organizations
Academic versus clinical views on lithium use (letter). Young, Jy 1040
Heart Failure see Cardiac Function
Heart Rate
Objective assessment of peritraumatic dissociation: psychophysiological indicators. Griffin, Au 1081–1088
Hemispheric Asymmetry see Cerebral Lateralization
Heschl's Gyrus
Sex-specific expression of Heschl's gyrus functional and structural abnormalities in paranoid schizophrenia. Rojas, De 1655–1662
5-HIAA see 5-Hydroxyindoleactic Acid
History
Anorexia nervosa in the eighteenth century (letter). Gordon, reply of Yudofsky, Jy 1041
DSM-III and its reception: a European view (festschrift). Pichot, Je suppl 47–54
Melvin Sabshin: integrator, innovator, and master of metaphor (festschrift). Andreasen, Je suppl 3–5
Recent developments in American psychiatry and Dr Melvin Sabshin's contributions to them (festschrift). Nishizono, Je suppl 73–76
HIV
Assisted suicide for HIV patients (letter). Chochinov, reply of Breitbart, Fe 294–295
HIV and depression (letter). Boland, reply of Rabkin, No 1632–1633
HIV infection among young adults with psychotic disorders. Susser, Je 864–866
HIV seroprevalence among suicide victims in New York City, 1991–1993. Marzuk, De 1720–1725
Progression of viral illness (letter). Kalichman, reply of Zorrilla, My 718
Severe life stress as a predictor of early disease progression in HIV infection. Evans, My 630–634
Stability of mood despite HIV illness progression in a group of homosexual men. Rabkin, Fe 231–238 (letter: Boland, reply of Rabkin, No 1632–1633)
HMOs see Health Maintenance Organizations
Holocaust
Dissociation and the Holocaust (letter). Steinberg, reply of Yehuda, My 720–721
Homelessness
Assertive community treatment and medication compliance in the homeless mentally ill. Dixon, Se 1302–1304
Cost-effectiveness evaluation of three ap-

proaches to case management for homeless mentally ill clients. Wolff, Mr 341–348
Homicide
Objective documentation of child abuse and dissociation in 12 murderers with dissociative identity disorder. Lewis, De 1703–1710
Seasonal variation in the occurrence of homicide in Finland. Tiihonen, De 1711–1714
Homocysteine
Folate, vitamin B_{12}, and homocysteine in major depressive disorder. Fava, Mr 426–428
Homosexuality
Homosexuality and older brothers (letters). Eiberson; Martin; Turner; reply of Blanchard, Ja 136–137
Homovanillic Acid
Origin of homovanillic acid in plasma (letter). Lambert, reply of Fulton, Ja 138–139
Hospital Psychiatry
Controlled study of psychiatric comorbidity in psychiatrically hospitalized young adults with substance abuse disorders. Grilo, Se 1305–1307
Economic reforms and the acute inpatient care of patients with schizophrenia: the Chinese experience. Phillips, Se 1228–1234
Effectiveness and cost of the inpatient treatment of posttraumatic stress disorder: comparison of three models of treatment. Fontana, Je 758–765
False positive results: a challenge for psychiatric screening in primary care. Leon, Oc 1462–1464
Inpatient treatment of combat veterans (letter). Denton, reply of Johnson, Jy 1038–1039
Managed care (letter). Light, Mr 443
Predicting readmission to the psychiatric hospital in a managed care environment: implications for quality indicators. Lyons, Mr 337–340
Utility of the initial therapeutic alliance in evaluating psychiatric patients' risk of violence. Beauford, Se 1272–1276
Validity of utilization management criteria for psychiatry. Goldman, Mr 349–354
Violence by patients admitted to a private psychiatric hospital. Tardiff, Ja 88–93 (letter: Dhossche, reply of Tardiff, Oc 1480–1481)
Human Immunodeficiency Virus see HIV
Huntington's Disease
Clinical genetics, I: Huntington's disease: from disease to gene (image, neuro). Tamminga, Je 725
Clinical genetics, II: Huntington's disease: from the gene to pathophysiology (image, neuro). DiFiglia, Au 1046
HVA see Homovanillic Acid
5-Hydroxyindoleacetic Acid
Central serotonin activity and aggression: inverse relationship with prolactin response to *d*-fenfluramine, but not CSF 5-HIAA concentration, in human subjects. Coccaro, Oc 1430–1435
CSF 5-HIAA and family history of antisocial personality disorder in newborns. Constantino, De 1771–1773
Hyperammonemia
Carnitine for valproic acid-induced hyperammonemia (letter). Raby, Au 1168–1169
Hyperventilation
Respiratory psychophysiology of panic disorder: three respiratory challenges in 98 subjects. Papp, No 1557–1565
Response to hyperventilation and 5.5% CO_2 inhalation of subjects with types of specific phobia, panic disorder, or no mental disorder. Antony, Au 1089–1095
Hypnosis
Hypnotizability used for diagnostic confirmation? (letter). Frankel, reply of Stein, Ap 587
Hypomania see Mania
Hyponatremia
Recurrent hyponatremia associated with sertraline and lofepramine (letter). Bouman, Ap 580

I

ICD (all versions) see Diagnosis and Classification
Images in Neuroscience
Clinical genetics, I: Huntington's disease: from disease to gene. Tamminga, Je 725
Clinical genetics, II: Huntington's disease: from the gene to pathophysiology. DiFiglia, Au 1046
Clinical genetics, III: Alzheimer's disease: from genes to pathogenesis. Selkoe, Se 1198
Clinical genetics, IV: Alzheimer's disease: from gene to pathology. Jay, Oc 1359
Clinical genetics, V: association of genetic and personality characteristics. Lahti, No 1496
Clinical genetics, VI: linkage and association in complex genetic diseases. Sanders, De 1640
Image on progressive dysarthria (letter). O'Shanick, reply of Selnes, Ap 584–585
Molecular biology, III: tracking DNA: the Southern blot. Duman, Ja 3
Molecular biology, IV: identifying DNA transcription factors. Nestler, Fe 146
Molecular biology, V: immediate early genes. Nestler, Mr 312
Molecular biology, VI: metaphase preparation of normal human chromosomes with spectral karyotyping. Ried, Ap 447
Molecular biology, VII: spectral karyotyping analysis in diagnostic cytogenetics. Ried, My 594
Images in Psychiatry
al-Razi (Rhazes), 865–925. Daghestani, No 1602
Durkin versus Durbin (letter). Burger, Se 1325
Grete Bibring, MD, 1899–1977. Brown, Se 1292
Harry Stack Sullivan, 1892–1949. Havens, Au 1145
Jules Baillarger, 1809–1891. Bourgeois, Fe 262
Massachusetts Mental Health Center. Tsuang, Mr 423
McLean Hospital. de Marneffe, Ja 109
Menninger Hospital. Gabbard, Je 852
Michael Shepherd: 1923–1995. Eisenberg, My 681
Payne Whitney Clinic. Makari, De 1751
Pennsylvania Hospital. Sudak, Ap 547
Rauwolfia serpentina: the first herbal antipsychotic. Bhatara, Jy 894
Samuel Hahnemann, 1755–1843. Rampes, Oc 1450
Imipramine
Double-blind comparison of sertraline, imipramine, and placebo in the treatment of dysthymia: psychosocial outcomes. Kocsis, Mr 390–395
Prophylactic efficacy of phenelzine and imipramine in chronic atypical depression: likelihood of recurrence on discontinuation after 6 months' remission. Stewart, Ja 31–36
Immune Function
Plasma levels of cytokines and soluble cytokine receptors during treatment with haloperidol. Pollmächer, De 1763–1765
Severe life stress as a predictor of early disease progression in HIV infection. Evans, My 630–634
Impulse Control Disorder
Compulsive computer use (letter). Belsare, Fe 289
Dispositional predictors of problem gambling in male adolescents. Vitaro, De 1769–1770
Incest see Child Abuse; Sexual Abuse
Indians, American see Native Americans
Infants
CSF 5-HIAA and family history of antisocial personality disorder in newborns. Constantino, De 1771–1773
Information Processing
Attentional impairments in deficit and nondeficit forms of schizophrenia. Buchanan, Mr 363–370
Clinical correlates of memory in schizophrenia: differential links between depression, positive and negative symptoms, and two types of memory impairment. Brébion, No 1538–1543
Cognitive deficit measures in schizophrenia: factor structure and clinical correlates (festschrift). Lieh-Mak, Je suppl 39–46
Modifiable neuronal connections: an overview for psychiatrists. Jeffery, Fe 156–164
Visual information-processing impairments in deficit and nondeficit schizophrenia. Bustillo, My 647–654
Visual perception in medicated schizophrenic patients (letters). Bonnet; Schwartz; reply of O'Donnell, Ap 585–587
Informative Morphogenetic Variants
Informative morphogenetic variants in patients with schizophrenia and alcohol-dependent patients: beyond the Waldrop scale. Trixler, My 691–693
Informed Consent
Durable power of attorney and informed consent with Alzheimer's disease patients: a clinical study. Dukoff, Au 1070–1075
Injury see Self-Injurious Behavior
Inositol
Reduced frontal cortex inositol levels in postmortem brain of suicide victims and patients with bipolar disorder. Shimon, Au 1148–1150
Inpatients see Hospital Psychiatry
Insanity Defense
Reviewing a review (letters). Slovenko; Tanay; reply of Appelbaum, Fe 295–296
Insomnia
Clinical factors contributing to the differential diagnosis of primary insomnia and insomnia related to mental disorders. Nowell, Oc 1412–1416
Prevalence, burden, and treatment of insomnia in primary care. Simon, Oc 1417–1423
Insurance
Economic reforms and the acute inpatient

care of patients with schizophrenia: the Chinese experience. Phillips, Se 1228–1234
Intelligence
Association of premorbid intellectual function with cerebral metabolism in Alzheimer's disease: implications for the cognitive reserve hypothesis. Alexander, Fe 165–172
Premorbid brain size as a determinant of reserve capacity against intellectual decline in Alzheimer's disease. Mori, Ja 18–24
Schizophrenia and the myth of intellectual decline. Russell, My 635–639
International Medical Graduates
Possible discrimination in recruitment of psychiatry residents? Balon, No 1608–1609
Internet
Internet addiction, internet psychotherapy (letter). Stein, reply of Huang, Je 890
Interpersonal Psychotherapy
Interpersonal psychotherapy for depressed antepartum women: a pilot study. Spinelli, Jy 1028–1030
Interviewing
Comparability of telephone and face-to-face interviews in assessing axis I and II disorders. Rohde, No 1593–1598
Divergences between clinical and research methods for assessing personality disorders: implications for research and the evolution of axis II. Westen, Jy 895–903
Telemedicine in psychiatry: making the dream reality (letter). Bear, Je 884–885
IQ see Intelligence
Irritable Bowel Syndrome
Treatment of irritable bowel syndrome with fluvoxamine (letter). Emmanuel, My 711–712
Italy
Italian psychiatric reform (letters). Balon; Pergami; reply of Fioritti, Oc 1485–1486
Reform said or done? the case of Emilia-Romagna within the Italian psychiatric context. Fioritti, Ja 94–98 (letters: Balon; Pergami; reply of Fioritti, Oc 1485–1486)

J

Jews
Vulnerability of Jews to affective disorders. Levav, Jy 941–947

K

Karyotyping see Spectral Karyotyping
Ketamine
Association of ketamine-induced psychosis with focal activation of the prefrontal cortex in healthy volunteers. Breier, Je 805–811
Kleptomania
Response of kleptomania and mixed mania to valproate (letter). Kmetz, Ap 580–581
Korean Conflict see Combat; Posttraumatic Stress Disorder
Koro
Koro and homicidal behavior (letter). Lewis, Au 1169

L

Laboratory Analysis
Lithium assay errors (letter). Lovell, Oc 1477
Lactate see Sodium Lactate
Lamotrigine
Lamotrigine for treatment-refractory bipolar disorder (letter). Labbate, Se 1317
Lamotrigine treatment of rapid cycling bipolar disorder (letter). Kusumakar, Au 1171–1172
Language see also Speech
Small planum temporale volume in Down's syndrome: a volumetric MRI study. Frangou, Oc 1424–1429
Late Luteal Phase Dysphoric Disorder
Seasonality of symptoms in women with late luteal phase dysphoric disorder. Maskall, Oc 1436–1441
Lawsuits see Forensic Psychiatry; specific cases
Length of Stay
Predicting readmission to the psychiatric hospital in a managed care environment: implications for quality indicators. Lyons, Mr 337–340
Validity of utilization management criteria for psychiatry. Goldman, Mr 349–354
Lesbian Relationships see Homosexuality
Leukocytes
Reduced G protein functions and immunoreactive levels in mononuclear leukocytes of patients with depression. Avissar, Fe 211–217
Lewy Body Variant of Alzheimer's Disease see Alzheimer's Disease
Lewy bodies (letters). Curran; Birkett, reply of Weiner, Se 1322–1323
Life Events
Physical health and negative life events (letter). Dinnen, Ja 138
Relapse in young paranoid schizophrenic patients: a prospective study of stressful life events, P300 measures, and coping. Pallanti, Je 792–798
Severe life stress as a predictor of early disease progression in HIV infection. Evans, My 630–634
Light Therapy
Light visor maintenance of light box response (letter). Clark, Au 1172
Photic maculopathy in a patient receiving bright light therapy (letter). Gallenga, Se 1319
Limbic Regions see Brain Structure
Lithium
Academic versus clinical views on lithium use (letter). Young, Jy 1040
Catatonia 20 years later (letter). Looper, Je 883
Effectiveness of restarting lithium treatment after its discontinuation in bipolar I and bipolar II disorders. Tondo, Ap 548–550
Lithium assay errors (letter). Lovell, Oc 1477
Lithium treatment of conduct disorders in adolescents. Rifkin, Ap 554–555
Nephrotic syndrome associated with lithium therapy (letter). Gill, Se 1318–1319
Reduced morbidity after gradual discontinuation of lithium treatment for bipolar I and II disorders: a replication study. Baldessarini, Ap 551–553
Valproate prophylaxis in a prospective clinical trial of refractory bipolar disorder. Denicoff, Oc 1456–1458
Liver Function
Pemoline and hepatotoxicity (letter). McCurry, My 713–714
Lofepramine
Recurrent hyponatremia associated with sertraline and lofepramine (letter). Bouman, Ap 580
Loxapine
PET evidence that loxapine is an equipotent blocker of 5-HT_2 and D_2 receptors: implications for the treatment of schizophrenia. Kapur, No 1525–1529
Luteinizing Hormone
Luteinizing hormone pulse characteristics in depressed women. Meller, Oc 1454–1455

M

Magnetic Brain Stimulation
Subconvulsive magnetic brain stimulation no replacement for ECT (letter). Swartz, My 716–717
Magnetic Resonance Imaging
Auditory hallucinations and the temporal cortical response to speech in schizophrenia: a functional magnetic resonance imaging study. Woodruff, De 1676–1682
MRI-defined vascular depression. Krishnan, Ap 497–501
MRI study of the corpus callosum in autism. Piven, Au 1051–1056
Magnetic Resonance Spectroscopy
Brain proton magnetic resonance spectroscopy (^{1}H-MRS) in Alzheimer's disease: changes after treatment with xanomeline, an M_1 selective cholinergic agonist. Satlin, Oc 1459–1461
^{19}F magnetic resonance spectroscopy investigation in vivo of acute and steady-state brain fluvoxamine levels in obsessive-compulsive disorder. Strauss, Ap 516–522
Lower levels of nucleoside triphosphate in the basal ganglia of depressed subjects: a phosphorous-31 magnetic resonance spectroscopy study. Moore, Ja 116–118
Maintenance Treatment
Which elderly patients with remitted depression remain well with continued interpersonal psychotherapy after discontinuation of antidepressant medication? Reynolds, Jy 958–962
Managed Care
Cost-effectiveness of psychiatric care (editorial). Sharfstein, Je 723–724
Lesson in history, circa 2047 (editorial). Shore, Mr 307–311
Managed care (letter). Light, Mr 443
Predicting readmission to the psychiatric hospital in a managed care environment: implications for quality indicators. Lyons, Mr 337–340
Mania
Nefazodone-induced mania (letter). Dubin, Ap 578–579
Phenomenology of adolescent and adult mania in hospitalized patients with bipolar disorder. McElroy, Ja 44–49
Psychotic mania associated with fenfluramine and phentermine use (letter). Raison, My 711
Response of kleptomania and mixed mania to valproate (letter). Kmetz, Ap 580–581
Tramadol-induced mania (letter). Watts, No 1624
Treatment of acute mania with gabapentin (letter). Stanton, Fe 287
MAOIs see Antidepressants

Massachusetts Mental Health Center
Massachusetts Mental Health Center (image, psych). Tsuang, Mr 423
McLean Hospital
McLean Hospital (image, psych). de Marneffe, Ja 109
Medical Students see Education, Medical
Medication see Drugs, Psychotropic
Melancholia see Depression
Memory
Association of subjective memory complaints with subsequent cognitive decline in community-dwelling elderly individuals with baseline cognitive impairment. Schofield, My 609–615
Clinical and neurocognitive aspects of source monitoring errors in schizophrenia. Vinogradov, No 1530–1537
Clinical correlates of memory in schizophrenia: differential links between depression, positive and negative symptoms, and two types of memory impairment. Brébion, No 1538–1543
Consistency of memory for combat-related traumatic events in veterans of Operation Desert Storm. Southwick, Fe 173–177 (letters: Roemer; French; reply of Southwick, No 1628–1629)
Consistency of traumatic memories (letters). Roemer; French; reply of Southwick, No 1628–1629
Does risperidone improve verbal working memory in treatment-resistant schizophrenia? Green, Je 799–804
False memories of cult abuse (letter). Yeager, Mr 435
Modifiable neuronal connections: an overview for psychiatrists. Jeffery, Fe 156–164
Men
Eating disorders in males: a report on 135 patients. Carlat, Au 1127–1132
Menninger Hospital
Menninger Hospital (image, psych). Gabbard, Je 852
Mental Health Services, Delivery and Utilization of
Effectiveness of community-based screening for depression. Greenfield, Oc 1391–1397
Increased health care utilization as a function of participation in trauma research. Sansone, Jy 1025–1027
Lesson in history, circa 2047 (editorial). Shore, Mr 307–311
New perspectives in mental health services in Shanghai (festschrift). Zhang, Je suppl 55–58
Psychiatry in the framework of primary health care: a threat or boost to psychiatry? (festschrift). Sartorius, Je suppl 67–72
Reform said or done? the case of Emilia-Romagna within the Italian psychiatric context. Fioritti, Ja 94–98 (letters: Balon; Pergami; reply of Fioritti, Oc 1485–1486)
Mental Illness see Psychopathology
Metabolism
Anterior cingulate gyrus dysfunction and selective attention deficits in schizophrenia: [^{15}O]H_2O PET study during single-trial Stroop task performance. Carter, De 1670–1675
Anterior cingulate gyrus volume and glucose metabolism in autistic disorder. Haznedar, Au 1047–1050
Association of ketamine-induced psychosis with focal activation of the prefrontal cortex in healthy volunteers. Breier, Je 805–811
Decreased anterior cingulate gyrus metabolic rate in schizophrenia. Haznedar, My 682–684
Effects of methylphenidate on regional brain glucose metabolism in humans: relationship to dopamine D_2 receptors. Volkow, Ja 50–55
Fenfluramine and the cytochrome P450 system (letter). Fogelson, Mr 436–437
Fluoroquinolone inhibition of clozapine metabolism (letter). Markowitz, Je 881
Gender differences in cerebellar metabolism: test-retest reproducibility. Volkow, Ja 119–121
Inverse relationship of peripheral thyrotropin-stimulating hormone levels to brain activity in mood disorders. Marangell, Fe 224–230
Low glucose metabolism during brain stimulation in older Down's syndrome subjects at risk for Alzheimer's disease prior to dementia. Pietrini, Au 1063–1069
Methadone
Are supplementary services provided during methadone maintenance really cost-effective? Kraft, Se 1214–1219
Methodology
Characterizing quality of life among patients with chronic mental illness: a critical examination of the self-report methodology. Atkinson, Ja 99–105 (letters: Arfken; Rohland; reply of Atkinson, Oc 1478–1479)
Methylphenidate
Effects of methylphenidate on regional brain glucose metabolism in humans: relationship to dopamine D_2 receptors. Volkow, Ja 50–55
Metronidazole
Metronidazole-induced pychotic disorder (letter). Schreiber, Au 1170–1171
Milieu Treatment
Menninger Hospital (image, psych). Gabbard, Je 852
Military
Posttraumatic stress disorder associated with peacekeeping duty in Somalia for US military personnel. Litz, Fe 178–184 (correction: My 722) (letter: Hall, reply of Litz, Oc 1482–1483)
Molecular Biology
Molecular biology, III: tracking DNA: the Southern blot (image, neuro). Duman, Ja 3
Molecular biology, IV: identifying DNA transcription factors (image, neuro). Nestler, Fe 146
Molecular biology, V: immediate early genes (image, neuro). Nestler, Mr 312
Molecular biology, VI: metaphase preparation of normal human chromosomes with spectral karyotyping (image, neuro). Ried, Ap 447
Molecular biology, VII: spectral karyotyping analysis in diagnostic cytogenetics (image, neuro). Ried, My 594
Monoamine Metabolites
Cerebrospinal fluid monoamine metabolites in childhood-onset schizophrenia. Jacobsen, Ja 69–74
Monoamine Oxidase Inhibitors see Antidepressants
Monoclonal Antibody D8/17
B lymphocyte antigen D8/17: a peripheral marker for childhood-onset obsessive-compulsive disorder and Tourette's syndrome? Murphy, Mr 402–407
Mood Disorders see also Bipolar Disorder; Depression; Mania; Seasonal Affective Disorder
Comparison of patients with early-, typical-, and late-onset affective psychosis. Sax, Se 1299–1301
Deteriorated affective disorder a rarity? (letter). Köhler, Mr 442–443
DST studies in psychotic depression: a meta-analysis. Nelson, No 1497–1503
High intracellular calcium concentrations in transformed lymphoblasts from subjects with bipolar I disorder. Emamghoreishi, Jy 976–982
High levels of $G_s\alpha$ in platelets of euthymic patients with bipolar affective disorder. Mitchell, Fe 218–223
Inverse relationship of peripheral thyrotropin-stimulating hormone levels to brain activity in mood disorders. Marangell, Fe 224–230
Vulnerability of Jews to affective disorders. Levav, Jy 941–947
Mortality
Mortality of elderly patients with psychiatric disorders. Zubenko, Oc 1360–1368
Mothers
Interaction between birth complications and early maternal rejection in predisposing individuals to adult violence: specificity to serious, early-onset violence. Raine, Se 1265–1271
MRI see Magnetic Resonance Imaging
Munchausen Syndrome see Factitious Illness
Muscles
Contractures in neuroleptic malignant syndrome (letter). Craddock, Mr 436

N

Naltrexone
Naltrexone for alcoholic adolescents (letter). Lifrak, Mr 439–440
Naltrexone treatment of hallucinogen persisting perception disorder (letter). Lerner, Mr 437
Sequential use of naltrexone in the treatment of relapsing alcoholism (letter). Farren, My 714
National Depression Screening Day
Effectiveness of community-based screening for depression. Greenfield, Oc 1391–1397
Native Americans
Firewater myth and response to alcohol in Mission Indians. Garcia-Andrade, Jy 983–988
Prevalence and characteristics of trauma and posttraumatic stress disorder in a Southwestern American Indian tribe. Robin, No 1582–1588
Nefazodone
Nefazodone and visual side effects (letter). Schwartz, Jy 1038
Nefazodone-induced hypoglycemia in a diabetic patient with major depression (letter). Warnock, Fe 288–289
Nefazodone-induced mania (letter). Dubin, Ap 578–579

Negative Symptoms
Comparison of efficacy of social skills training for deficit and nondeficit negative symptoms in schizophrenia. Kopelowicz, Mr 424–425
Negative symptoms: a path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine. Tollefson, Ap 466–474
Revisiting the factor structure for positive and negative symptoms: evidence from a large heterogeneous group of psychiatric patients. Toomey, Mr 371–377
Nemiah, John C
Festschrift for John Nemiah (letter). McDermott, Ap 584
Nemonapride
Nemonapride for the treatment of schizophrenia (letter). Satoh, Fe 292
Neurobiology
Childhood-onset schizophrenia: biological markers in relation to clinical characteristics. Alaghband-Rad, Ja 64–68
Modifiable neuronal connections: an overview for psychiatrists. Jeffery, Fe 156–164
Neurobiological basis of social attachment. Insel, Je 726–735
Synaptic elimination, neurodevelopment, and the mechanism of hallucinated "voices" in schizophrenia. Hoffman, De 1683–1689
Neurocognitive Deficits see Cognition
Neuroendocrine Dysfunction
Luteinizing hormone pulse characteristics in depressed women. Meller, Oc 1454–1455
Neuroleptic Malignant Syndrome
Atypical neuroleptic malignant syndrome associated with risperidone treatment (letter). Newman, Oc 1475
Case-control study of neuroleptic malignant syndrome. Sachdev, Au 1156–1158
Contractures in neuroleptic malignant syndrome (letter). Craddock, Mr 436
Diazepam-responsive neuroleptic malignant syndrome: a diagnostic subtype? (letter). Miyaoka, Je 882
Neuroleptic malignant syndrome following initiation of clozapine therapy (letter). Dalkilic, Je 881–882
Neuroleptics see also specific drugs
Age at onset and gender of schizophrenic patients in relation to neuroleptic resistance. Meltzer, Ap 475–482
Case-control study of neuroleptic malignant syndrome. Sachdev, Au 1156–1158
Low use of neuroleptic drugs in the treatment of psychotic major depression. Mulsant, Ap 559–561
Meta-analysis of postmortem studies of Alzheimer's disease-like neuropathology in schizophrenia. Baldessarini, Je 861–863 (correction: Au 1180)
Neuroleptics and bone mineral density (letter). Al-Adwani, Au 1173
Neuropsychological Functioning see Cognition
Neuropsychology see Cognition
Neurotensin
CSF neurotensin concentrations and antipsychotic treatment in schizophrenia and schizoaffective disorder. Sharma, Jy 1019–1021
Neurotransmitters see also specific neurotransmitters
CSF neurotensin concentrations and antipsychotic treatment in schizophrenia and schizoaffective disorder. Sharma, Jy 1019–1021
Schizophrenia and the parvalbumin-containing class of cortical local circuit neurons. Woo, Jy 1013–1015
Newborns see Infants
Nicotine
ADHD and maternal smoking during pregnancy (letter). Chabrol, reply of Milberger, Au 1177–1178
Major depression following smoking cessation. Covey, Fe 263–265
What happens to anxiety levels on giving up smoking? West, No 1589–1592
Nomenclature see Diagnosis and Classification
Norepinephrine
Effects of Alzheimer's disease severity on cerebrospinal fluid norepinephrine concentration. Elrod, Ja 25–30
Normal Functioning
Normatology: a review and commentary with reference to abortion and physician-assisted suicide (festschrift). Brodie, Je suppl 13–19
Toward a strategy for healthy adolescent development (festschrift). Hamburg, Je suppl 7–12
Novelty Seeking
Clinical genetics, V: association of genetic and personality characteristics (image, neuro). Lahti, No 1496

O

Obesity
Psychotic episode associated with dexfenfluramine (letter). Preval, No 1624–1625
Object Relations
Borderline personality disorder and transitional objects (letter). LaPorta, Oc 1484–1485
Transitional objects and borderline personality disorder. Cardasis, Fe 250–255 (letter: LaPorta, Oc 1484–1485)
Obsessive-Compulsive Disorder
Addition of desipramine to serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder. Barr, Se 1293–1295
B lymphocyte antigen D8/17: a peripheral marker for childhood-onset obsessive-compulsive disorder and Tourette's syndrome? Murphy, Mr 402–407
Effect of prefrontal repetitive transcranial magnetic stimulation in obsessive-compulsive disorder: a preliminary study. Greenberg, Je 867–869
^{19}F magnetic resonance spectroscopy investigation in vivo of acute and steady-state brain fluvoxamine levels in obsessive-compulsive disorder. Strauss, Ap 516–522
Hallucinogen-induced relief of obsessions and compulsions (letter). Moreno, Jy 1037–1038
Identification of children with pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections by a marker associated with rheumatic fever. Swedo, Ja 110–112 (letter: Hollander, reply of Swedo, No 1630–1631)
Obsessive-compulsive disorder in patients with schizophrenia or schizoaffective disorder. Eisen, Fe 271–273 (letter: Werner, reply of Eisen, No 1635–1636)
Obsessive-compulsive disorder in the community: an epidemiologic survey with clinical reappraisal. Stein, Au 1120–1126
Obsessive-compulsive disorder with and without tics in an epidemiological sample of adolescents. Zohar, Fe 274–276
Obsessive-compulsive symptoms in schizophrenia (letter). Werner, reply of Eisen, No 1635–1636
Paroxetine for treatment of obsessive-compulsive disorder and comorbid stuttering (letter). Murray, Jy 1037
Placebo-controlled trial of fluoxetine and phenelzine for obsessive-compulsive disorder. Jenike, Se 1261–1264
Rapid benefit of intravenous pulse loading of clomipramine in obsessive-compulsive disorder. Koran, Mr 396–401
Repetitive behaviors and D8/17 positivity (letter). Hollander, reply of Swedo, No 1630–1631
Ritual handwashing (letter). Lewis, Au 1172–1173
Stability of diagnosis of obsessive-compulsive disorder in the Epidemiologic Catchment Area study. Nelson, Je 826–831
Symptoms of obsessive-compulsive disorder. Leckman, Jy 911–917
Treatment of risperidone-induced obsessive-compulsive symptoms with sertraline (letter). Dodt, Ap 582
Use of fluoxetine for obsessive-compulsive behavior in adults with autism (letter). Koshes, Ap 578
Olanzapine
Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol. Tollefson, Se 1248–1254
High-dose olanzapine for treatment-refractory schizophrenia (letter). Sheitman, No 1626
Negative symptoms: a path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine. Tollefson, Ap 466–474
Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Tollefson, Ap 457–465
Propranolol treatment of olanzapine-induced akathisia (letter). Kurzthaler, Se 1316
Treatment of psychotic depression (letter). DeBattista, No 1625–1626
Olfactory Function
Olfactory identification deficits in schizophrenia: correlation with duration of illness. Moberg, Jy 1016–1018
Ondansetron
Augmentation of clozapine therapy with ondansetron (letter). Briskin, Au 1171
Onset of Illness
Age at onset and gender of schizophrenic patients in relation to neuroleptic resistance. Meltzer, Ap 475–482
Cerebrospinal fluid monoamine metabolites in childhood-onset schizophrenia. Jacobsen, Ja 69–74
Childhood-onset schizophrenia: biological

markers in relation to clinical characteristics. Alaghband-Rad, Ja 64–68
Comparison of patients with early-, typical-, and late-onset affective psychosis. Sax, Se 1299–1301
Obstetric complications and age at onset in schizophrenia: an international collaborative meta-analysis of individual patient data. Verdoux, Se 1220–1227
Phenomenology of adolescent and adult mania in hospitalized patients with bipolar disorder. McElroy, Ja 44–49

Opiates
Delta sleep-inducing peptide in opioid detoxification (letter). Soyka, My 714–715
Opiate withdrawal with dextromethorphan (letter). Bisaga, Ap 584
Propofol for sedation during rapid opiate detoxification (letter). DeMaria, Fe 290–291

Organic Mental Disorders see Brain Disorders

Orgasmic Dysfunction see Sexual Function

Outcome
Bulimia outcome (letters). Reiss; Fairburn; reply of Keel, De 1791–1792
Outcome in bulimia nervosa. Keel, Mr 313–321 (letters: Reiss; Fairburn; reply of Keel, De 1791–1792)
Which elderly patients with remitted depression remain well with continued interpersonal psychotherapy after discontinuation of antidepressant medication? Reynolds, Jy 958–962

Overdose
Risperidone overdose (letter). Moore, Fe 289–290

Oxytocin
Neurobiological basis of social attachment. Insel, Je 726–735

P

Pancreas
Pancreatitis associated with risperidone treatment? (letter). Berent, Ja 130–131

PANDAS see Obsessive-Compulsive Disorder

Panic
Abnormal brain hemodynamic responses during passive orthostatic challenge in panic disorder. Faravelli, Mr 378–383
Association of panic disorder with a history of traumatic suffocation. Bouwer, No 1566–1570
Basilar artery response to hyperventilation in panic disorder. Ball, No 1603–1604
Behavioral and neuroendocrine responses to sodium lactate infusion in subjects with posttraumatic stress disorder. Jensen, Fe 266–268
Benzodiazepines and exposure-based cognitive behavior therapies for panic disorder: conclusions from combined treatment trials. Spiegel, Je 773–781
Candidate gene study of eight $GABA_A$ receptor subunits in panic disorder. Crowe, Au 1096–1100
CO_2 challenge in nonclinical subjects (letter). Perna, Je 886–887
Exacerbation of respiratory symptoms in patients with panic disorder (letter). Bouwer, My 712–713
Multicenter collaborative panic disorder severity scale. Shear, No 1571–1575
Panic-agoraphobic spectrum: a descriptive approach to the assessment and treatment of subtle symptoms (festschrift). Cassano, Je suppl 27–38
Panic disorder and quality of life: variables predictive of functional impairment. Hollifield, Je 766–772
Panic mnemonic (letter). Berber, Mr 438
Respiratory psychophysiology of panic disorder: three respiratory challenges in 98 subjects. Papp, No 1557–1565
Response to hyperventilation and 5.5% CO_2 inhalation of subjects with types of specific phobia, panic disorder, or no mental disorder. Antony, Au 1089–1095
Vitamin C for paroxetine- and fluvoxamine-associated bleeding (letter). Tielens, Je 883–884

Papaverine
Efficacy of papaverine addition for treatment-refractory major depression (letter). Malison, Ap 579–580

Parkinsonian Symptoms see Extrapyramidal Side Effects

Paroxetine
Chronic schizophrenia: response to clozapine, risperidone, and paroxetine (case conf). Patel, Ap 543–546
Delirium associated with paroxetine and benztropine combination (letter). Armstrong, Ap 581–582
Paroxetine for treatment of obsessive-compulsive disorder and comorbid stuttering (letter). Murray, Jy 1037
Paroxetine treatment of sexual disinhibition in dementia (letter). Stewart, Oc 1474
Pindolol-paroxetine combination (letter). Isaac, reply of Berman, De 1790–1791
Vitamin C for paroxetine- and fluvoxamine-associated bleeding (letter). Tielens, Je 883–884

Patient Care
E-mail therapy (letter). Rothchild, Oc 1476–1477
Misrepresentational review (letter). Fancher, Oc 1485

Payne Whitney Clinic
Payne Whitney Clinic (image, psych). Makari, De 1751

Peacekeeping Duty
Peacekeeping duty and PTSD (letter). Hall, reply of Litz, Oc 1482–1483
PTSD after a peacekeeping mission (letter). Ehlich, Se 1319–1320

Pediatric Autoimmune Neuropsychiatric Disorders Associated With Streptococcal Infections see Obsessive-Compulsive Disorder

Pemoline
Pemoline and hepatotoxicity (letter). McCurry, My 713–714

Pennsylvania Hospital
Pennsylvania Hospital (image, psych). Sudak, Ap 547

Pentagastrin
Effects of the cholecystokinin agonist pentagastrin in patients with generalized anxiety disorder. Brawman-Mintzer, My 700–702

Perception
Refugees' time perspective and mental health. Beiser, Jy 996–1002

Perfectionism
Perfectionism in anorexia nervosa (letter). Szabo, reply of Kaye, Ja 132

Personal Therapy
Three-year trials of personal therapy among schizophrenic patients living with or independent of family, I: description of study and effects on relapse rates. Hogarty, No 1504–1513
Three-year trials of personal therapy among schizophrenic patients living with or independent of family, II: effects on adjustment of patients. Hogarty, No 1514–1524

Personality
Clinical genetics, V: association of genetic and personality characteristics (image, neuro). Lahti, No 1496
Lack of evidence for allelic association between personality traits and the dopamine D_4 receptor gene polymorphisms. Jönsson, My 697–699

Personality Disorders see also specific diagnoses
Comorbidity between personality and dysthymic disorders: historical and conceptual issues (letter). Brieger, reply of Riso, Jy 1039–1040
Concept and boundaries of personality disorders (festschrift). López-Ibor, Je suppl 21–25
Divergences between clinical and research methods for assessing personality disorders: implications for research and the evolution of axis II. Westen, Jy 895–903
Finding the "person" in personality disorders (editorial). Gabbard, Jy 891–893

PET see Positron Emission Tomography

Pharmacology see Drugs, Psychotropic

Phenelzine
Placebo-controlled trial of fluoxetine and phenelzine for obsessive-compulsive disorder. Jenike, Se 1261–1264
Prophylactic efficacy of phenelzine and imipramine in chronic atypical depression: likelihood of recurrence on discontinuation after 6 months' remission. Stewart, Ja 31–36

Phentermine
Psychotic mania associated with fenfluramine and phentermine use (letter). Raison, My 711

Phobia see also Agoraphobia
Response to hyperventilation and 5.5% CO_2 inhalation of subjects with types of specific phobia, panic disorder, or no mental disorder. Antony, Au 1089–1095

Phototherapy see Light Therapy

Physical Illness and Impairment see also Somatoform Disorders; specific disorders
Linking combat and physical health: the legacy of World War II in men's lives. Elder, Mr 330–336
Panic disorder and quality of life: variables predictive of functional impairment. Hollifield, Je 766–772
Traumatic grief as a risk factor for mental and physical morbidity. Prigerson, My 616–623

Physician-Assisted Suicide
Assisted suicide for HIV patients (letter). Chochinov, reply of Breitbart, Fe 294–295
Normatology: a review and commentary with reference to abortion and physician-assisted suicide (festschrift). Brodie, Je suppl 13–19
Physician-assisted suicide and abortion (letter). Dobscha, Au 1173–1174

Physician-assisted suicide in Oregon (letters). Hamilton; Goodwin, reply of Ganzini, Se 1326–1328

Pimozide

Relative efficacy of haloperidol and pimozide in children and adolescents with Tourette's disorder. Sallee, Au 1057–1062

Pindolol

Effect of pindolol in hastening response to fluoxetine in the treatment of major depression: a double-blind, placebo-controlled trial. Berman, Ja 37–43 (letter: Isaac, reply of Berman, De 1790–1791)

Pindolol-paroxetine combination (letter). Isaac, reply of Berman, De 1790–1791

Pitocin

Pitocin induction and autism (letter). Fein, Mr 438–439

Planum Temporale see Brain Structure

Small planum temporale volume in Down's syndrome: a volumetric MRI study. Frangou, Oc 1424–1429

Polypharmacy see Drug Combinations

Position Statements

Position statement on discrimination against persons with previous psychiatric treatment (off acts). American Psychiatric Association Council on Psychiatry and Law, Jy 1042

Positron Emission Tomography

Anterior cingulate gyrus dysfunction and selective attention deficits in schizophrenia: [^{15}O]H_2O PET study during single-trial Stroop task performance. Carter, De 1670–1675

Association of premorbid intellectual function with cerebral metabolism in Alzheimer's disease: implications for the cognitive reserve hypothesis. Alexander, Fe 165–172

Effects of methylphenidate on regional brain glucose metabolism in humans: relationship to dopamine D_2 receptors. Volkow, Ja 50–55

Emotional activation of limbic circuitry in elderly normal subjects in a PET study. Paradiso, Mr 384–389

Gender differences in cerebellar metabolism: test-retest reproducibility. Volkow, Ja 119–121

Low glucose metabolism during brain stimulation in older Down's syndrome subjects at risk for Alzheimer's disease prior to dementia. Pietrini, Au 1063–1069

PET evidence that loxapine is an equipotent blocker of 5-HT_2 and D_2 receptors: implications for the treatment of schizophrenia. Kapur, No 1525–1529

PET study of competition between intravenous cocaine and [^{11}C]raclopride at dopamine receptors in human subjects. Schlaepfer, Se 1209–1213

PET study of greater visual activation in schizophrenia. Taylor, Se 1296–1298

Reduced serotonin responsivity in depression (letter). Brown, reply of Mann, Mr 442

Serotonergic modulation of dopamine measured with [^{11}C]raclopride and PET in normal human subjects. Smith, Ap 490–496

Postpartum Depression

Comorbid postpartum depression and bereavement: a complicated case (case conf). Stowe, Mr 418–422

Posttraumatic Stress Disorder

Behavioral and neuroendocrine responses to sodium lactate infusion in subjects with posttraumatic stress disorder. Jensen, Fe 266–268

Consistency of memory for combat-related traumatic events in veterans of Operation Desert Storm. Southwick, Fe 173–177 (letters: Roemer; French; reply of Southwick, No 1628–1629)

Consistency of traumatic memories (letters). Roemer; French; reply of Southwick, No 1628–1629

Effectiveness and cost of the inpatient treatment of posttraumatic stress disorder: comparison of three models of treatment. Fontana, Je 758–765

Elevated CSF corticotropin-releasing factor concentrations in posttraumatic stress disorder. Bremner, My 624–629

Full and partial posttraumatic stress disorder: findings from a commun.·· survey. Stein, Au 1114–1119

Inpatient treatment of combat veterans (letter). Denton, reply of Johnson, Jy 1038–1039

Dissociation and the Holocaust (letter). Steinberg, reply of Yehuda, My 720–721

Objective assessment of peritraumatic dissociation: psychophysiological indicators. Griffin, Au 1081–1088

One-year follow-up of survivors of a mass shooting. North, De 1696–1702

Outcome of psychotherapy among early adolescents after trauma. Goenjian, Ap 536–542

Peacekeeping duty and PTSD (letter). Hall, reply of Litz, Oc 1482–1483

Posttraumatic stress disorder and functioning and quality of life outcomes in a nationally representative sample of male Vietnam veterans. Zatzick, De 1690–1695

Posttraumatic stress disorder associated with peacekeeping duty in Somalia for US military personnel. Litz, Fe 178–184 (correction: My 722) (letter: Hall, reply of Litz, Oc 1482–1483)

Posttraumatic stress disorder in a community group of former prisoners of war: a normative response to severe trauma. Engdahl, No 1576–1581

Prevalence and characteristics of trauma and posttraumatic stress disorder in a Southwestern American Indian tribe. Robin, No 1582–1588

Prevalence and risk factors for posttraumatic stress disorder among chemically dependent adolescents. Deykin, Je 752–757

PTSD after a peacekeeping mission (letter). Ehlich, Se 1319–1320

Startle reflex abnormalities in women with sexual assault-related PTSD. Morgan, Au 1076–1080

Systematic desensitization as an alternative exposure strategy for PTSD (letter). Frueh, Fe 287–288

Traumatophilic diathesis, complemental series, and the original conceptual basis of PTSD (letter). Good, Fe 296

Unusual flashbacks in a Vietnam veteran (letter). Mayer, My 713

What is PTSD? (editorial). Hales, Fe 143–145

Practice Guideline

Practice guideline for the treatment of patients with Alzheimer's disease and other dementias of late life. American Psychiatric Association, My suppl (correction: Au 1180)

Practice guideline for the treatment of patients with schizophrenia. American Psychiatric Association, Ap suppl (letters: Dickson; Liberman; reply of Herz, De 1792–1794)

Schizophrenia practice guideline (letters). Dickson; Liberman; reply of Herz, De 1792–1794

Practice Research Network

Practice-based research in psychiatry. Zarin, Se 1199–1208

Prediction

Utility of the initial therapeutic alliance in evaluating psychiatric patients' risk of violence. Beauford, Se 1272–1276

Pregnancy

ADHD and maternal smoking during pregnancy (letter). Chabrol, reply of Milberger, Au 1177–1178

Effects of pregnancy on suicidal behavior (letter). Sharma, reply of Marzuk, Oc 1479–1480

Interpersonal psychotherapy for depressed antepartum women: a pilot study. Spinelli, Jy 1028–1030

Lower risk of suicide during pregnancy. Marzuk, Ja 122–123 (letter: Sharma, reply of Marzuk, Oc 1479–1480)

Maternal infectious illness and schizophrenia (letter). Stöber, reply of Wright, Fe 292–293

Psychotropic treatment during pregnancy (letter). Pinkofsky, My 718–719

Premenstrual Syndrome see also Late Luteal Phase Dysphoric Disorder

Blunted serotonin response to fenfluramine challenge in premenstrual dysphoric disorder. FitzGerald, Ap 556–558

Premenstrual syndrome: evidence for symptom stability across cycles. Bloch, De 1741–1746

Premorbid Functioning

Premorbid social functioning in schizophrenia and bipolar disorder: similarities and differences. Cannon, No 1544–1550

Prevention of Mental Illness

Sustained change in parents receiving preventive interventions for families with depression. Beardslee, Ap 510–515

Primary Care

Defeat Depression Campaign: psychiatry in the public arena (festschrift). Paykel, Je suppl 59–65

Mental disorders and disability among patients in a primary care group practice. Olfson, De 1734–1740

Psychiatry's future (letters). King; Downs; Gilman, reply of Shore, Se 1325–1326

Somatization in cross-cultural perspective: a World Health Organization study in primary care. Gureje, Jy 989–995

Prisoners of War

Posttraumatic stress disorder in a community group of former prisoners of war: a normative response to severe trauma. Engdahl, No 1576–1581

Prognosis

Outcome in bulimia nervosa. Keel, Mr 313–321 (letters: Reiss; Fairburn; reply of Keel, De 1791–1792)

Prediction of low body weight at long-term follow-up in acute anorexia nervosa by low body weight at referral. Hebebrand, Ap 566–569
Prolactin
Central serotonin activity and aggression: inverse relationship with prolactin response to *d*-fenfluramine, but not CSF 5-HIAA concentration, in human subjects. Coccaro, Oc 1430–1435
Propofol
Propofol for sedation during rapid opiate detoxification (letter). DeMaria, Fe 290–291
Propranolol
Propranolol treatment of olanzapine-induced akathisia (letter). Kurzthaler, Se 1316
Pseudodementia see Dementia
Psychiatry see also Academic Psychiatry
Disputing psychiatry's redefinition (letter). Clemens, reply of Lieberman, No 1633–1635
Festschrift in honor of Melvin Sabshin, MD—Medical Director, American Psychiatric Association, 1974–1997 (festschrift). Andreasen, Je suppl 1
Physician-assisted suicide in Oregon (letters). Hamilton; Goodwin, reply of Ganzini, Se 1326–1328
Practice-based research in psychiatry. Zarin, Se 1199–1208
Psychiatry in the framework of primary health care: a threat or boost to psychiatry? (festschrift). Sartorius, Je suppl 67–72
Psychiatry's future (letters). King; Downs; Gilman, reply of Shore, Se 1325–1326
Psychotherapy's role in psychiatry (letter). Busch, reply of Lieberman, Oc 1481–1482
Recent developments in American psychiatry and Dr Melvin Sabshin's contributions to them (festschrift). Nishizono, Je suppl 73–76
What is psychiatry? (editorial). Andreasen, My 591–593
Psychodynamic Therapy
Biased book review (letter). Schwartz, reply of Hartmann, Je 888
Psychological Tests see Tests, Psychological
Psychomotor Symptoms
Psychomotor symptoms of depression. Sobin, Ja 4–17
Psychopathology see also specific diagnoses
Breast cancer risk in psychiatric patients (letters). Goodwin; Torrey; Mortensen; reply of Halbreich, Ap 588–590
Long-term mental health effects of the Chernobyl disaster: an epidemiologic survey in two former Soviet regions. Havenaar, No 1605–1607
Mental disorders and disability among patients in a primary care group practice. Olfson, De 1734–1740
Mortality of elderly patients with psychiatric disorders. Zubenko, Oc 1360–1368
Psychopathology in women and men: focus on female hormones. Seeman, De 1641–1647
Religion and psychopathology (letter). Trappler, reply of Kendler, No 1636
Religion, psychopathology, and substance use and abuse: a multimeasure, genetic-epidemiologic study. Kendler, Mr 322–329 (letter: Trappler, reply of Kendler, No 1636)
Social consequences of psychiatric disorders, II: teenage parenthood. Kessler, Oc 1405–1411
Specific major mental disorders and criminality: a 26-year prospective study of the 1966 Northern Finland birth cohort. Tiihonen, Je 840–845
Psychopharmacology see Drugs, Psychotropic
Psychosis see also specific diagnoses
Association of ketamine-induced psychosis with focal activation of the prefrontal cortex in healthy volunteers. Breier, Je 805–811
Childhood-onset psychosis: evolution and comorbidity (case conf). Gartner, Fe 256–261
Clomiphene-induced psychosis (letter). Oyffe, Au 1169–1170
Comparison of patients with early-, typical-, and late-onset affective psychosis. Sax, Se 1299–1301
Evaluation of a complex case: the value of a drug washout period (case conf). Patel, De 1747–1750
HIV infection among young adults with psychotic disorders. Susser, Je 864–866
Low use of neuroleptic drugs in the treatment of psychotic major depression. Mulsant, Ap 559–561
Metronidazole-induced pychotic disorder (letter). Schreiber, Au 1170–1171
Psychotic depression (letter). Strauss, reply of Jeste, My 719–720
Psychotic episode associated with dexfenfluramine (letter). Preval, No 1624–1625
Risperidone treatment of methamphetamine psychosis (letter). Misra, Au 1170
Treatment of psychotic depression (letter). DeBattista, No 1625–1626
Psychosomatic Disorders see Physical Illness and Impairment; Somatoform Disorders
Psychotherapy
Creativity in psychodynamic psychotherapy (letter). Flegenheimer, reply of Nadelson, My 721
Disputing psychiatry's redefinition (letter). Clemens, reply of Lieberman, No 1633–1635
Economic impact of psychotherapy: a review. Gabbard, Fe 147–155
E-mail therapy (letter). Rothchild, Oc 1476–1477
Internet addiction, internet psychotherapy (letter). Stein, reply of Huang, Je 890
Medication and psychotherapy in the treatment of bulimia nervosa. Walsh, Ap 523–531
On wearing two hats: role conflict in serving as both psychotherapist and expert witness. Strasburger, Ap 448–456
Outcome of psychotherapy among early adolescents after trauma. Goenjian, Ap 536–542
Psychotherapy's role in psychiatry (letter). Busch, reply of Lieberman, Oc 1481–1482
Three-year trials of personal therapy among schizophrenic patients living with or independent of family, I: description of study and effects on relapse rates. Hogarty, No 1504–1513
Three-year trials of personal therapy among schizophrenic patients living with or independent of family, II: effects on adjustment of patients. Hogarty, No 1514–1524
We can talk: individual psychotherapy for schizophrenia (editorial). Fenton, No 1493–1495
Which depressed patients will respond to interpersonal psychotherapy? the role of abnormal EEG sleep profiles. Thase, Ap 502–509
Which elderly patients with remitted depression remain well with continued interpersonal psychotherapy after discontinuation of antidepressant medication? Reynolds, Jy 958–962
Psychotic Depression see Mood Disorders
PTSD see Posttraumatic Stress Disorder
Public Opinion
Defeat Depression Campaign: psychiatry in the public arena (festschrift). Paykel, Je suppl 59–65
Pulmonary Disease
Can pulmonary complications cause schizophrenia remission? (letter). Passman, Ja 130

Q

Quality of Care
Predicting readmission to the psychiatric hospital in a managed care environment: implications for quality indicators. Lyons, Mr 337–340
Quality of Life
Characterizing quality of life among patients with chronic mental illness: a critical examination of the self-report methodology. Atkinson, Ja 99–105 (letters: Arfken; Rohland; reply of Atkinson, Oc 1478–1479)
Panic disorder and quality of life: variables predictive of functional impairment. Hollifield, Je 766–772
Posttraumatic stress disorder and functioning and quality of life outcomes in a nationally representative sample of male Vietnam veterans. Zatzick, De 1690–1695
Self-reported life satisfaction (letters). Arfken; Rohland; reply of Atkinson, Oc 1478–1479

R

Rape
Objective assessment of peritraumatic dissociation: psychophysiological indicators. Griffin, Au 1081–1088
Startle reflex abnormalities in women with sexual assault-related PTSD. Morgan, Au 1076–1080
Rating Scales see Tests, Psychological
Rauwolfia Serpentina
Rauwolfia serpentina: the first herbal antipsychotic (image, psych). Bhatara, Jy 894
Recruitment
Possible discrimination in recruitment of psychiatry residents? Balon, No 1608–1609
Refugees
Refugees' time perspective and mental health. Beiser, Jy 996–1002
Relapse
Reduced morbidity after gradual discontinuation of lithium treatment for bipolar I and II disorders: a replication study. Baldessarini, Ap 551–553
Relapse in young paranoid schizophrenic patients: a prospective study of stressful life events, P300 measures, and coping. Pallanti, Je 792–798
Sequential use of naltrexone in the treatment of relapsing alcoholism (letter). Farren, My 714
Superiority of carbohydrate-deficient trans-

ferrin to γ-glutamyltransferase in detecting relapse in alcoholism. Schmidt, Ja 75–80
Three-year trials of personal therapy among schizophrenic patients living with or independent of family, I: description of study and effects on relapse rates. Hogarty, No 1504–1513
Relatives see Genetics
Release from Hospital
Predicting readmission to the psychiatric hospital in a managed care environment: implications for quality indicators. Lyons, Mr 337–340
Religion
Depression awareness training and the clergy (letter). Weaver, My 717–718
Religion and psychopathology (letter). Trappler, reply of Kendler, No 1636
Religion index for psychiatric research (letter). Koenig, Je 885–886
Religion, psychopathology, and substance use and abuse: a multimeasure, genetic-epidemiologic study. Kendler, Mr 322–329 (letter: Trappler, reply of Kendler, No 1636)
Vulnerability of Jews to affective disorders. Levav, Jy 941–947
REM Sleep see Sleep
Research
Durable power of attorney and informed consent with Alzheimer's disease patients: a clinical study. Dukoff, Au 1070–1075
Increased health care utilization as a function of participation in trauma research. Sansone, Jy 1025–1027
Practice-based research in psychiatry. Zarin, Se 1199–1208
Religion index for psychiatric research (letter). Koenig, Je 885–886
Replication (letter). Liberman, reply of Inderbitzin, Mr 440
Research without external funding in North American psychiatry. Silberman, Au 1159–1160
Residents
Possible discrimination in recruitment of psychiatry residents? Balon, No 1608–1609
Response to Treatment see Outcome
Reversed Symptoms see Depression—Diagnosis of
Rhazes
al-Razi (Rhazes), 865–925 (image, psych). Daghestani, No 1602
Rheumatic Fever
Identification of children with pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections by a marker associated with rheumatic fever. Swedo, Ja 110–112 (letter: Hollander, reply of Swedo, No 1630–1631)
Right to Refuse Treatment
Prospective study of patients' refusal of antipsychotic medication under a physician discretion review procedure. Kasper, Ap 483–489
Refusal of medical treatment: psychiatric emergency? (case conf). Stotland, Ja 106–108
Risk
Breast cancer risk in psychiatric patients (letters). Goodwin; Torrey; Mortensen; reply of Halbreich, Ap 588–590
Does growing old increase the risk for depression? Roberts, Oc 1384–1390
Lower risk of suicide during pregnancy. Marzuk, Ja 122–123 (letter: Sharma, reply of Marzuk, Oc 1479–1480)
Psychophysiological protective factors for male subjects at high risk for criminal behavior. Brennan, Je 853–855
Risperidone
Atypical neuroleptic malignant syndrome associated with risperidone treatment (letter). Newman, Oc 1475
Chronic schizophrenia: response to clozapine, risperidone, and paroxetine (case conf). Patel, Ap 543–546
Does risperidone improve verbal working memory in treatment-resistant schizophrenia? Green, Je 799–804
Pancreatitis associated with risperidone treatment? (letter). Berent, Ja 130–131
Protracted akathisia after risperidone withdrawal (letter). Rosebush, Mr 437–438
Risperidone for treatment of childhood schizophrenia (letter). Sourander, Oc 1476
Risperidone overdose (letter). Moore, Fe 289–290
Risperidone treatment of methamphetamine psychosis (letter). Misra, Au 1170
Treatment of risperidone-induced obsessive-compulsive symptoms with sertraline (letter). Dodt, Ap 582

S

Sabshin, Melvin
Festschrift in honor of Melvin Sabshin, MD—Medical Director, American Psychiatric Association, 1974–1997 (festschrift). Andreasen, Je suppl 1
Melvin Sabshin: integrator, innovator, and master of metaphor (festschrift). Andreasen, Je suppl 3–5
Recent developments in American psychiatry and Dr Melvin Sabshin's contributions to them (festschrift). Nishizono, Je suppl 73–76
Schizoaffective Disorder
CSF neurotensin concentrations and antipsychotic treatment in schizophrenia and schizoaffective disorder. Sharma, Jy 1019–1021
Obsessive-compulsive disorder in patients with schizophrenia or schizoaffective disorder. Eisen, Fe 271–273 (letter: Werner, reply of Eisen, No 1635–1636)
Schizophrenia—Diagnosis of
Informative morphogenetic variants in patients with schizophrenia and alcohol-dependent patients: beyond the Waldrop scale. Trixler, My 691–693
Obsessive-compulsive symptoms in schizophrenia (letter). Werner, reply of Eisen, No 1635–1636
On an engaging patient with paranoid schizophrenia (letters). Abrahamson; Moore, Au 1178
Psychosis and etiology (letter). Tremeau, reply of Maziade, Ja 132–134
Schizophrenia—Research in
Aberrant semantic activation in schizophrenia: a neurophysiological study. Nestor, My 640–646
Age at onset and gender of schizophrenic patients in relation to neuroleptic resistance. Meltzer, Ap 475–482
Age-related differences in formal thought disorder in chronically hospitalized schizophrenic patients: a cross-sectional study across nine decades. Harvey, Fe 205–210
Anterior cingulate gyrus dysfunction and selective attention deficits in schizophrenia: $[^{15}O]H_2O$ PET study during single-trial Stroop task performance. Carter, De 1670–1675
Attentional functioning in schizotypal personality disorder. Lees Roitman, My 655–660 (correction: Au 1180)
Attentional impairments in deficit and nondeficit forms of schizophrenia. Buchanan, Mr 363–370
Auditory hallucinations and the temporal cortical response to speech in schizophrenia: a functional magnetic resonance imaging study. Woodruff, De 1676–1682
Benzodiazepine receptor binding and schizophrenia (letter). Verhoeff, reply of Busatto, Oc 1480
Cerebrospinal fluid monoamine metabolites in childhood-onset schizophrenia. Jacobsen, Ja 69–74
Childhood-onset schizophrenia: biological markers in relation to clinical characteristics. Alaghband-Rad, Ja 64–68
Chromosomal fragile site 1q21 in schizophrenic patients (letter). Fananas, My 716
Clinical and neurocognitive aspects of source monitoring errors in schizophrenia. Vinogradov, No 1530–1537
Clinical correlates of memory in schizophrenia: differential links between depression, positive and negative symptoms, and two types of memory impairment. Brébion, No 1538–1543
Cognitive deficit measures in schizophrenia: factor structure and clinical correlates (festschrift). Lieh-Mak, Je suppl 39–46
Cognitive impairment in adolescents with schizophrenia. Kenny, No 1613–1615
Comparison of efficacy of social skills training for deficit and nondeficit negative symptoms in schizophrenia. Kopelowicz, Mr 424–425
Correlation between reduced in vivo benzodiazepine receptor binding and severity of psychotic symptoms in schizophrenia. Busatto, Ja 56–63 (correction: My 722) (letter: Verhoeff, reply of Busatto, Oc 1480)
CSF neurotensin concentrations and antipsychotic treatment in schizophrenia and schizoaffective disorder. Sharma, Jy 1019–1021
Cytoarchitecture of the entorhinal cortex in schizophrenia. Akil, Jy 1010–1012
Decreased anterior cingulate gyrus metabolic rate in schizophrenia. Haznedar, My 682–684
Decreased left frontal lobe N-acetylaspartate in schizophrenia. Deicken, My 688–690
Depressive symptoms in the early course of schizophrenia: relationship to familial psychiatric illness. Subotnik, No 1551–1556
Direct assessment of functional status in older patients with schizophrenia. Klapow, Jy 1022–1024
Does risperidone improve verbal working memory in treatment-resistant schizophrenia? Green, Je 799–804
Gene-environment interaction in vulnerability to schizophrenia: findings from the

Finnish Adoptive Family Study of Schizophrenia. Wahlberg, Mr 355–362
Maternal infectious illness and schizophrenia (letter). Stöber, reply of Wright, Fe 292–293
Meta-analysis of postmortem studies of Alzheimer's disease-like neuropathology in schizophrenia. Baldessarini, Je 861–863 (correction: Au 1180)
Neurocognitive deficits in schizophrenia (letter). Liberman, reply of Green, Mr 443–444
Obsessive-compulsive disorder in patients with schizophrenia or schizoaffective disorder. Eisen, Fe 271–273 (letter: Werner, reply of Eisen, No 1635–1636)
Obstetric complications and age at onset in schizophrenia: an international collaborative meta-analysis of individual patient data. Verdoux, Se 1220–1227
Olfactory identification deficits in schizophrenia: correlation with duration of illness. Moberg, Jy 1016–1018
PET study of greater visual activation in schizophrenia. Taylor, Se 1296–1298
Planum temporale asymmetry reversal in schizophrenia: replication and relationship to gray matter abnormalities. Barta, My 661–667
Plasma levels of cytokines and soluble cytokine receptors during treatment with haloperidol. Pollmächer, De 1763–1765
Premorbid social functioning in schizophrenia and bipolar disorder: similarities and differences. Cannon, No 1544–1550
Quantitative morphology of the cerebellum and fourth ventricle in childhood-onset schizophrenia. Jacobsen, De 1663–1669
Relapse in young paranoid schizophrenic patients: a prospective study of stressful life events, P300 measures, and coping. Pallanti, Je 792–798
Resemblance of psychotic symptoms and syndromes in affected sibling pairs from the Irish Study of High-Density Schizophrenia Families: evidence for possible etiologic heterogeneity. Kendler, Fe 191–198
Review (letter). Talbott, Au 1180
Revisiting the factor structure for positive and negative symptoms: evidence from a large heterogeneous group of psychiatric patients. Toomey, Mr 371–377
Schizophrenia and the myth of intellectual decline. Russell, My 635–639
Schizophrenia and the parvalbumin-containing class of cortical local circuit neurons. Woo, Jy 1013–1015
Sex differences in brain morphology in schizophrenia. Nopoulos, De 1648–1654
Sex-specific expression of Heschl's gyrus functional and structural abnormalities in paranoid schizophrenia. Rojas, De 1655–1662
Similar extent of brain dysmorphology in severely ill women and men with schizophrenia. Lauriello, Je 819–825
Size, shape, and orientation of neurons in the left and right hippocampus: investigation of normal asymmetries and alterations in schizophrenia. Zaidel, Je 812–818
SPECT studies of D_2 occupancy in low-dose haloperidol treatment (letter). Hirschowitz, My 715–716
Suicide and schizophrenia: a nationwide psychological autopsy study on age- and sex-specific clinical characteristics of 92 suicide victims with schizophrenia. Heilä, Se 1235–1242
Symptoms, subtype, and suicidality in patients with schizophrenia spectrum disorders. Fenton, Fe 199–204
Synaptic elimination, neurodevelopment, and the mechanism of hallucinated "voices" in schizophrenia. Hoffman, De 1683–1689
Three-dimensional cortical morphometry of the planum temporale in childhood-onset schizophrenia. Jacobsen, My 685–687
Unnatural practices, unspeakable actions: a study of delayed auditory feedback in schizophrenia. Goldberg, Je 858–860
Visual information-processing impairments in deficit and nondeficit schizophrenia. Bustillo, My 647–654
Visual perception in medicated schizophrenic patients (letters). Bonnet; Schwartz; reply of O'Donnell, Ap 585–587

Schizophrenia—Treatment of

Age at onset and gender of schizophrenic patients in relation to neuroleptic resistance. Meltzer, Ap 475–482
Augmentation of clozapine therapy with ondansetron (letter). Briskin, Au 1171
Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol. Tollefson, Se 1248–1254
Can pulmonary complications cause schizophrenia remission? (letter). Passman, Ja 130
Chronic schizophrenia: response to clozapine, risperidone, and paroxetine (case conf). Patel, Ap 543–546
Clozapine and fertility (letter). Dickson, Ap 582–583
Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Zimbroff, Je 782–791
Cyproheptadine: a potent in vivo serotonin antagonist (letter). Kapur, Je 884
Economic reforms and the acute inpatient care of patients with schizophrenia: the Chinese experience. Phillips, Se 1228–1234
High-dose olanzapine for treatment-refractory schizophrenia (letter). Sheitman, No 1626
Koro and homicidal behavior (letter). Lewis, Au 1169
Lethal interaction of clozapine and buspirone? (letter). Good, Oc 1472–1473
Negative symptoms: a path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine. Tollefson, Ap 466–474
Nemonapride for the treatment of schizophrenia (letter). Satoh, Fe 292
Neuroleptic malignant syndrome following initiation of clozapine therapy (letter). Dalkilic, Je 881–882
Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Tollefson, Ap 457–465
Pancreatitis associated with risperidone treatment? (letter). Berent, Ja 130–131
PET evidence that loxapine is an equipotent blocker of 5-HT_2 and D_2 receptors: implications for the treatment of schizophrenia. Kapur, No 1525–1529
Practice guideline for the treatment of patients with schizophrenia. American Psychiatric Association, Ap suppl (letters: Dickson; Liberman; reply of Herz, De 1792–1794)
Propranolol treatment of olanzapine-induced akathisia (letter). Kurzthaler, Se 1316
Risperidone for treatment of childhood schizophrenia (letter). Sourander, Oc 1476
Risperidone overdose (letter). Moore, Fe 289–290
Schizophrenia practice guideline (letters). Dickson; Liberman; reply of Herz, De 1792–1794
Three-year trials of personal therapy among schizophrenic patients living with or independent of family, I: description of study and effects on relapse rates. Hogarty, No 1504–1513
Three-year trials of personal therapy among schizophrenic patients living with or independent of family, II: effects on adjustment of patients. Hogarty, No 1514–1524
Time to clozapine response in a standardized trial. Conley, Se 1243–1247
Treatment of risperidone-induced obsessive-compulsive symptoms with sertraline (letter). Dodt, Ap 582
We can talk: individual psychotherapy for schizophrenia (editorial). Fenton, No 1493–1495

Schizotypal Personality Disorder

Attentional functioning in schizotypal personality disorder. Lees Roitman, My 655–660 (correction: Au 1180)

Season

Seasonal variation in the occurrence of homicide in Finland. Tiihonen, De 1711–1714

Seasonal Affective Disorder

Light visor maintenance of light box response (letter). Clark, Au 1172
Photic maculopathy in a patient receiving bright light therapy (letter). Gallenga, Se 1319
Rapid tryptophan depletion in drug-free depressed patients with seasonal affective disorder. Neumeister, Au 1153–1155
Seasonality of symptoms in women with late luteal phase dysphoric disorder. Maskall, Oc 1436–1441

Second Messenger System

High intracellular calcium concentrations in transformed lymphoblasts from subjects with bipolar I disorder. Emamghoreishi, Jy 976–982

Selective Serotonin Reuptake Inhibitors

Addition of desipramine to serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder. Barr, Se 1293–1295
Exacerbation of respiratory symptoms in patients with panic disorder (letter). Bouwer, My 712–713
Pindolol-paroxetine combination (letter). Isaac, reply of Berman, De 1790–1791
Sexual functioning in chronically depressed patients treated with SSRI antidepressants: a pilot study. Piazza, De 1757–1759

Self-Injurious Behavior

Dissociation in patients with borderline per-

sonality disorder (letter). Paris, reply of Brodsky, Ja 137–138
Semantic Activation see Evoked Potentials
Sensory Gating see Evoked Potentials
Serotonin
Blunted serotonin response to fenfluramine challenge in premenstrual dysphoric disorder. FitzGerald, Ap 556–558
Central serotonin activity and aggression: inverse relationship with prolactin response to *d*-fenfluramine, but not CSF 5-HIAA concentration, in human subjects. Coccaro, Oc 1430–1435
CSF 5-HIAA and family history of antisocial personality disorder in newborns. Constantino, De 1771–1773
Cyproheptadine: a potent in vivo serotonin antagonist (letter). Kapur, Je 884
PET evidence that loxapine is an equipotent blocker of 5-HT_2 and D_2 receptors: implications for the treatment of schizophrenia. Kapur, No 1525–1529
Possible association of a polymorphism of the tryptophan hydroxylase gene with suicidal behavior in depressed patients. Mann, Oc 1451–1453
Rapid tryptophan depletion in drug-free depressed patients with seasonal affective disorder. Neumeister, Au 1153–1155
Reduced serotonin responsivity in depression (letter). Brown, reply of Mann, Mr 442
Seasonal variation in the occurrence of homicide in Finland. Tiihonen, De 1711–1714
Serotonergic modulation of dopamine measured with [^{11}C]raclopride and PET in normal human subjects. Smith, Ap 490–496
Sertindole
Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Zimbroff, Je 782–791
Sertraline
Double-blind comparison of sertraline, imipramine, and placebo in the treatment of dysthymia: psychosocial outcomes. Kocsis, Mr 390–395
Recurrent hyponatremia associated with sertraline and lofepramine (letter). Bouman, Ap 580
Sertraline and desmethylsertraline in human breast milk and nursing infants. Stowe, Se 1255–1260
Treatment of risperidone-induced obsessive-compulsive symptoms with sertraline (letter). Dodt, Ap 582
Sex Differences
Age at onset and gender of schizophrenic patients in relation to neuroleptic resistance. Meltzer, Ap 475–482
Gender differences in cerebellar metabolism: test-retest reproducibility. Volkow, Ja 119–121
Psychopathology in women and men: focus on female hormones. Seeman, De 1641–1647
Sex differences in brain morphology in schizophrenia. Nopoulos, De 1648–1654
Sex-specific expression of Heschl's gyrus functional and structural abnormalities in paranoid schizophrenia. Rojas, De 1655–1662
Similar extent of brain dysmorphology in severely ill women and men with schizophrenia. Lauriello, Je 819–825
Suicide and schizophrenia: a nationwide psychological autopsy study on age- and sex-specific clinical characteristics of 92 suicide victims with schizophrenia. Heilä, Se 1235–1242
Sexual Abuse see also Child Abuse
False memories of cult abuse (letter). Yeager, Mr 435
Reported pathological childhood experiences associated with the development of borderline personality disorder. Zanarini, Au 1101–1106
Sexual Behavior
Characteristics of 36 subjects reporting compulsive sexual behavior. Black, Fe 243–249 (letter: Kafka, No 1632)
Compulsive sexual behavior characteristics (letter). Kafka, No 1632
Paroxetine treatment of sexual disinhibition in dementia (letter). Stewart, Oc 1474
Sexual Function
Sexual functioning in chronically depressed patients treated with SSRI antidepressants: a pilot study. Piazza, De 1757–1759
Shepherd, Michael
Michael Shepherd: 1923–1995 (image, psych). Eisenberg, My 681
Siblings
Homosexuality and older brothers (letters). Eiberson; Martin; Turner; reply of Blanchard, Ja 136–137
Resemblance of psychotic symptoms and syndromes in affected sibling pairs from the Irish Study of High-Density Schizophrenia Families: evidence for possible etiologic heterogeneity. Kendler, Fe 191–198
Side Effects see specific drugs
Single Photon Emission Computed Tomography
Correlation between reduced in vivo benzodiazepine receptor binding and severity of psychotic symptoms in schizophrenia. Busatto, Ja 56–63 (correction: My 722) (letter: Verhoeff, reply of Busatto, Oc 1480)
SPECT studies of D_2 occupancy in low-dose haloperidol treatment (letter). Hirschowitz, My 715–716
Skin
Objective assessment of peritraumatic dissociation: psychophysiological indicators. Griffin, Au 1081–1088
Sleep
Clinical factors contributing to the differential diagnosis of primary insomnia and insomnia related to mental disorders. Nowell, Oc 1412–1416
Prevalence, burden, and treatment of insomnia in primary care. Simon, Oc 1417–1423
Sleep deprivation combined with consecutive sleep phase advance as a fast-acting therapy in depression: an open pilot trial in medicated and unmedicated patients. Berger, Je 870–872
Which depressed patients will respond to interpersonal psychotherapy? the role of abnormal EEG sleep profiles. Thase, Ap 502–509
Smoking see Nicotine
Social Phobia
Dopamine reuptake site densities in patients with social phobia. Tiihonen, Fe 239–242
Social phobia and stuttering (letter). Schneier, Ja 131
Social Relationships
Neurobiological basis of social attachment. Insel, Je 726–735
Social support: a genetic-epidemiologic analysis. Kendler, Oc 1398–1404
Three-year trials of personal therapy among schizophrenic patients living with or independent of family, II: effects on adjustment of patients. Hogarty, No 1514–1524
Social Skills Training
Comparison of efficacy of social skills training for deficit and nondeficit negative symptoms in schizophrenia. Kopelowicz, Mr 424–425
Sodium Lactate
Behavioral and neuroendocrine responses to sodium lactate infusion in subjects with posttraumatic stress disorder. Jensen, Fe 266–268
Somalia
Posttraumatic stress disorder associated with peacekeeping duty in Somalia for US military personnel. Litz, Fe 178–184 (correction: My 722) (letter: Hall, reply of Litz, Oc 1482–1483)
Somatization see Somatoform Disorders
Somatoform Disorders see also Physical Illness and Impairment
Somatization in cross-cultural perspective: a World Health Organization study in primary care. Gureje, Jy 989–995
Spectral Karyotyping
Molecular biology, VI: metaphase preparation of normal human chromosomes with spectral karyotyping (image, neuro). Ried, Ap 447
Molecular biology, VII: spectral karyotyping analysis in diagnostic cytogenetics (image, neuro). Ried, My 594
Speech
Image on progressive dysarthria (letter). O'Shanick, reply of Selnes, Ap 584–585
Startle Response
Startle reflex abnormalities in women with sexual assault-related PTSD. Morgan, Au 1076–1080
State Hospitals see Hospital Psychiatry
Steroids
Androgenic activity in autism (letter). Tordjman, No 1626–1627
Androgens and alcohol (letter). Wiseman, Jy 1040–1041
Psychopathology in women and men: focus on female hormones. Seeman, De 1641–1647
Streptococcal Antibodies
B lymphocyte antigen D8/17: a peripheral marker for childhood-onset obsessive-compulsive disorder and Tourette's syndrome? Murphy, Mr 402–407
Stress see also Posttraumatic Stress Disorder
Relapse in young paranoid schizophrenic patients: a prospective study of stressful life events, P300 measures, and coping. Pallanti, Je 792–798
Severe life stress as a predictor of early disease progression in HIV infection. Evans, My 630–634
Stress reactivity in bipolar patients and its relation to prior history of disorder. Hammen, Je 856–857
Stroke
Alternative treatment for poststroke depression (letter). Mårtensson, Ap 583–584

Brainstem evoked response abnormalities in late-life depression with vascular disease. Kalayam, Jy 970–975
Stuttering
Clozapine-induced stuttering (letter). Ebeling, Oc 1473
Paroxetine for treatment of obsessive-compulsive disorder and comorbid stuttering (letter). Murray, Jy 1037
Social phobia and stuttering (letter). Schneier, Ja 131
Substance Abuse see also Addiction; Alcohol and Alcoholism; specific disorders
Comparison of induced and independent major depressive disorders in 2,945 alcoholics. Schuckit, Jy 948–957
Controlled study of psychiatric comorbidity in psychiatrically hospitalized young adults with substance abuse disorders. Grilo, Se 1305–1307
Homicidal behavior in drug abusing psychiatric patients (letter). Dhossche, reply of Salloum, Je 888–889
One-year follow-up of secondary versus primary mental disorder in persons with comorbid substance use disorders. Dixon, No 1610–1612
PET study of competition between intravenous cocaine and [^{11}C]raclopride at dopamine receptors in human subjects. Schlaepfer, Se 1209–1213
Prevalence and risk factors for posttraumatic stress disorder among chemically dependent adolescents. Deykin, Je 752–757
Religion, psychopathology, and substance use and abuse: a multimeasure, genetic-epidemiologic study. Kendler, Mr 322–329 (letter: Trappler, reply of Kendler, No 1636)
Risperidone treatment of methamphetamine psychosis (letter). Misra, Au 1170
Substance abuse and ADHD (letter). Hughes, Ja 132
Sucrose
Evidence of preference for a high-concentration sucrose solution in alcoholic men. Kampov-Polevoy, Fe 269–270 (letter: Hirsch, reply of Kampov-Polevoy, No 1631–1632)
Suicide
Characteristics of borderline personality disorder associated with suicidal behavior. Brodsky, De 1715–1719
Clinical case: unknown (case conf). Michels, No 1599–1601
Effects of pregnancy on suicidal behavior (letter). Sharma, reply of Marzuk, Oc 1479–1480
HIV seroprevalence among suicide victims in New York City, 1991–1993. Marzuk, De 1720–1725
Lower risk of suicide during pregnancy. Marzuk, Ja 122–123 (letter: Sharma, reply of Marzuk, Oc 1479–1480)
Possible association of a polymorphism of the tryptophan hydroxylase gene with suicidal behavior in depressed patients. Mann, Oc 1451–1453
Reduced frontal cortex inositol levels in postmortem brain of suicide victims and patients with bipolar disorder. Shimon, Au 1148–1150
Suicide and schizophrenia: a nationwide psychological autopsy study on age- and sex-specific clinical characteristics of 92 suicide victims with schizophrenia. Heilä, Se 1235–1242
Symptoms, subtype, and suicidality in patients with schizophrenia spectrum disorders. Fenton, Fe 199–204
Sullivan, Harry Stack
Harry Stack Sullivan, 1892–1949 (image, psych). Havens, Au 1145
Support
Are supplementary services provided during methadone maintenance really cost-effective? Kraft, Se 1214–1219
Sydenham's Chorea
Hair pulling in a patient with Sydenham's chorea (letter). Stein, Se 1320
Identification of children with pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections by a marker associated with rheumatic fever. Swedo, Ja 110–112 (letter: Hollander, reply of Swedo, No 1630–1631)
Symptoms see Diagnosis and Classification; Negative Symptoms
Systematic Desensitization
Systematic desensitization as an alternative exposure strategy for PTSD (letter). Frueh, Fe 287–288

T

T_3 see Thyroid Function
T_4 see Thyroid Function
***Tarasoff* Decision**
Tarasoff ruling and reporting to the authorities (letter). Balon, Se 1321
Tardive Dyskinesia
Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol. Tollefson, Se 1248–1254
Teenage Parenthood see Adolescents
Telemedicine
Telemedicine in psychiatry: making the dream reality (letter). Bear, Je 884–885
Temporal Lobes see Brain Disorders
Terminal Illness
"Are you depressed?" screening for depression in the terminally ill. Chochinov, My 674–676
Tests, Diagnostic see Diagnosis and Classification
Tests, Psychological
Montgomery-Åsberg severity gradations (letter). Mittmann, Se 1320–1321
Multicenter collaborative panic disorder severity scale. Shear, No 1571–1575
Theophylline
Fluvoxamine-induced theophylline toxicity (letter). DeVane, Se 1317–1318
Therapeutic Alliance
On wearing two hats: role conflict in serving as both psychotherapist and expert witness. Strasburger, Ap 448–456
Utility of the initial therapeutic alliance in evaluating psychiatric patients' risk of violence. Beauford, Se 1272–1276
Thought Disorder
Age-related differences in formal thought disorder in chronically hospitalized schizophrenic patients: a cross-sectional study across nine decades. Harvey, Fe 205–210
Gene-environment interaction in vulnerability to schizophrenia: findings from the Finnish Adoptive Family Study of Schizophrenia. Wahlberg, Mr 355–362
Thyroid Function
Inverse relationship of peripheral thyrotropin-stimulating hormone levels to brain activity in mood disorders. Marangell, Fe 224–230
Tics
Decreased motor inhibition in Tourette's disorder: evidence from transcranial magnetic stimulation. Ziemann, Se 1277–1284
Obsessive-compulsive disorder with and without tics in an epidemiological sample of adolescents. Zohar, Fe 274–276
Time Course of Drug Effects
Rapid benefit of intravenous pulse loading of clomipramine in obsessive-compulsive disorder. Koran, Mr 396–401
Tourette's Disorder
B lymphocyte antigen D8/17: a peripheral marker for childhood-onset obsessive-compulsive disorder and Tourette's syndrome? Murphy, Mr 402–407
Child psychiatry comes of age: growing sophistication, evolving strategies (editorial). Rapoport, Au 1043–1045
Decreased motor inhibition in Tourette's disorder: evidence from transcranial magnetic stimulation. Ziemann, Se 1277–1284
Relative efficacy of haloperidol and pimozide in children and adolescents with Tourette's disorder. Sallee, Au 1057–1062
Training see Education, Medical; Education, Psychiatric
Tramadol
Tramadol-induced mania (letter). Watts, No 1624
Transcranial Doppler Ultrasonography
Basilar artery response to hyperventilation in panic disorder. Ball, No 1603–1604
Transcranial Magnetic Stimulation
Decreased motor inhibition in Tourette's disorder: evidence from transcranial magnetic stimulation. Ziemann, Se 1277–1284
Effect of prefrontal repetitive transcranial magnetic stimulation in obsessive-compulsive disorder: a preliminary study. Greenberg, Je 867–869
Mood improvement following daily left prefrontal repetitive transcranial magnetic stimulation in patients with depression: a placebo-controlled crossover trial. George, De 1752–1756
Trauma see also Posttraumatic Stress Disorder
Association of panic disorder with a history of traumatic suffocation. Bouwer, No 1566–1570
Increased health care utilization as a function of participation in trauma research. Sansone, Jy 1025–1027
Posttraumatic stress disorder in a community group of former prisoners of war: a normative response to severe trauma. Engdahl, No 1576–1581
Traumatic Grief see Grief
Treatment, Involuntary, see Right to Refuse Treatment
Trichotillomania
Hair pulling in a patient with Sydenham's chorea (letter). Stein, Se 1320
Trichotillomania: behavioral symptom or clini-

cal syndrome? (case conf). O'Sullivan, Oc 1442–1449
Tricyclics see Antidepressants
Triiodothyronine see Thyroid Function
Tropicamide
Apolipoprotein E ∈4 allele and pupillary response to tropicamide. Higuchi, My 694–696
L-Tryptophan
Lack of relapse with tryptophan depletion following successful treatment with ECT. Cassidy, Au 1151–1152
Rapid tryptophan depletion in drug-free depressed patients with seasonal affective disorder. Neumeister, Au 1153–1155
Twins
Social support: a genetic-epidemiologic analysis. Kendler, Oc 1398–1404
Twin concordance for attention deficit hyperactivity disorder: a comparison of teachers' and mothers' reports. Sherman, Ap 532–535

U

Uncontrolled Buying
Uncontrolled buying (letter). Maier, reply of Lejoyeux, Oc 1477–1478
Urge to splurge (letter). Black, reply of Lejoyeux, No 1629–1630
Utilization see Mental Health Services, Delivery and Utilization of
Utilization Review
Validity of utilization management criteria for psychiatry. Goldman, Mr 349–354

V

Valproate
Carnitine for valproic acid-induced hyperammonemia (letter). Raby, Au 1168–1169
Response of kleptomania and mixed mania to valproate (letter). Kmetz, Ap 580–581
Valproate prophylaxis in a prospective clinical trial of refractory bipolar disorder. Denicoff, Oc 1456–1458
Vascular Depression see Depression—Diagnosis of
Vascular Disease
Brainstem evoked response abnormalities in late-life depression with vascular disease. Kalayam, Jy 970–975
Vasopressin
Neurobiological basis of social attachment. Insel, Je 726–735
Venlafaxine
Emergence of adverse events following discontinuation of treatment with extended-release venlafaxine. Fava, De 1760–1762
Withdrawal syndrome after discontinuation of venlafaxine (letter). Agelink, Oc 1473–1474
Ventricle Size
Premorbid brain size as a determinant of reserve capacity against intellectual decline in Alzheimer's disease. Mori, Ja 18–24
Sex differences in brain morphology in schizophrenia. Nopoulos, De 1648–1654
Similar extent of brain dysmorphology in severely ill women and men with schizophrenia. Lauriello, Je 819–825
Veterans see Combat; Posttraumatic Stress Disorder
Vietnam War see Combat; Posttraumatic Stress Disorder
Violence
Androgenic activity in autism (letter). Tordjman, No 1626–1627
Central serotonin activity and aggression: inverse relationship with prolactin response to *d*-fenfluramine, but not CSF 5-HIAA concentration, in human subjects. Coccaro, Oc 1430–1435
Homicidal behavior in drug abusing psychiatric patients (letter). Dhossche, reply of Salloum, Je 888–889
Interaction between birth complications and early maternal rejection in predisposing individuals to adult violence: specificity to serious, early-onset violence. Raine, Se 1265–1271
Koro and homicidal behavior (letter). Lewis, Au 1169
Seasonal variation in the occurrence of homicide in Finland. Tiihonen, De 1711–1714
Utility of the initial therapeutic alliance in evaluating psychiatric patients' risk of violence. Beauford, Se 1272–1276
Violence and cocaine (letter). Dhossche, reply of Tardiff, Oc 1480–1481
Violence by patients admitted to a private psychiatric hospital. Tardiff, Ja 88–93 (letter: Dhossche, reply of Tardiff, Oc 1480–1481)
Virtual Reality
Virtual reality therapy for fear of flying (letter). North, Ja 130
Visual Processing see Information Processing
Vitamins
Folate, vitamin B_{12}, and homocysteine in major depressive disorder. Fava, Mr 426–428
Vitamin C for paroxetine- and fluvoxamine-associated bleeding (letter). Tielens, Je 883–884

W

War see Combat
Water Dysregulation see Hyponatremia
Weight
Prediction of low body weight at long-term follow-up in acute anorexia nervosa by low body weight at referral. Hebebrand, Ap 566–569
White Matter Hyperintensities see Brain Disorders
Withdrawal of Drugs
Delta sleep-inducing peptide in opioid detoxification (letter). Soyka, My 714–715
Effectiveness of restarting lithium treatment after its discontinuation in bipolar I and bipolar II disorders. Tondo, Ap 548–550
Emergence of adverse events following discontinuation of treatment with extended-release venlafaxine. Fava, De 1760–1762
Evaluation of a complex case: the value of a drug washout period (case conf). Patel, De 1747–1750
Major depression following smoking cessation. Covey, Fe 263–265
Opiate withdrawal with dextromethorphan (letter). Bisaga, Ap 584
Persistent delirium following cessation of heavy alcohol consumption: diagnostic and treatment implications (case conf). Hersh, Je 846–851
Prophylactic efficacy of phenelzine and imipramine in chronic atypical depression: likelihood of recurrence on discontinuation after 6 months' remission. Stewart, Ja 31–36
Propofol for sedation during rapid opiate detoxification (letter). DeMaria, Fe 290–291
Protracted akathisia after risperidone withdrawal (letter). Rosebush, Mr 437–438
Reduced morbidity after gradual discontinuation of lithium treatment for bipolar I and II disorders: a replication study. Baldessarini, Ap 551–553
What happens to anxiety levels on giving up smoking? West, No 1589–1592
Withdrawal syndrome after discontinuation of venlafaxine (letter). Agelink, Oc 1473–1474
Women
Bipolar women (letter). Zibin, reply of Leibenluft, Mr 441
Luteinizing hormone pulse characteristics in depressed women. Meller, Oc 1454–1455
Premenstrual syndrome: evidence for symptom stability across cycles. Bloch, De 1741–1746
Seasonality of symptoms in women with late luteal phase dysphoric disorder. Maskall, Oc 1436–1441
Startle reflex abnormalities in women with sexual assault-related PTSD. Morgan, Au 1076–1080

X

Xanomeline
Brain proton magnetic resonance spectroscopy (^{1}H-MRS) in Alzheimer's disease: changes after treatment with xanomeline, an M_1 selective cholinergic agonist. Satlin, Oc 1459–1461